BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
b cell lymphoma stage i 2005:2010[pubdate] *count=100
1969 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
b cell lymphoma stage i
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 1969
1.
Lupu M, Sullivan EW, Westfall TE, Little MT, Weigler BJ, Moore PF, Stroup PA, Zellmer E, Kuhr C, Storb R:
Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma.
J Am Vet Med Assoc
; 2006 Mar 1;228(5):728-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic
cell
transplant donor for a dog with T-
cell lymphoma
.
Histologic examination and immunophenotyping of biopsy specimens confirmed a
stage
V (b) T-
cell
malignant
lymphoma
.
TREATMENT AND OUTCOME: Clinical remission was attained by use of 2 chemotherapy cycles, followed by an allogeneic hematopoietic
cell
transplant performed at 18 weeks after diagnosis.
Remission has been confirmed by normal results of serum thymidine kinase assays and the absence of peripheral blood clonal T-
cell
receptor gene rearrangements.
Outcome of allogeneic hematopoietic
cell
transplantation in dogs can be excellent because of improved donor-recipient selection by use of molecular dog leukocyte antigen typing, compared with early attempts, and better prevention of graft versus host disease, better supportive care, and substitution of peripheral blood mononuclear cells for bone marrow.
[MeSH-major]
Dog Diseases / therapy. Hematopoietic Stem
Cell
Transplantation / veterinary. Histocompatibility Antigens / immunology. Immunosuppression / veterinary.
Lymphoma
, T-
Cell
/ veterinary
[MeSH-minor]
Animals. Cyclosporine / pharmacology. Dogs. Graft Survival. Granulocyte Colony-Stimulating Factor / pharmacology. Hematopoietic Stem
Cell
Mobilization. Histocompatibility Testing. Male. Transplantation Chimera. Transplantation, Homologous / veterinary. Treatment Outcome. Whole-Body Irradiation / veterinary
Hazardous Substances Data Bank.
CYCLOSPORIN A
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16506937.001).
[ISSN]
0003-1488
[Journal-full-title]
Journal of the American Veterinary Medical Association
[ISO-abbreviation]
J. Am. Vet. Med. Assoc.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Histocompatibility Antigens; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83HN0GTJ6D / Cyclosporine
2.
Koç ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Carter WD, Gold DP, Stewart ME, Ghalie RG, Bender JF:
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
J Immunother
; 2010 Feb-Mar;33(2):178-84
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-
cell lymphoma
.
We evaluated the efficacy and safety of patient-specific immunotherapy with mitumprotimut-T idiotype keyhole limpet hemocyanin and granulocyte-monocyte colony-stimulating factor (GM-CSF) following rituximab in patients with follicular B-
cell lymphoma
.
Patients with previously untreated or relapsed/refractory CD20+ follicular
lymphoma
received 4 weekly infusions of rituximab and those with a complete response (CR), partial response (PR), or stable disease received mitumprotimut-T and GM-CSF injections subcutaneously.
Among 103 patients treated with rituximab, 92 (54 relapsed/refractory and 38 previously untreated) received mitumprotimut-T/GM-CSF; median age was 53 years, 91% had
stage
III to IV disease, and 59% had failed earlier therapy.
[MeSH-major]
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy.
Lymphoma
, B-
Cell
/ therapy.
Lymphoma
, Follicular / therapy. Recombinant Fusion Proteins / administration & dosage
Genetic Alliance.
consumer health - Follicular Lymphoma
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20145546.001).
[ISSN]
1537-4513
[Journal-full-title]
Journal of immunotherapy (Hagerstown, Md. : 1997)
[ISO-abbreviation]
J. Immunother.
[Language]
eng
[Publication-type]
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antigens, Neoplasm; 0 / Immunoglobulin Idiotypes; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 4F4X42SYQ6 / Rituximab; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 9013-72-3 / Hemocyanin; FV4Y0JO2CX / keyhole-limpet hemocyanin
3.
Al-Saleem T, Al-Mondhiry H:
Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms.
Blood
; 2005 Mar 15;105(6):2274-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunoproliferative small intestinal disease (IPSID): a model for mature B-
cell
neoplasms.
IPSID is a variant of the B-
cell lymphoma
of mucosa-associated lymphoid tissue (MALT), which involves mainly the proximal small intestine resulting in malabsorption, diarrhea, and abdominal pain.
IPSID lymphomas reveal excessive plasma
cell
differentiation and produce truncated alpha heavy chain proteins lacking the light chains as well as the first constant domain.
Early-
stage
IPSID responds to antibiotics (30%-70% complete remission).
Most untreated IPSID patients progress to lymphoplasmacytic and immunoblastic
lymphoma
invading the intestinal wall and mesenteric lymph nodes, and may metastasize to a distant organ.
IPSID
lymphoma
shares clinical, morphologic, and molecular features with MALT
lymphoma
, lymphoplasmacytic
lymphoma
, and plasma
cell
neoplasms.
[MeSH-major]
Campylobacter Infections. Campylobacter jejuni. Immunoproliferative Small Intestinal Disease.
Lymphoma
, B-
Cell
, Marginal Zone. Plasma Cells / immunology
[MeSH-minor]
Adolescent. Adult. Africa. B-
Cell
-Specific Activator Protein / genetics. B-
Cell
-Specific Activator Protein / immunology. Child. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 9 / genetics. Chromosomes, Human, Pair 9 / immunology. Female. Humans. Immunoglobulin Light Chains / genetics. Immunoglobulin Light Chains / immunology. Immunoglobulin Variable Region / genetics. Immunoglobulin Variable Region / immunology. Immunoglobulin alpha-Chains / genetics. Immunoglobulin alpha-Chains / immunology. Intestine, Small / immunology. Intestine, Small / pathology. Lymph Nodes / immunology. Lymph Nodes / pathology. Male. Mesentery / immunology. Mesentery / pathology. Middle East. Sequence Deletion / genetics. Sequence Deletion / immunology. Translocation, Genetic / genetics. Translocation, Genetic / immunology
MedlinePlus Health Information.
consumer health - Campylobacter Infections
.
The Weizmann Institute of Science GeneCards and MalaCards databases.
gene/protein/disease-specific - MalaCards for immunoproliferative small intestinal disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15542584.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / B-Cell-Specific Activator Protein; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin Variable Region; 0 / Immunoglobulin alpha-Chains; 0 / PAX5 protein, human
[Number-of-references]
78
Advertisement
4.
Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, Schuster SJ, Dyer MJ, Horne H, Teoh N, Wegener WA, Goldenberg DM:
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.
J Clin Oncol
; 2009 Jul 10;27(20):3346-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent
non
-
Hodgkin
's
lymphoma
: phase I/II results.
PURPOSE: This is a multicenter phase I/II dose-finding study in relapsed/refractory B-
cell
non
-
Hodgkin
's
lymphoma
(NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.
PATIENTS AND METHODS: Eighty-two patients (median age, 64 years; 79%
stage
III/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg/m(2) of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity.
In follicular
lymphoma
, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors > 5 cm, and Follicular
Lymphoma
International Prognostic Index > or = 2), and at all dose levels.
In marginal zone
lymphoma
, five (83%) of six patients had ORs, with two CRs/CRus (33%), and in diffuse large B-
cell lymphoma
, three (43%) of seven patients achieved partial responses.
[MeSH-major]
Antibodies, Monoclonal / therapeutic use.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. B-Lymphocytes / drug effects. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fatigue / chemically induced. Female. Fever / chemically induced. Headache / chemically induced. Humans. Kaplan-Meier Estimate.
Lymphoma
, B-
Cell
/ drug therapy.
Lymphoma
, B-
Cell
/ metabolism.
Lymphoma
, B-
Cell
/ pathology. Male. Middle Aged. Pruritus / chemically induced. Recurrence. Treatment Outcome
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19451441.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00285428/ NCT00596804
[Grant]
United Kingdom / Medical Research Council / / MC/ U132670597
[Publication-type]
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / veltuzumab
5.
Stefanovic A, Morgensztern D, Fong T, Lossos IS:
Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database.
Leuk Lymphoma
; 2008 Jul;49(7):1311-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pulmonary marginal zone
lymphoma
: a single centre experience and review of the SEER database.
Pulmonary marginal zone
lymphoma
is a rare disease arising from bronchial-associated lymphoid tissue (BALT).
There is limited information on clinical presentation, natural history and treatment of this type of
lymphoma
.
We conducted a retrospective review of patients with biopsy-proven BALT
lymphoma
treated at our institution and patients from the surveillance epidemiology and end results (SEER) database.
Twenty-one patients (median age 57) with disease
stage
IE (n = 10) and IV (n = 11), were treated at our institution.
We identified 326 patients (59% females and 41% males; median age 68 [30 to 85) with BALT
lymphoma
in the SEER database.
Fifty-five per cent had
stage
IE, 10%
stage
IIE, 3%
stage
IIIE, and 22%
stage
IV disease.
[MeSH-major]
Lung Neoplasms.
Lymphoma
, B-
Cell
, Marginal Zone
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18604720.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
6.
Carotta S, Nutt SL:
Losing B cell identity.
Bioessays
; 2008 Mar;30(3):203-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Losing
B cell
identity.
The transcription factor Pax5 is essential for the initial commitment of hematopoietic progenitors to the
B cell
lineage.
Recently, our understanding of the lineage commitment process has been extended with the finding that Pax5 is also continuously required throughout
B cell
development to reinforce commitment, as inactivation of Pax5 in mature B cells results in their
de
-differentiation to a progenitor
stage
that is capable of multi-lineage potential.
The reliance of
B cell
identity on a single gene is not without its problems as the loss of Pax5 results in
B cell
malignancies in mouse models and mutation in human PAX5 is the most-common genetic lesion in acute lymphoblastic leukemia.
[MeSH-major]
B-
Cell
-Specific Activator Protein / physiology. B-Lymphocytes / cytology. Gene Expression Regulation
[MeSH-minor]
Animals.
Cell
Differentiation.
Cell
Lineage. Disease Models, Animal. Hematopoietic Stem Cells / cytology. Humans. Mice. Models, Biological. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ metabolism
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18293359.001).
[ISSN]
1521-1878
[Journal-full-title]
BioEssays : news and reviews in molecular, cellular and developmental biology
[ISO-abbreviation]
Bioessays
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human
[Number-of-references]
34
7.
Vlădăreanu AM, Onisâi M, Ciufu C, Bumbea H, Cîşleanu D, Voican I, Nicolescu A, Radeşi S, Vintilescu A, Băluţă C, Dobrea C, Savlovschi C, Grecu L, Serban D, Serafim G:
Splenectomy--a therapeutic option in splenic marginal zone cell lymphoma.
Rom J Intern Med
; 2009;47(2):191-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Splenectomy--a therapeutic option in splenic marginal zone
cell lymphoma
.
Lymph node and bone marrow biopsy together with flowcytometry established the diagnosis of Malignant
non
-
Hodgkin
Lymphoma
--Atypical Splenic Marginal Zone B-
cell lymphoma
(aberrant expression of CD5)
stage
IVB, with leukemic picture, complicated with autoimmune hemolytic anemia with highly positive Coombs' tests.
[MeSH-major]
Lymphoma
, B-
Cell
, Marginal Zone / pathology.
Lymphoma
, B-
Cell
, Marginal Zone / surgery. Splenectomy. Splenic Neoplasms / pathology. Splenic Neoplasms / surgery
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20067170.001).
[ISSN]
1220-4749
[Journal-full-title]
Romanian journal of internal medicine = Revue roumaine de médecine interne
[ISO-abbreviation]
Rom J Intern Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Romania
8.
Terpos E, Politou M, Viniou N, Rahemtulla A:
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
Leuk Lymphoma
; 2005 Dec;46(12):1699-707
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Macrophage inflammatory protein-1 alpha (MIP-1alpha) is a member of the CC chemokine family and is primarily associated with
cell
adhesion and migration.
MIP-1alpha protein levels were elevated in the bone marrow plasma of MM patients and correlated with disease
stage
and activity.
Genetic Alliance.
consumer health - Multiple myeloma
.
MedlinePlus Health Information.
consumer health - Multiple Myeloma
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16263571.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Carrier Proteins; 0 / Chemokine CCL3; 0 / Chemokine CCL4; 0 / Macrophage Inflammatory Proteins; 0 / Membrane Glycoproteins; 0 / RANK Ligand; 0 / Receptor Activator of Nuclear Factor-kappa B; 0 / TNFRSF11A protein, human; 0 / TNFSF11 protein, human; 0 / Tnfrsf11a protein, mouse; 0 / Tnfsf11 protein, mouse
[Number-of-references]
44
9.
Guillaume N, Gouilleux-Gruart V, Claisse JF, Troussard X, Lepelley P, Damaj G, Royer B, Garidi R, Lefrere JJ:
Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.
Leuk Lymphoma
; 2007 Aug;48(8):1556-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-
cell
chronic lymphocytic leukemia.
ZAP-70 and CD38 expression can identify B-
cell
chronic lymphocytic leukemia with an inferior clinical outcome.
Forty-one untreated and
stage
A patients, either ZAP-70(+)CD38(+) or ZAP-70(-)CD38(-), were tested to determine the MDR1 status.
[MeSH-major]
Antigens, CD38 / metabolism. Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-
Cell
/ metabolism. Membrane Glycoproteins / metabolism. P-Glycoprotein / metabolism. ZAP-70 Protein-Tyrosine Kinase / metabolism
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, B-cell, chronic
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Leuk Lymphoma. 2007 Aug;48(8):1468-9
[
17701575.001
]
(PMID = 17701587.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / ABCB1 protein, human; 0 / Membrane Glycoproteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
10.
Na II, Kang HJ, Park YH, Lee SS, Yoo HJ, Choe DH, Ryoo BY, Yang SH:
Prognostic factors for classifying extranodal NK/T cell lymphoma, nasal type, as lymphoid neoplasia.
Eur J Haematol
; 2007 Jul;79(1):1-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors for classifying extranodal NK/T
cell lymphoma
, nasal type, as lymphoid neoplasia.
This study evaluated the applicability of prognostic factors commonly used for diagnosis of classical
lymphoma
outcomes to extranodal NK/T
cell lymphoma
, nasal type (NTCL).
RLDH was associated with
stage
(I-II vs. III-IV), lymph node involvement (LNI), and International Prognostic Index score (<2 vs. > or =2).
Poor performance status and advanced
stage
were common in patients with local tumor invasiveness (LTI).
In multivariate analysis, the predictive values of LDH level, B symptom, performance status, and
stage
remained significant whereas those of LTI and LNI did not.
[MeSH-major]
Killer Cells, Natural / immunology.
Lymphoma
, T-
Cell
/ classification. Nose Neoplasms / classification
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17598834.001).
[ISSN]
0902-4441
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
EC 1.1.1.27 / L-Lactate Dehydrogenase
11.
Pope E, Weitzman S, Ngan B, Walsh S, Morel K, Williams J, Stein S, Garzon M, Knobler E, Lieber C, Turchan K, Wargon O, Tsuchiya A:
Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous Lymphoma.
J Cutan Med Surg
; 2010 Jan-Feb;14(1):1-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mycosis fungoides in the pediatric population: report from an international Childhood Registry of Cutaneous
Lymphoma
.
BACKGROUND/OBJECTIVES: There are limited data on the clinical presentation and progression of pediatric cutaneous
lymphoma
.
The most common MF presentation was patch
stage
(68%), followed by hypopigmentation (59%) and plaque
stage
disease (50%).
All patients presented with early-
stage
disease and received skin-directed therapy (topical steroids, 73%; light therapy, 54%; or combination therapy, 35%).
CONCLUSIONS: Pediatric patients with MF present in the first decade of life, with early-
stage
disease and unusual forms such as hypopigmented variant.
Further patient enrollment will provide information regarding natural history, treatment response, and overall prognosis of pediatric cutaneous T-
cell lymphoma
(CTCL).
[MeSH-major]
Lymphoma
, T-
Cell
, Cutaneous / epidemiology. Mycosis Fungoides / epidemiology. Skin Neoplasms / epidemiology
Genetic Alliance.
consumer health - Mycosis fungoides
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20128983.001).
[ISSN]
1203-4754
[Journal-full-title]
Journal of cutaneous medicine and surgery
[ISO-abbreviation]
J Cutan Med Surg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
12.
Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U, Saura Grau S, Rodríguez Franco C:
Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non-Hodgkin lymphoma.
Clin Transl Oncol
; 2009 Sep;11(9):604-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-
cell
non
-
Hodgkin
lymphoma
.
BACKGROUND: The results of CHOP-21 (cyclophosphamide, doxorubicin, vincristine and prednisone given every 21 days) for the treatment of aggressive B-
cell lymphoma
have recently been improved by the addition of rituximab and by increasing the dose density.
PATIENTS AND METHODS: We present our experience with R-CHOP-14 in a retrospective single-centre review of 50 patients consecutively treated for aggressive B-
cell lymphoma
.
Stage
III-IV was present in 62% of the patients and international prognostic index was high-to-intermediate risk or high risk in 32% of the patients.
CONCLUSIONS: In our experience the combination of RCHOP- 14 is highly effective in patients with aggressive B-
cell lymphoma
.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage.
Lymphoma
, B-
Cell
/ therapy
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 1993 Sep 30;329(14 ):987-94
[
8141877.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
N Engl J Med. 1993 Apr 8;328(14):1002-6
[
7680764.001
]
[Cites]
Blood. 2004 Aug 1;104(3):634-41
[
15016643.001
]
[Cites]
J Clin Oncol. 1984 Nov;2(11):1281-8
[
6387060.001
]
[Cites]
Acta Haematol. 2006;115(1-2):22-7
[
16424645.001
]
[Cites]
Hematol Oncol. 2008 Mar;26(1):27-32
[
17868190.001
]
[Cites]
Leuk Lymphoma. 2005 Apr;46(4):541-7
[
16019482.001
]
[Cites]
Blood. 2004 Aug 1;104(3):626-33
[
14982884.001
]
[Cites]
J Clin Oncol. 2006 Jul 1;24(19):3121-7
[
16754935.001
]
[Cites]
N Engl J Med. 1992 Nov 5;327(19):1342-9
[
1383819.001
]
[Cites]
Haematologica. 2006 Apr;91(4):496-502
[
16537117.001
]
[Cites]
N Engl J Med. 2002 Jan 24;346(4):235-42
[
11807147.001
]
[Cites]
Lancet Oncol. 2006 May;7(5):379-91
[
16648042.001
]
[Cites]
Lancet Oncol. 2008 Feb;9(2):105-16
[
18226581.001
]
(PMID = 19776000.001).
[ISSN]
1699-3055
[Journal-full-title]
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[ISO-abbreviation]
Clin Transl Oncol
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
13.
Khodabakhshi R, Yahyazadeh-Jabbari SH, Gohari MR, Shahidi J, Ameri A:
Treatment and prognosis of epithelial ovarian cancer: five year multi-center study.
Saudi Med J
; 2008 Dec;29(12):1735-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: From a total of 98 patients, there were 81 (82.6%) epithelial, 12 (12.2%) germ
cell
, 4 (4.1%) granulosa
cell
tumors, and one case of
lymphoma
.
Stage
III was the most common
stage
(44.9%).
The most important prognostic factors were the initial
stage
(p=0.034), and the extent of surgical procedure (p=0.045).
[MeSH-major]
Neoplasms, Germ
Cell
and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
Genetic Alliance.
consumer health - Ovarian cancer
.
Genetic Alliance.
consumer health - Ovarian epithelial cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19082223.001).
[ISSN]
0379-5284
[Journal-full-title]
Saudi medical journal
[ISO-abbreviation]
Saudi Med J
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
Saudi Arabia
14.
Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A:
Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.
J Clin Oncol
; 2010 Dec 1;28(34):5074-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dose intensity of chemotherapy in patients with relapsed
Hodgkin
's
lymphoma
.
PURPOSE: High-dose chemotherapy (HDCT) followed by autologous stem-
cell
transplantation (PBSCT) has become the standard treatment for patients with relapsed
Hodgkin
's
lymphoma
(HL).
Patients with
stage
IV, early relapse, multiple relapse, anemia, or B symptoms had a higher risk of recurrence (P < .001).
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Hodgkin
Disease / drug therapy. Neoplasm Recurrence, Local / drug therapy
[MeSH-minor]
Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Humans. Kaplan-Meier Estimate. Methotrexate / administration & dosage. Methotrexate / adverse effects. Peripheral Blood Stem
Cell
Transplantation. Prognosis
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20975066.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
15.
Nemajerova A, Palacios G, Nowak NJ, Matsui S, Petrenko O:
Targeted deletion of p73 in mice reveals its role in T cell development and lymphomagenesis.
PLoS One
; 2009;4(11):e7784
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Targeted deletion of p73 in mice reveals its role in T
cell
development and lymphomagenesis.
We show here that p73 acts as a T
cell
-specific tumor suppressor in a genetically defined mouse model, and that concomitant ablation of p53 and p73 predisposes mice to an increased incidence of thymic lymphomas compared to the loss of p53 alone.
Our results demonstrate a causal role for loss of p73 in progression of T
cell
lymphomas to the
stage
of aggressive, disseminated disease.
We provide evidence that tumorigenesis in mice lacking p53 and p73 proceeds through mechanisms involving altered patterns of gene expression, defects in early T
cell
development, impaired apoptosis, and the ensuing accumulation of chromosomal aberrations.
Collectively, our data imply that tumor suppressive properties of p73 are highly dependent on cellular context, wherein p73 plays a major role in T
cell
development and neoplasia.
[MeSH-major]
DNA-Binding Proteins / genetics. Gene Deletion.
Lymphoma
/ metabolism. Nuclear Proteins / genetics. T-Lymphocytes / cytology. Tumor Suppressor Proteins / genetics
MedlinePlus Health Information.
consumer health - Lymphoma
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 2000 Mar 2;404(6773):99-103
[
10716451.001
]
[Cites]
Mutat Res. 2009 Jan 15;660(1-2):22-32
[
19000702.001
]
[Cites]
Nature. 2002 Apr 4;416(6880):560-4
[
11932750.001
]
[Cites]
Cell. 2002 Apr;109 Suppl:S45-55
[
11983152.001
]
[Cites]
Nat Rev Cancer. 2002 Aug;2(8):605-15
[
12154353.001
]
[Cites]
Int J Cancer. 2002 Nov 1;102(1):15-9
[
12353228.001
]
[Cites]
J Biol Chem. 2002 Oct 18;277(42):39156-62
[
12114514.001
]
[Cites]
Nat Immunol. 2003 Jun;4(6):533-9
[
12717433.001
]
[Cites]
Mol Cell Biol. 2003 Aug;23(16):5540-55
[
12897129.001
]
[Cites]
Leukemia. 2003 Sep;17(9):1845-50
[
12970785.001
]
[Cites]
Clin Cancer Res. 2003 Nov 15;9(15):5642-51
[
14654547.001
]
[Cites]
Clin Cancer Res. 2004 Jan 15;10(2):626-33
[
14760085.001
]
[Cites]
Nat Rev Immunol. 2004 Apr;4(4):278-89
[
15057786.001
]
[Cites]
Cancer Res. 2004 Apr 1;64(7):2449-60
[
15059898.001
]
[Cites]
Cancer Genet Cytogenet. 2004 May;151(1):36-51
[
15120909.001
]
[Cites]
Carcinogenesis. 2004 Jun;25(6):1069-75
[
14754877.001
]
[Cites]
Cancer Cell. 2004 Jul;6(1):85-9
[
15261144.001
]
[Cites]
Nature. 1992 Mar 19;356(6366):215-21
[
1552940.001
]
[Cites]
Curr Biol. 1994 Jan 1;4(1):1-7
[
7922305.001
]
[Cites]
Mol Carcinog. 1995 Sep;14(1):16-22
[
7546219.001
]
[Cites]
Genes Dev. 1996 Mar 1;10(5):553-65
[
8598286.001
]
[Cites]
Genes Dev. 1996 Aug 15;10(16):2038-54
[
8769647.001
]
[Cites]
Genes Dev. 1996 Aug 15;10(16):2055-66
[
8769648.001
]
[Cites]
Cell. 1997 Aug 22;90(4):809-19
[
9288759.001
]
[Cites]
Nature. 1997 Sep 11;389(6647):191-4
[
9296498.001
]
[Cites]
Cancer Res. 1997 Oct 1;57(19):4408-13
[
9331104.001
]
[Cites]
Cancer Res. 1999 Jul 15;59(14):3352-6
[
10416592.001
]
[Cites]
Immunity. 1999 Jul;11(1):91-101
[
10435582.001
]
[Cites]
Cancer Res. 2004 Dec 15;64(24):8882-90
[
15604248.001
]
[Cites]
Cancer Cell. 2005 Apr;7(4):363-73
[
15837625.001
]
[Cites]
Mutat Res. 2005 Aug 25;576(1-2):4-21
[
16038709.001
]
[Cites]
Oncogene. 2005 Aug 18;24(35):5521-4
[
16007185.001
]
[Cites]
Cancer Cell. 2006 Feb;9(2):109-20
[
16473278.001
]
[Cites]
Nat Rev Immunol. 2007 Jan;7(1):64-75
[
17170755.001
]
[Cites]
Nat Rev Cancer. 2007 Mar;7(3):165-8
[
17332760.001
]
[Cites]
Oncogene. 2007 Aug 9;26(36):5280-9
[
17325664.001
]
[Cites]
Mol Cell. 2007 Aug 17;27(4):647-59
[
17707235.001
]
[Cites]
Genet Med. 2007 Sep;9(9):585-95
[
17873646.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3102-11
[
17656647.001
]
[Cites]
Genes Dev. 2008 Oct 1;22(19):2677-91
[
18805989.001
]
[Cites]
EMBO J. 2002 Mar 15;21(6):1447-55
[
11889050.001
]
(PMID = 19907659.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
[Other-IDs]
NLM/ PMC2771421
16.
Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, Coluccia P, Accorsi P, Confalonieri G, Tavecchia L, Verga L, Ravagnani F, Iacone A, Pogliani EM, Pioltelli P:
Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.
Transfus Apher Sci
; 2009 Aug;41(1):33-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of poor peripheral blood stem
cell
mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.
Patients' characteristics, including age, sex,
stage
of the underlying disease (complete or partial remission), diagnosis, previously administered radio/chemotherapy regimens, time-lapse from last chemotherapy before mobilization and mobilization schedule (including dose of GF) were considered as possibly predictive of poor or failed mobilization.
Therefore, a patient who fails a first mobilization (and when an HLA-compatible related on unrelated donor is not available) could undergo a second attempt either with different mobilization schedule or by using different GF, such as stem
cell
factor, growth hormone (GH), or more recently newly introduced drugs such as AMD3100, alone or in combination with rHuG- or -rHuGM-CSF.
[MeSH-major]
Neoplasms / surgery. Peripheral Blood Stem
Cell
Transplantation / methods
[MeSH-minor]
Adult. Antigens, CD34 / blood. Follow-Up Studies. Hematopoiesis. Hematopoietic Stem
Cell
Mobilization / methods. Humans. Leukemia, Lymphocytic, Chronic, B-
Cell
/ surgery. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery. Leukemia, Myeloid, Acute / surgery.
Lymphoma
,
Non
-
Hodgkin
/ surgery. Multiple Myeloma / surgery. Retrospective Studies. Survival Analysis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19540167.001).
[ISSN]
1473-0502
[Journal-full-title]
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
[ISO-abbreviation]
Transfus. Apher. Sci.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD34
17.
Peled JU, Sellers RS, Iglesias-Ussel MD, Shin DM, Montagna C, Zhao C, Li Z, Edelmann W, Morse HC 3rd, Scharff MD:
Msh6 protects mature B cells from lymphoma by preserving genomic stability.
Am J Pathol
; 2010 Nov;177(5):2597-608
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Msh6 protects mature B cells from
lymphoma
by preserving genomic stability.
Most human B-
cell
non
-
Hodgkin
's lymphomas arise from germinal centers.
Reminiscent of the neoplasms arising in patients with Lynch syndrome III, mice deficient in MSH6 die prematurely of
lymphoma
.
In this study, we characterized the B-
cell
tumors in MSH6-deficient mice and describe their histological, immunohistochemical, and molecular features, which include moderate microsatellite instability.
Based on histological markers and gene expression, the tumor cells seem to be at or beyond the germinal center
stage
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nat Rev Immunol. 2002 Dec;2(12):920-32
[
12461565.001
]
[Cites]
N Engl J Med. 2003 Mar 6;348(10):919-32
[
12621137.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4126-31
[
12651942.001
]
[Cites]
Blood. 2003 May 1;101(9):3574-80
[
12511417.001
]
[Cites]
Immunol Rev. 2003 Aug;194:177-95
[
12846815.001
]
[Cites]
Cancer Res. 2003 Jul 15;63(14):3894-8
[
12873980.001
]
[Cites]
Curr Opin Genet Dev. 1999 Feb;9(1):89-96
[
10072354.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6850-5
[
10359802.001
]
[Cites]
Immunity. 1999 Sep;11(3):309-16
[
10514009.001
]
[Cites]
Am J Hum Genet. 1999 Nov;65(5):1291-8
[
10521294.001
]
[Cites]
Nature. 2004 Dec 2;432(7017):635-9
[
15577913.001
]
[Cites]
Nat Rev Cancer. 2005 Apr;5(4):251-62
[
15803153.001
]
[Cites]
Cancer Res. 2005 Apr 1;65(7):2626-35
[
15805259.001
]
[Cites]
J Pathol. 2005 May;206(1):76-86
[
15772984.001
]
[Cites]
Cancer Cell. 2005 May;7(5):445-55
[
15894265.001
]
[Cites]
Annu Rev Biochem. 2005;74:681-710
[
15952900.001
]
[Cites]
Oncogene. 2005 May 19;24(22):3544-53
[
15688022.001
]
[Cites]
Mol Carcinog. 2005 Dec;44(4):285-92
[
16240453.001
]
[Cites]
Fam Cancer. 2005;4(4):323-33
[
16341812.001
]
[Cites]
J Immunol. 2005 Dec 15;175(12):7837-47
[
16339519.001
]
[Cites]
J Exp Med. 2006 Jan 23;203(1):63-72
[
16380510.001
]
[Cites]
Chem Rev. 2006 Feb;106(2):302-23
[
16464007.001
]
[Cites]
Carcinogenesis. 2006 Apr;27(4):682-92
[
16332722.001
]
[Cites]
Oncologist. 2006 Apr;11(4):384-92
[
16614234.001
]
[Cites]
Oncogene. 2006 Apr 20;25(17):2531-6
[
16331258.001
]
[Cites]
Nat Rev Mol Cell Biol. 2006 May;7(5):335-46
[
16612326.001
]
[Cites]
FEBS J. 2006 Oct;273(19):4504-15
[
16956364.001
]
[Cites]
Curr Biol. 2006 Sep 19;16(18):R808-10
[
16979551.001
]
[Cites]
Clin Cancer Res. 2006 Nov 1;12(21):6379-85
[
17085649.001
]
[Cites]
Science. 2007 Jan 26;315(5811):528-31
[
17185562.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1616-20
[
17251349.001
]
[Cites]
Cancer Res. 2007 Mar 15;67(6):2439-47
[
17363561.001
]
[Cites]
Lancet Neurol. 2007 Apr;6(4):340-51
[
17362838.001
]
[Cites]
Int Immunol. 2007 Apr;19(4):545-56
[
17329233.001
]
[Cites]
Mol Cell. 2007 May 25;26(4):565-78
[
17531814.001
]
[Cites]
Mol Cell. 2007 May 25;26(4):579-92
[
17531815.001
]
[Cites]
Clin Genet. 2007 Jun;71(6):499-500
[
17539898.001
]
[Cites]
Nat Immunol. 2007 Jul;8(7):705-14
[
17558410.001
]
[Cites]
Nature. 2007 Jun 21;447(7147):966-71
[
17515920.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10956-61
[
17573527.001
]
[Cites]
Nucleic Acids Res. 2007;35(12):4114-23
[
17567610.001
]
[Cites]
J Exp Med. 2007 Aug 6;204(8):1989-98
[
17664295.001
]
[Cites]
Nat Immunol. 2007 Oct;8(10):1132-9
[
17828269.001
]
[Cites]
J Immunol. 2007 Nov 15;179(10):6808-19
[
17982071.001
]
[Cites]
Carcinogenesis. 2007 Dec;28(12):2427-33
[
17804422.001
]
[Cites]
J Immunol. 2003 Sep 15;171(6):2889-95
[
12960311.001
]
[Cites]
Mol Carcinog. 2003 Dec;38(4):155-9
[
14639654.001
]
[Cites]
Nat Immunol. 2004 Feb;5(2):224-9
[
14716311.001
]
[Cites]
Gastroenterology. 2004 Jul;127(1):17-25
[
15236168.001
]
[Cites]
J Exp Med. 2004 Jul 5;200(1):47-59
[
15238604.001
]
[Cites]
J Exp Med. 2004 Jul 5;200(1):61-8
[
15238605.001
]
[Cites]
Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):91-9
[
15264277.001
]
[Cites]
Cancer Cell. 2004 Aug;6(2):139-50
[
15324697.001
]
[Cites]
Nat Immunol. 2004 Nov;5(11):1117-23
[
15489857.001
]
[Cites]
Gene. 1994 Sep 30;147(2):157-60
[
7926794.001
]
[Cites]
Curr Biol. 1994 Jul 1;4(7):573-83
[
7953531.001
]
[Cites]
Anticancer Res. 1994 Jul-Aug;14(4B):1635-9
[
7979199.001
]
[Cites]
Science. 1995 Jun 2;268(5215):1336-8
[
7761852.001
]
[Cites]
Cell. 1995 Jul 28;82(2):321-30
[
7628020.001
]
[Cites]
Nat Genet. 1995 Sep;11(1):64-70
[
7550317.001
]
[Cites]
Cancer Res. 1996 Aug 15;56(16):3842-9
[
8706033.001
]
[Cites]
Nat Genet. 1996 Nov;14(3):312-5
[
8896561.001
]
[Cites]
Blood. 1997 Apr 1;89(7):2276-82
[
9116269.001
]
[Cites]
J Biol Chem. 1997 Oct 17;272(42):26382-7
[
9334212.001
]
[Cites]
Cell. 1997 Nov 14;91(4):467-77
[
9390556.001
]
[Cites]
Genetics. 1998 Apr;148(4):1637-46
[
9560383.001
]
[Cites]
Blood. 1998 Jun 15;91(12):4677-85
[
9616165.001
]
[Cites]
Science. 1998 Jun 12;280(5370):1750-2
[
9624052.001
]
[Cites]
Leukemia. 1998 Jun;12(6):845-59
[
9639410.001
]
[Cites]
Immunity. 1998 Jul;9(1):127-34
[
9697842.001
]
[Cites]
Eur J Hum Genet. 2008 Jan;16(1):62-72
[
17851451.001
]
[Cites]
Nat Rev Immunol. 2008 Jan;8(1):22-33
[
18097447.001
]
[Cites]
Nat Genet. 2008 Jan;40(1):108-12
[
18066064.001
]
[Cites]
Nature. 2008 Feb 14;451(7180):841-5
[
18273020.001
]
[Cites]
Annu Rev Immunol. 2008;26:481-511
[
18304001.001
]
[Cites]
Annu Rev Immunol. 2008;26:261-92
[
18370922.001
]
[Cites]
Biochemistry. 2008 Jun 10;47(23):6199-207
[
18484749.001
]
[Cites]
PLoS Genet. 2008 Jun;4(6):e1000092
[
18551179.001
]
[Cites]
J Immunol. 2008 Jul 15;181(2):1299-306
[
18606684.001
]
[Cites]
DNA Repair (Amst). 2008 Aug 2;7(8):1392-8
[
18562254.001
]
[Cites]
Oncogene. 2008 Aug 7;27(34):4752-6
[
18408759.001
]
[Cites]
Hum Genet. 2008 Sep;124(2):105-22
[
18709565.001
]
[Cites]
J Exp Med. 2008 Sep 1;205(9):1949-57
[
18678733.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16248-53
[
18854411.001
]
[Cites]
DNA Repair (Amst). 2009 Jan 1;8(1):137-41
[
18952008.001
]
[Cites]
Genet Med. 2009 Jan;11(1):42-65
[
19125127.001
]
[Cites]
Blood. 2009 Jul 16;114(3):547-54
[
19478044.001
]
[Cites]
J Immunol. 2009 Sep 1;183(5):3188-94
[
19648273.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18698-703
[
19837692.001
]
[Cites]
Nat Rev Clin Oncol. 2010 Apr;7(4):197-208
[
20177404.001
]
[Cites]
Haematologica. 2010 May;95(5):841-4
[
20015892.001
]
[Cites]
Nat Genet. 1999 Nov;23(3):359-62
[
10545954.001
]
[Cites]
J Exp Med. 2000 Feb 7;191(3):579-84
[
10662804.001
]
[Cites]
Blood. 2000 Mar 1;95(5):1767-72
[
10688836.001
]
[Cites]
Lab Invest. 2000 Feb;80(2):159-69
[
10701686.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):803-7
[
10706084.001
]
[Cites]
Blood. 2000 Apr 15;95(8):2719-21
[
10753856.001
]
[Cites]
Leuk Res. 2000 Aug;24(8):719-32
[
10936424.001
]
[Cites]
Cell. 2000 Sep 1;102(5):553-63
[
11007474.001
]
[Cites]
Cell. 2000 Sep 1;102(5):565-75
[
11007475.001
]
[Cites]
J Exp Med. 2000 Dec 18;192(12):1833-40
[
11120779.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
[
11309499.001
]
[Cites]
Nature. 2001 Jul 19;412(6844):341-6
[
11460166.001
]
[Cites]
Cancer Res. 2001 Nov 1;61(21):7934-42
[
11691815.001
]
[Cites]
Am J Hum Genet. 2002 Jan;70(1):26-37
[
11709755.001
]
[Cites]
Bioinformatics. 2002 Jan;18(1):207-8
[
11836235.001
]
[Cites]
J Exp Med. 2002 May 6;195(9):1187-92
[
11994423.001
]
[Cites]
J Exp Med. 2002 May 6;195(9):1193-8
[
11994424.001
]
[Cites]
Blood. 2002 Jul 1;100(1):246-58
[
12070034.001
]
(PMID = 20934970.001).
[ISSN]
1525-2191
[Journal-full-title]
The American journal of pathology
[ISO-abbreviation]
Am. J. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30CA013330; United States / NCI NIH HHS / CA / CA072649-13; United States / NCI NIH HHS / CA / R01-CA72649; United States / NCI NIH HHS / CA / R01 CA072649-13; United States / NCI NIH HHS / CA / R01 CA093484; United States / NCI NIH HHS / CA / R01-CA102705; United States / NCI NIH HHS / CA / R01 CA076329; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA102705; United States / NCI NIH HHS / CA / R01 CA102705-08; United States / NCI NIH HHS / CA / R01-CA76329; United States / NIGMS NIH HHS / GM / T32 GM007288; United States / NCI NIH HHS / CA / R01 CA072649; United States / NCI NIH HHS / CA / R01-CA93484; United States / NCI NIH HHS / CA / CA102705-08; United States / NCI NIH HHS / CA / P30 CA013330; United States / NIGMS NIH HHS / GM / T32-GM007288
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
[Other-IDs]
NLM/ PMC2966815
18.
Blijlevens NM, Donnelly JP, de Pauw BE:
Microbiologic consequences of new approaches to managing hematologic malignancies.
Rev Clin Exp Hematol
; 2005 Dec;9(2):E2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
With the growing use of potent immunosuppressive purine analogues, fludarabine, pentostatin and cladibrine, and anti-T and anti-
B cell
antibodies, such as rituximab and campath, in the management of lymphoreticular malignancies, in combination with increasing emphasis on dose intensity, the number of patients at risk has almost reached levels encountered in recipients of allogenic stem
cell
grafts as a consequence of long-lasting deficiencies in the cellular immunity.
The spectrum of opportunistic pathogens are shifting as anti-leukemic and anti-
lymphoma
therapy become more intensive and bone marrow transplant practices evolve.
During the past decades we have even observed an increased incidence of invasive fungal infections in patients who are not in an end
stage
of their underlying disease.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16864116.001).
[ISSN]
1825-151X
[Journal-full-title]
Reviews in clinical and experimental hematology
[ISO-abbreviation]
Rev Clin Exp Hematol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Italy
[Chemical-registry-number]
0 / Immunosuppressive Agents
[Number-of-references]
85
19.
Nguyen XC, Lee WW, Amin AM, Eo JS, Bang SM, Lee JS, Kim SE:
Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-cell Lymphoma.
Nucl Med Mol Imaging
; 2010 Apr;44(1):39-44
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tumor Burden Assessed by the Maximum Standardized Uptake Value and Greatest Diameter on FDG-PET Predicts Prognosis in Untreated Diffuse Large B-
cell Lymphoma
.
PURPOSE: It is uncertain whether the tumor burden as assessed using FDG-PET has prognostic significance in newly diagnosed diffuse large B-
cell lymphoma
(DLBCL).
MATERIALS AND METHODS: Forty-two DLBCL patients (age, 57.4 ± 15.5 years; male/female = 25/17;
stage I
/II/III/IV=5/17/10/10) who underwent FDG-PET before chemotherapy were enrolled.
Among six variables [Ann Arbor
stage
, %Ki-67 expression, International Prognostic Index (IPI), MaxSUV, greatest diameter, and SIMaxSUV] investigated, only SIMaxSUV was found to be a single determinant of progression-free and overall survivals by multivariate analyses (p < 0.05).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 24899936.001).
[ISSN]
1869-3474
[Journal-full-title]
Nuclear medicine and molecular imaging
[ISO-abbreviation]
Nucl Med Mol Imaging
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC4042962
[Keywords]
NOTNLM ; FDG-PET / Greatest diameter / Lymphoma / Prognosis / SUV / Size-incorporated maxSUV
20.
Nosari A, Tedeschi A, Ricci F, Montillo M:
Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.
Haematologica
; 2008 Feb;93(2):e30-1
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Characteristics and
stage
of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.
We have treated 67 patients, 8
non
-
Hodgkin
's
lymphoma
and 59 chronic lymphocytic leukemia (CLL) with campath.
[MeSH-minor]
Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized.
Cell
Count. Drug Administration Schedule. Female. Humans. Immune System / cytology. Male. Middle Aged. Remission Induction. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Haematologica. 2007 Jun;92(6):784-94
[
17550851.001
]
(PMID = 18245646.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
21.
Shanafelt TD, Rabe KG, Kay NE, Zent CS, Call TG, Slager SL, Bowen DA, Schwager SM, Nowakowski GS:
Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia.
Leuk Lymphoma
; 2010 Jul;51(7):1233-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Statin and
non
-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai
stage
0 chronic lymphocytic leukemia.
Statins and
non
-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications.
In vitro studies suggest that statins and NSAIDs may have potential as anticancer therapies in low-grade
non
-
Hodgkin
lymphomas including chronic lymphocytic leukemia (CLL), and a recent observational study found statin use was associated with improved event free survival in patients with follicular
lymphoma
.
We therefore conducted an observational cohort study of 686 patients with newly diagnosed Rai
stage
0 CLL to evaluate whether statin or NSAID use was related to their clinical outcome or influenced the efficacy of rituximab therapy.
Although previous studies suggested statins may improve event free survival among patients with follicular
lymphoma
, we find no impact of statins on time to initial therapy in this large study of patients with Rai
stage
0 CLL.
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
MedlinePlus Health Information.
consumer health - Statins
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Haematol. 2007 Nov;139(3):398-404
[
17910629.001
]
[Cites]
Leuk Lymphoma. 2007 Dec;48(12):2412-7
[
18067017.001
]
[Cites]
Cancer Immunol Immunother. 2008 Mar;57(3):347-58
[
17668203.001
]
[Cites]
Leuk Lymphoma. 2008 Jan;49(1):49-56
[
18203011.001
]
[Cites]
Invest New Drugs. 2008 Apr;26(2):139-49
[
18094935.001
]
[Cites]
PLoS Med. 2008 Mar 25;5(3):e64
[
18366248.001
]
[Cites]
Atherosclerosis. 2008 Apr;197(2):829-39
[
17826781.001
]
[Cites]
Br J Haematol. 2008 May;141(5):615-21
[
18373706.001
]
[Cites]
Br J Haematol. 2008 May;141(5):607-14
[
18384436.001
]
[Cites]
Ann Pharmacother. 2008 Sep;42(9):1208-15
[
18648016.001
]
[Cites]
J Clin Oncol. 2008 Nov 20;26(33):5486; author reply 5486
[
18936467.001
]
[Cites]
Leukemia. 2008 Dec;22(12):2184-92
[
18784741.001
]
[Cites]
N Engl J Med. 2009 Jan 8;360(2):192; author reply 193
[
19129537.001
]
[Cites]
Lancet. 2009 Apr 11;373(9671):1301-9
[
19328542.001
]
[Cites]
J Clin Oncol. 2010 Jan 20;28(3):412-7
[
20008638.001
]
[Cites]
JAMA. 2002 Jan 16;287(3):337-44
[
11790213.001
]
[Cites]
Br J Haematol. 2001 Dec;115(4):854-61
[
11843819.001
]
[Cites]
Cancer Res. 2002 Oct 15;62(20):5711-9
[
12384529.001
]
[Cites]
Br J Haematol. 2003 Apr;121(2):287-95
[
12694251.001
]
[Cites]
Exp Hematol. 2003 Sep;31(9):779-83
[
12962723.001
]
[Cites]
Int J Oncol. 2003 Oct;23(4):1055-69
[
12963986.001
]
[Cites]
Exp Cell Res. 1984 Jul;153(1):91-8
[
6610562.001
]
[Cites]
Biochem Biophys Res Commun. 1994 Mar 30;199(3):1209-15
[
8147861.001
]
[Cites]
Lipids. 1997 Mar;32(3):255-62
[
9076662.001
]
[Cites]
Blood. 1998 Aug 15;92(4):1406-14
[
9694730.001
]
[Cites]
Atheroscler Suppl. 2004 Oct;5(3):67-80
[
15531278.001
]
[Cites]
J Clin Invest. 2005 Apr;115(4):959-68
[
15776112.001
]
[Cites]
Blood. 2005 Jul 15;106(2):650-7
[
15802535.001
]
[Cites]
Leukemia. 2005 Jul;19(7):1216-23
[
15858619.001
]
[Cites]
Clin Immunol. 2006 Jul;120(1):76-90
[
16473553.001
]
[Cites]
J Clin Oncol. 2006 Jul 1;24(19):3218-9; author reply 3219-20
[
16809747.001
]
[Cites]
Leuk Lymphoma. 2006 Jun;47(6):1053-61
[
16840197.001
]
[Cites]
J Clin Oncol. 2006 Oct 1;24(28):4634-41
[
17008705.001
]
[Cites]
Leuk Lymphoma. 2006 Dec;47(12):2625-34
[
17169808.001
]
[Cites]
Immunology. 2007 Mar;120(3):315-24
[
17140403.001
]
[Cites]
Cancer Chemother Pharmacol. 2007 Sep;60(4):545-53
[
17186240.001
]
(PMID = 20496995.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / K23 CA113408; United States / NCI NIH HHS / CA / CA113408
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 4F4X42SYQ6 / Rituximab
[Other-IDs]
NLM/ NIHMS549713; NLM/ PMC3913168
22.
[Case report of synchronous manifestation of two malignant tumors--cervical cancer and malignant lymphoma].
Akush Ginekol (Sofiia)
; 2010;49(5):64-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Case report of synchronous manifestation of two malignant tumors--cervical cancer and malignant
lymphoma
].
Affected lymph nodes in cervical cancer is different and depends on the
stage
and histological type of tumor (squamous and adenocarcinoma) and is an important prognostic factor.
Malignant
non
-
Hodgkin
's
lymphoma
populations (NHL) originale from the lymph organs and from their populations downstream lymphoid Stem
cell
to mature lymphocytes that have opportunities for transformation and proliferation.
We present the random case developed cervical cancer and malignant
lymphoma
.
[MeSH-major]
Lymphoma
/ pathology. Uterine Cervical Neoplasms / pathology
Genetic Alliance.
consumer health - Cervical cancer
.
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21268405.001).
[ISSN]
0324-0959
[Journal-full-title]
Akusherstvo i ginekologii︠a︡
[ISO-abbreviation]
Akush Ginekol (Sofiia)
[Language]
bul
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Bulgaria
23.
Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen S, Cathomas R:
Primary manifestation of small lymphocytic lymphoma in the prostate.
Onkologie
; 2009 Oct;32(10):586-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary manifestation of small lymphocytic
lymphoma
in the prostate.
BACKGROUND: Infiltration of
non
-haematopoietic organs by small lymphocytic
lymphoma
/chronic lymphocytic leukaemia (SLL/CLL) is not unusual in late-
stage
disease and thus quite frequently encountered in post-mortem examinations.
[MeSH-major]
Leukemia, Lymphocytic, Chronic, B-
Cell
/ pathology. Leukemia, Lymphocytic, Chronic, B-
Cell
/ therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 S. Karger AG, Basel.
[CommentIn]
Onkologie. 2009 Oct;32(10):550-1
[
19816069.001
]
(PMID = 19816076.001).
[ISSN]
1423-0240
[Journal-full-title]
Onkologie
[ISO-abbreviation]
Onkologie
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Switzerland
[Number-of-references]
17
24.
Pedersen LM, Jürgensen GW, Johnsen HE:
Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-cell lymphoma.
Br J Haematol
; 2005 Mar;128(6):813-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Serum levels of inflammatory cytokines at diagnosis correlate to the bcl-6 and CD10 defined germinal centre (GC) phenotype and bcl-2 expression in patients with diffuse large B-
cell lymphoma
.
Circulating inflammatory cytokines have a prognostic impact independent of the information provided by the International Prognostic Index (IPI) in diffuse large B-
cell lymphoma
(DLBCL).
The present study characterized prognostic cytokines in relation to
stage
-specific B-
cell
differentiation antigens and bcl-2 protein expression, assessed by immunohistochemistry in
de
novo DLBCL.
Serum levels of interleukin 6 (IL-6) and tumour necrosis factor alpha (TNF-alpha) were found to be significantly lower in patients with a germinal centre (GC) phenotype (co-expression of bcl-6 and CD10) compared with the
non
-GC phenotype.
However, IL-6 and VEGF, combined with
non
-GC phenotype and bcl-2 positivity, respectively, had a similar independent prognostic power as the IPI.
In conclusion, our data suggest that inflammatory cytokines are differently distributed in the GC and
non
-GC phenotypes and correlate to bcl-2 expression.
[MeSH-major]
Cytokines / metabolism. DNA-Binding Proteins / metabolism.
Lymphoma
, B-
Cell
/ blood.
Lymphoma
, Large B-
Cell
, Diffuse / blood. Neprilysin / metabolism. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Transcription Factors / metabolism
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15755285.001).
[ISSN]
0007-1048
[Journal-full-title]
British journal of haematology
[ISO-abbreviation]
Br. J. Haematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Cytokines; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.11 / Neprilysin
25.
Fujita Y, Abe R, Sasaki M, Honda A, Furuichi M, Asano Y, Norisugi O, Shimizu T, Shimizu H:
Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides.
Clin Cancer Res
; 2006 May 1;12(9):2670-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early
stage
of mycosis fungoides.
PURPOSE: Mycosis fungoides (MF), a common type of cutaneous T
cell lymphoma
with an indolent clinical course, has the characteristic that malignant T
cell
clones are recruited into the skin from the early disease stages.
Recently, CCR10 and CTACK/CCL27 were proposed to play a role in the recruitment of other types of cutaneous T
cell lymphoma
.
Genetic Alliance.
consumer health - Mycosis fungoides
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16675558.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / CCL27 protein, human; 0 / CCR10 protein, human; 0 / Chemokine CCL27; 0 / Chemokines, CC; 0 / Receptors, CCR10; 0 / Receptors, Chemokine
26.
Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH:
Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
J Am Coll Nutr
; 2007 Feb;26(1):49-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and
non
-
Hodgkin
's
lymphoma
.
OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and
Non
-
Hodgkin
's
lymphoma
(NHL).
Comparisons were made to
stage
of treatment (maintenance 6 with post-therapy), type of treatment (chemotherapy and radiation with only chemotherapy) and type of malignancy (ALL with NHL).
[MeSH-major]
Lymphoma
,
Non
-
Hodgkin
/ blood. Nutritional Status. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Acute Non Lymphoblastic Leukemia
.
Genetic Alliance.
consumer health - Lymphoblastic lymphoma
.
MedlinePlus Health Information.
consumer health - Vitamin A
.
Hazardous Substances Data Bank.
CHOLESTEROL
.
Hazardous Substances Data Bank.
VITAMIN A
.
Hazardous Substances Data Bank.
ZINC, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17353583.001).
[ISSN]
0731-5724
[Journal-full-title]
Journal of the American College of Nutrition
[ISO-abbreviation]
J Am Coll Nutr
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Hemoglobins; 0 / Serum Albumin; 0 / Trace Elements; 0 / Vitamins; 11103-57-4 / Vitamin A; 97C5T2UQ7J / Cholesterol; J41CSQ7QDS / Zinc
27.
Valsami S, Pappa V, Rontogianni D, Kontsioti F, Papageorgiou E, Dervenoulas J, Karmiris T, Papageorgiou S, Harhalakis N, Xiros N, Nikiforakis E, Economopoulos T:
A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin's lymphoma: a potential prognostic role of MUM1/IRF4.
Haematologica
; 2007 Oct;92(10):1343-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A clinicopathological study of B-
cell
differentiation markers and transcription factors in classical
Hodgkin
's
lymphoma
: a potential prognostic role of MUM1/IRF4.
BACKGROUND AND OBJECTIVES: Although most patients with classical
Hodgkin
's
lymphoma
(CHL) are cured, a significant minority are refractory to treatment.
The aim of our study was to detect B-
cell
differentiation markers and transcription factors in CHL in order to define subgroups with different histogeneses and prognoses.
DESIGN AND METHODS: We evaluated 107 cases of CHL for BCL6, CD79a, MUM1/IRF4 and B-
cell
transcription factors BOB.1, OCT.2 expression by immunohistochemistry.
Univariate analysis showed that age of 45 or more,
stage
III and IV disease and MUM/IRF4 negative status were associated with significantly shorter time to progression (TTP) and overall survival (OS).
[MeSH-major]
Cell
Differentiation.
Hodgkin
Disease / metabolism.
Hodgkin
Disease / pathology. Interferon Regulatory Factors / metabolism.
Lymphoma
, B-
Cell
/ metabolism.
Lymphoma
, B-
Cell
/ pathology. Transcription Factors / metabolism
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17768115.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Biomarkers; 0 / Interferon Regulatory Factors; 0 / Transcription Factors; 0 / interferon regulatory factor-4
28.
Lee YS, Dutta A:
MicroRNAs in cancer.
Annu Rev Pathol
; 2009;4:199-227
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The pattern of miRNA expression can be correlated with cancer type,
stage
, and other clinical variables, so miRNA profiling can be used as a tool for cancer diagnosis and prognosis. miRNA expression analyses also suggest oncogenic (or tumor-suppressive) roles of miRNAs. miRNAs play roles in almost all aspects of cancer biology, such as proliferation, apoptosis, invasion/metastasis, and angiogenesis.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Cell Biol. 2007 Mar;27(6):2240-52
[
17242205.001
]
[Cites]
Cancer Res. 2007 Mar 1;67(5):2345-50
[
17332367.001
]
[Cites]
J Biol Chem. 2007 Mar 16;282(11):8256-64
[
17220301.001
]
[Cites]
J Biol Chem. 2005 Apr 29;280(17):16635-41
[
15722555.001
]
[Cites]
J Cell Physiol. 2005 Jul;204(1):280-5
[
15648093.001
]
[Cites]
Trends Genet. 2005 Jun;21(6):322-6
[
15922829.001
]
[Cites]
Immunol Cell Biol. 2007 Aug-Sep;85(6):458-62
[
17621315.001
]
[Cites]
Oncogene. 2007 Sep 6;26(41):6099-105
[
17384677.001
]
[Cites]
Oncogene. 2007 Sep 13;26(42):6133-40
[
17404574.001
]
[Cites]
Nature. 2005 Jun 9;435(7043):839-43
[
15944709.001
]
[Cites]
Nat Cell Biol. 2005 Jul;7(7):719-23
[
15937477.001
]
[Cites]
Nat Genet. 2005 Jul;37(7):766-70
[
15965474.001
]
[Cites]
Science. 2005 Jul 8;309(5732):310-1
[
15919954.001
]
[Cites]
Cancer Res. 2005 Jul 15;65(14):6029-33
[
16024602.001
]
[Cites]
Science. 2001 Oct 26;294(5543):858-62
[
11679671.001
]
[Cites]
Science. 2001 Oct 26;294(5543):862-4
[
11679672.001
]
[Cites]
Science. 2002 Sep 20;297(5589):2056-60
[
12154197.001
]
[Cites]
Genes Dev. 2002 Oct 1;16(19):2491-6
[
12368260.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9
[
12434020.001
]
[Cites]
Science. 2002 Dec 20;298(5602):2283
[
12493874.001
]
[Cites]
RNA. 2003 Mar;9(3):277-9
[
12592000.001
]
[Cites]
Nature. 2003 Sep 25;425(6956):415-9
[
14508493.001
]
[Cites]
Cell. 2003 Oct 17;115(2):199-208
[
14567917.001
]
[Cites]
Cell. 2003 Oct 17;115(2):209-16
[
14567918.001
]
[Cites]
Mol Cancer Res. 2003 Oct;1(12):882-91
[
14573789.001
]
[Cites]
Genes Chromosomes Cancer. 2004 Feb;39(2):167-9
[
14695998.001
]
[Cites]
Cell. 2003 Dec 26;115(7):787-98
[
14697198.001
]
[Cites]
Genes Dev. 2003 Dec 15;17(24):3011-6
[
14681208.001
]
[Cites]
Science. 2004 Jan 2;303(5654):95-8
[
14631048.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
[
14973191.001
]
[Cites]
Science. 2004 Apr 30;304(5671):734-6
[
15118162.001
]
[Cites]
Cancer Res. 2004 May 1;64(9):3087-95
[
15126345.001
]
[Cites]
Cancer Res. 2004 Jun 1;64(11):3753-6
[
15172979.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60
[
15284443.001
]
[Cites]
Genome Res. 2004 Oct;14(10A):1902-10
[
15364901.001
]
[Cites]
EMBO J. 2004 Oct 13;23(20):4051-60
[
15372072.001
]
[Cites]
Mol Cell Biol. 1989 Jun;9(6):2657-64
[
2548084.001
]
[Cites]
Cell. 1993 Dec 3;75(5):843-54
[
8252621.001
]
[Cites]
Cell. 1993 Dec 3;75(5):855-62
[
8252622.001
]
[Cites]
Nature. 1998 Feb 19;391(6669):806-11
[
9486653.001
]
[Cites]
Trends Biochem Sci. 1998 Jun;23(6):198-9
[
9644970.001
]
[Cites]
Nature. 2004 Nov 11;432(7014):235-40
[
15531877.001
]
[Cites]
Nature. 2004 Nov 11;432(7014):231-5
[
15531879.001
]
[Cites]
Nature. 2004 Nov 11;432(7014):226-30
[
15538371.001
]
[Cites]
RNA. 2004 Dec;10(12):1957-66
[
15525708.001
]
[Cites]
Cell. 2005 Jan 14;120(1):15-20
[
15652477.001
]
[Cites]
Cell. 2005 Jan 14;120(1):21-4
[
15652478.001
]
[Cites]
Nature. 2005 Feb 17;433(7027):769-73
[
15685193.001
]
[Cites]
Cancer Sci. 2005 Feb;96(2):111-5
[
15723655.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32
[
15738415.001
]
[Cites]
Cell. 2005 Mar 11;120(5):623-34
[
15766526.001
]
[Cites]
Cell. 2005 Mar 11;120(5):635-47
[
15766527.001
]
[Cites]
Nature. 2005 Mar 17;434(7031):338-45
[
15735639.001
]
[Cites]
Cancer Res. 2007 Sep 15;67(18):8433-8
[
17823410.001
]
[Cites]
Cancer Res. 2007 Sep 15;67(18):8699-707
[
17875710.001
]
[Cites]
Blood. 2007 Oct 1;110(7):2631-40
[
17586726.001
]
[Cites]
RNA. 2007 Oct;13(10):1668-74
[
17698639.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15484-9
[
17855557.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15472-7
[
17875987.001
]
[Cites]
Cancer Res. 2007 Oct 1;67(19):8994-9000
[
17908999.001
]
[Cites]
Dev Biol. 2007 Oct 15;310(2):442-53
[
17765889.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10
[
17890317.001
]
[Cites]
Cancer Sci. 2007 Dec;98(12):1845-52
[
17888029.001
]
[Cites]
Cancer Sci. 2007 Dec;98(12):1914-20
[
17892514.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Sep 9;334(4):1351-8
[
16039986.001
]
[Cites]
Cancer Res. 2005 Aug 15;65(16):7065-70
[
16103053.001
]
[Cites]
Cell. 2005 Aug 26;122(4):553-63
[
16122423.001
]
[Cites]
Science. 2005 Sep 2;309(5740):1577-81
[
16141076.001
]
[Cites]
J Pathol. 2005 Oct;207(2):243-9
[
16041695.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9
[
16166262.001
]
[Cites]
J Biol Chem. 2007 Jan 26;282(4):2135-43
[
17135249.001
]
[Cites]
J Biol Chem. 2007 Jan 26;282(4):2130-4
[
17135268.001
]
[Cites]
Int J Cancer. 2007 Mar 1;120(5):1046-54
[
17149698.001
]
[Cites]
Genes Chromosomes Cancer. 2007 Apr;46(4):336-47
[
17243163.001
]
[Cites]
Mol Cell Biol. 2007 Mar;27(5):1859-67
[
17194750.001
]
[Cites]
Cancer Res. 2007 Feb 15;67(4):1419-23
[
17308078.001
]
[Cites]
Cancer Res. 2007 Feb 15;67(4):1424-9
[
17308079.001
]
[Cites]
Leuk Lymphoma. 2007 Feb;48(2):410-2
[
17325905.001
]
[Cites]
Nature. 2005 Dec 1;438(7068):685-9
[
16258535.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19075-80
[
16365291.001
]
[Cites]
Nucleic Acids Res. 2006;34(2):e9
[
16434699.001
]
[Cites]
Cancer Res. 2006 Feb 1;66(3):1277-81
[
16452179.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
[
16461460.001
]
[Cites]
Gene Ther. 2006 Mar;13(6):496-502
[
16195701.001
]
[Cites]
Cancer Cell. 2006 Mar;9(3):189-98
[
16530703.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92
[
16505370.001
]
[Cites]
Cell. 2006 Mar 24;124(6):1169-81
[
16564011.001
]
[Cites]
Nucleic Acids Res. 2006;34(6):1765-71
[
16582102.001
]
[Cites]
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2014-24
[
16609010.001
]
[Cites]
Oncogene. 2006 Apr 20;25(17):2537-45
[
16331254.001
]
[Cites]
Gene. 2006 May 10;372:137-41
[
16503100.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9
[
16641092.001
]
[Cites]
Nature. 2006 May 25;441(7092):537-41
[
16724069.001
]
[Cites]
Endocr Relat Cancer. 2006 Jun;13(2):497-508
[
16728577.001
]
[Cites]
Cell. 2006 Jun 2;125(5):887-901
[
16751099.001
]
[Cites]
Gastroenterology. 2006 Jun;130(7):2113-29
[
16762633.001
]
[Cites]
Cancer Cell. 2006 Jun;9(6):435-43
[
16766263.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41
[
16754881.001
]
[Cites]
Cancer Res. 2006 Jun 15;66(12):6097-104
[
16778182.001
]
[Cites]
Nat Genet. 2006 Jul;38(7):813-8
[
16751773.001
]
[Cites]
RNA. 2006 Jul;12(7):1161-7
[
16738409.001
]
[Cites]
Genes Dev. 2006 Aug 15;20(16):2202-7
[
16882971.001
]
[Cites]
Mol Cancer. 2006;5:29
[
16854228.001
]
[Cites]
Nat Genet. 2006 Sep;38(9):1060-5
[
16878133.001
]
[Cites]
J Cell Biol. 2006 Aug 28;174(5):677-87
[
16923828.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Sep;91(9):3584-91
[
16822819.001
]
[Cites]
Biochem Biophys Res Commun. 2006 Oct 13;349(1):59-68
[
16934749.001
]
[Cites]
Mol Cancer. 2006;5:24
[
16784538.001
]
[Cites]
Cancer Res. 2006 Sep 15;66(18):9090-8
[
16982751.001
]
[Cites]
J Cell Biochem. 2006 Oct 15;99(3):671-8
[
16924677.001
]
[Cites]
J Clin Oncol. 2006 Oct 10;24(29):4677-84
[
16966691.001
]
[Cites]
Mol Cell Biol. 2006 Nov;26(21):8191-201
[
16940181.001
]
[Cites]
Cancer Res. 2006 Nov 15;66(22):10843-8
[
17108120.001
]
[Cites]
PLoS Biol. 2006 Jul;4(7):e210
[
16756390.001
]
[Cites]
J Cell Physiol. 2007 Feb;210(2):370-7
[
17111382.001
]
[Cites]
Nat Struct Mol Biol. 2006 Dec;13(12):1097-101
[
17099701.001
]
[Cites]
Cancer Res. 2006 Dec 15;66(24):11590-3
[
17178851.001
]
[Cites]
J Virol. 2007 Jan;81(2):1033-6
[
17079300.001
]
[Cites]
J Biol Chem. 2007 Jan 12;282(2):1479-86
[
17110380.001
]
[Cites]
Cell Cycle. 2006 Dec;5(24):2835-8
[
17172864.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19983-8
[
18056640.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6
[
18056805.001
]
[Cites]
RNA. 2008 Jan;14(1):35-42
[
18025253.001
]
[Cites]
Cancer Res. 2007 Dec 15;67(24):11612-20
[
18089790.001
]
[Cites]
Immunity. 2007 Dec;27(6):825-7
[
18093533.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20350-5
[
18077375.001
]
[Cites]
Science. 2007 Dec 21;318(5858):1931-4
[
18048652.001
]
[Cites]
Methods. 2008 Jan;44(1):22-30
[
18158129.001
]
[Cites]
Cancer Res. 2007 Mar 15;67(6):2456-68
[
17363563.001
]
[Cites]
Science. 2007 Mar 16;315(5818):1576-9
[
17322030.001
]
[Cites]
Genome Biol. 2007;8(2):R27
[
17326821.001
]
[Cites]
Retrovirology. 2007;4:5
[
17442096.001
]
[Cites]
Mol Endocrinol. 2007 May;21(5):1132-47
[
17312270.001
]
[Cites]
Nat Genet. 2007 May;39(5):673-7
[
17401365.001
]
[Cites]
Nat Cell Biol. 2005 Jun;7(6):633-6
[
15908945.001
]
[Cites]
Nature. 2005 Jun 9;435(7043):828-33
[
15944707.001
]
[Cites]
Nature. 2005 Jun 9;435(7043):834-8
[
15944708.001
]
[Cites]
Mol Cancer. 2007;6:5
[
17222355.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1604-9
[
17242365.001
]
[Cites]
Cancer Res. 2007 Feb 1;67(3):976-83
[
17283129.001
]
[Cites]
Science. 2001 Aug 3;293(5531):834-8
[
11452083.001
]
[Cites]
Science. 2001 Oct 26;294(5543):853-8
[
11679670.001
]
[Cites]
Methods. 2008 Jan;44(1):31-8
[
18158130.001
]
[Cites]
Cell. 2007 Dec 28;131(7):1273-86
[
18155131.001
]
[Cites]
Genome Biol. 2007;8(8):R166
[
17697356.001
]
[Cites]
Nat Rev Genet. 2008 Feb;9(2):102-14
[
18197166.001
]
[Cites]
Curr Protoc Mol Biol. 2008 Jan;Chapter 26:Unit26.7
[
18231982.001
]
[Cites]
Genome Biol. 2007;8(10):R214
[
17922911.001
]
[Cites]
Oncogene. 2007 Apr 26;26(19):2799-803
[
17072344.001
]
[Cites]
Genes Dev. 2007 May 1;21(9):1025-30
[
17437991.001
]
[Cites]
JAMA. 2007 May 2;297(17):1901-8
[
17473300.001
]
[Cites]
Blood. 2007 May 15;109(10):4399-405
[
17284533.001
]
[Cites]
J Biol Chem. 2007 May 11;282(19):14328-36
[
17363372.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 May 8;104(19):8017-22
[
17470785.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 May 8;104(19):7957-62
[
17483472.001
]
[Cites]
Nucleic Acids Res. 2007;35(9):2885-92
[
17439965.001
]
[Cites]
Mol Cell Biol. 2007 Jun;27(11):3970-81
[
17403906.001
]
[Cites]
Nat Rev Genet. 2007 Jun;8(6):413-23
[
17486121.001
]
[Cites]
Mol Cancer Ther. 2007 May;6(5):1483-91
[
17483436.001
]
[Cites]
Blood. 2007 Jun 1;109(11):4944-51
[
17327404.001
]
[Cites]
Drug Discov Today. 2007 Jun;12(11-12):452-8
[
17532529.001
]
[Cites]
Mol Cell Biol. 2007 Jun;27(12):4238-47
[
17438130.001
]
[Cites]
PLoS Pathog. 2007 May 11;3(5):e65
[
17500590.001
]
[Cites]
Oncogene. 2007 May 31;26(26):3769-76
[
17173072.001
]
[Cites]
Cancer Res. 2007 Jun 1;67(11):5148-55
[
17545593.001
]
[Cites]
Neuron. 2007 Jun 7;54(5):813-29
[
17553428.001
]
[Cites]
Science. 2007 Jun 8;316(5830):1484-8
[
17510325.001
]
[Cites]
Mol Cell. 2007 Jun 8;26(5):731-43
[
17540598.001
]
[Cites]
Mol Cell. 2007 Jun 8;26(5):745-52
[
17540599.001
]
[Cites]
World J Gastroenterol. 2007 May 28;13(20):2883-8
[
17569129.001
]
[Cites]
Cancer Res. 2007 Jun 15;67(12):5699-707
[
17575136.001
]
[Cites]
Nature. 2007 Jun 28;447(7148):1130-4
[
17554337.001
]
[Cites]
Oncogene. 2007 Jun 28;26(30):4442-52
[
17237814.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10980-5
[
17581865.001
]
[Cites]
Int J Cancer. 2007 Sep 1;121(5):1156-61
[
17487835.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11400-5
[
17600087.001
]
[Cites]
Nature. 2007 Jul 5;448(7149):83-6
[
17589500.001
]
[Cites]
Mol Cell. 2007 Jul 6;27(1):91-105
[
17612493.001
]
[Cites]
Cancer Res. 2007 Jul 1;67(13):6031-43
[
17616659.001
]
[Cites]
Cancer Res. 2007 Jul 1;67(13):6092-9
[
17616664.001
]
[Cites]
Cancer Res. 2007 Jul 1;67(13):6130-5
[
17616669.001
]
[Cites]
Cell Cycle. 2007 Jul 1;6(13):1586-93
[
17554199.001
]
[Cites]
J Pathol. 2007 Aug;212(4):368-77
[
17471471.001
]
[Cites]
Oncogene. 2007 Jul 26;26(34):5017-22
[
17297439.001
]
[Cites]
Nucleic Acids Res. 2007;35(13):4535-41
[
17584784.001
]
[Cites]
Nat Genet. 2007 Aug;39(8):1033-7
[
17643101.001
]
[Cites]
Blood. 2007 Aug 15;110(4):1330-3
[
17496199.001
]
[Cites]
J Biol Chem. 2007 Aug 10;282(32):23716-24
[
17569667.001
]
[Cites]
Gastroenterology. 2007 Aug;133(2):647-58
[
17681183.001
]
[Cites]
Curr Biol. 2007 Aug 7;17(15):1298-307
[
17656095.001
]
[Cites]
EMBO J. 2007 Aug 8;26(15):3699-708
[
17627278.001
]
[Cites]
Cancer Sci. 2007 Sep;98(9):1482-90
[
17608773.001
]
[Cites]
Cancer Res. 2007 Aug 15;67(16):7713-22
[
17699775.001
]
[Cites]
Cell Cycle. 2007 Aug 15;6(16):2005-9
[
17721077.001
]
[Cites]
Nat Methods. 2007 Sep;4(9):721-6
[
17694064.001
]
[Cites]
Mol Cell. 2007 Oct 26;28(2):328-36
[
17964270.001
]
[Cites]
Mol Cancer. 2007;6:54
[
17716371.001
]
[Cites]
J Biol Chem. 2007 Nov 9;282(45):32773-9
[
17724023.001
]
[Cites]
PLoS One. 2007;2(11):e1133
[
17989771.001
]
[Cites]
Cancer Res. 2007 Nov 15;67(22):11001-11
[
18006846.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19291-6
[
18042700.001
]
[Cites]
Science. 2005 Oct 14;310(5746):317-20
[
16224024.001
]
[Cites]
Leukemia. 2005 Nov;19(11):2013-6
[
16167061.001
]
[Cites]
N Engl J Med. 2005 Oct 27;353(17):1793-801
[
16251535.001
]
[Cites]
Nat Genet. 2005 Nov;37(11):1163-5
[
16254559.001
]
[Cites]
Cancer Res. 2005 Nov 1;65(21):9628-32
[
16266980.001
]
(PMID = 18817506.001).
[ISSN]
1553-4014
[Journal-full-title]
Annual review of pathology
[ISO-abbreviation]
Annu Rev Pathol
[Language]
ENG
[Grant]
United States / NIAMS NIH HHS / AR / AR053948-03; United States / NIAMS NIH HHS / AR / R01 AR053948; United States / NIAMS NIH HHS / AR / AR 053948; United States / NIAMS NIH HHS / AR / R01 AR053948-03
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MicroRNAs
[Number-of-references]
209
[Other-IDs]
NLM/ NIHMS153379; NLM/ PMC2769253
29.
Reece D, Imrie K, Stevens A, Smith CA, Hematology Disease Site Groupof Cancer Care Ontario’s Program in Evidence-based Care:
Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
Curr Oncol
; 2006 Oct;13(5):160-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Bortezomib in multiple myeloma and
lymphoma
: a systematic review and clinical practice guideline.
QUESTIONS: In patients with multiple myeloma, Waldenström macroglobulinemia, or
lymphoma
, what is the efficacy of bortezomib alone or in combination as measured by survival, quality of life, disease control (for example, time to progression), response duration, or response rate?What is the toxicity associated with the use of bortezomib?Which patients are more or less likely to benefit from treatment with bortezomib?
No randomized trials were retrieved for
lymphoma
.
Bortezomib is recommended as the preferred treatment option in patients with myeloma relapsing within 1 year of the conclusion of initial treatment; it may also be a reasonable option in patients relapsing at least 1 year after autologous stem-
cell
transplantation.
PRACTICE GUIDELINE: This evidence-based series applies to adult patients with myeloma, Waldenström macroglobulinemia, or
lymphoma
of any type,
stage
, histology, or performance status.
RECOMMENDATIONS: Based on the results of a large well-conducted rct, which represents the only published randomized study in relapsed myeloma, the Hematology Disease Site Group (dsg) offers the following recommendations: For patients with myeloma refractory to or relapsing within 1 year of the conclusion of initial or subsequent treatment or treatments, including autologous stem-
cell
transplantation, and who are candidates for further chemotherapy, bortezomib is recommended as the preferred treatment option.Bortezomib is also a reasonable option for patients relapsing at least 1 year after autologous stem-
cell
transplantation.
However, evaluation of these other options is beyond the scope of this practice guideline.For patients with myeloma relapsing at least 1 year after the conclusion of alkylating agent-based chemotherapy who are candidates for further chemotherapy, further treatment with alkylating agent-based chemotherapy is recommended.Evidence is insufficient to support the use of bortezomib in patients with
non
-
Hodgkin
lymphoma
or Waldenström macroglobulinemia outside of clinical trials.
The Hematology dsg recognizes that thalidomide is an active agent in multiple myeloma patients who have relapsed after autologous stem-
cell
transplantation or who are refractory to alkylating agent-based chemotherapy.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ann Intern Med. 1986 Jul;105(1):8-11
[
3717812.001
]
[Cites]
N Engl J Med. 2005 Jun 16;352(24):2487-98
[
15958804.001
]
[Cites]
Cancer. 1981 Apr 15;47(8):1923-9
[
7226087.001
]
[Cites]
N Engl J Med. 2003 Jun 26;348(26):2609-17
[
12826635.001
]
[Cites]
Blood. 2004 Jul 15;104(2):336-9
[
15054044.001
]
[Cites]
Blood. 2004 Aug 1;104(3):607-18
[
15090448.001
]
[Cites]
Blood. 2004 Sep 1;104(5):1386-95
[
15155468.001
]
[Cites]
Br J Haematol. 2004 Oct;127(2):165-72
[
15461622.001
]
[Cites]
Mayo Clin Proc. 2005 Dec;80(12):1578-82
[
16342650.001
]
[Cites]
J Clin Oncol. 1995 Feb;13(2):502-12
[
7844612.001
]
[Cites]
J Clin Oncol. 1998 Mar;16(3):1226-31
[
9508211.001
]
[Cites]
Blood. 2001 Jul 15;98(2):492-4
[
11435324.001
]
[Cites]
Ann Intern Med. 2002 Apr 16;136(8):619-29
[
11955031.001
]
[Cites]
J Clin Oncol. 2005 Feb 1;23(4):676-84
[
15613699.001
]
[Cites]
N Engl J Med. 1984 May 24;310(21):1353-6
[
6546971.001
]
(PMID = 22792013.001).
[ISSN]
1198-0052
[Journal-full-title]
Current oncology (Toronto, Ont.)
[ISO-abbreviation]
Curr Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Canada
[Other-IDs]
NLM/ PMC3394599
[Keywords]
NOTNLM ; Bortezomib / Velcade / clinical practice guideline / lymphoma / multiple myeloma / systematic review
30.
Guedez L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG:
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Blood
; 2005 Feb 15;105(4):1660-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt
lymphoma cell
line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
Here, for the first time, we address the role of TIMP-1 in the pathogenesis of B-
cell
lymphomas.
An Epstein-Barr virus (EBV)-negative Burkitt
lymphoma cell
line with ectopic TIMP-1 expression (TIMP-1JD38) was used to identify genes induced/repressed by TIMP-1.
Analysis revealed changes of genes coding for B-
cell
growth/differentiation, transcription, and
cell
cycle regulators.
TIMP-1 repressed expression of germinal center (GC) markers CD10, Bcl-6, PAX-5 and up-regulated plasma
cell
-associated antigens CD138, MUM-1/IRF-4, XBP-1, and CD44, suggesting a plasma
cell
differentiation.
This incomplete plasmacytic differentiation occurs without altering
cell
proliferation, and despite c-Myc deregulation, indicating an arrested plasmacytic/plasmablastic
stage
of differentiation.
Further validation in human
lymphoma cell
lines and in primary B-
cell
tumors demonstrated a predominant TIMP-1 expression in tumors with plasmacytic/plasmablastic phenotypes, including multiple myelomas.
[MeSH-major]
Burkitt
Lymphoma
/ pathology.
Cell
Differentiation / physiology. Plasma Cells / pathology. Tissue Inhibitor of Metalloproteinase-1 / physiology
[MeSH-minor]
B-Lymphocytes / cytology. B-Lymphocytes / enzymology. B-Lymphocytes / metabolism.
Cell
Cycle Proteins / antagonists & inhibitors.
Cell
Cycle Proteins / biosynthesis.
Cell
Line, Tumor.
Cell
Proliferation. Down-Regulation / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / physiology. Humans. Lymphoid Tissue / enzymology. Lymphoid Tissue / pathology.
Lymphoma
, B-
Cell
/ enzymology.
Lymphoma
, B-
Cell
/ genetics.
Lymphoma
, B-
Cell
/ pathology. Multiple Myeloma / enzymology. Multiple Myeloma / genetics. Oligonucleotide Array Sequence Analysis. Repressor Proteins / physiology. Transcription Factors / antagonists & inhibitors. Transcription Factors / biosynthesis. Transcription, Genetic / physiology. Up-Regulation / genetics
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15479729.001).
[ISSN]
0006-4971
[Journal-full-title]
Blood
[ISO-abbreviation]
Blood
[Language]
eng
[Publication-type]
Journal Article; Validation Studies
[Publication-country]
United States
[Chemical-registry-number]
0 / Cell Cycle Proteins; 0 / Repressor Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Transcription Factors
31.
Wessels G, Bernard Hesseling P:
Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
Transfus Apher Sci
; 2005 Feb;32(1):27-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Perspectives of the management of childhood
lymphoma
: experience at Tygerberg Hospital, Western Cape, South Africa.
Hodgkin
's disease (HD) in children corresponds to a large degree to HD in adults.
Non
-
Hodgkin
's
Lymphoma
(NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.
For practical reasons clinicians generally classify and treat NHL in children as either B-
cell
or T-
cell
disease.
Lymphoblastic or T-
cell
NHL is treated with regimens normally used for acute lymphoblastic leukaemia (e.g.
BFM protocols) or modified leukaemia treatments for leukaemia-
lymphoma
syndromes (e.g. LSA2L2).
Three consecutive regimens have been used to treat B-
cell
NHL over the past 22 years.
Although toxicity has increased with the increased intensity of the treatment regimen, EFS has improved from 25% to 87% for all B-
cell
NHL.
The majority of patients had
stage
III and IV disease.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Hodgkin
Disease / therapy.
Lymphoma
,
Non
-
Hodgkin
/ therapy
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
DACARBAZINE
.
Hazardous Substances Data Bank.
MECHLORETHAMINE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
MECHLORETHAMINE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
Hazardous Substances Data Bank.
VINBLASTINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15737871.001).
[ISSN]
1473-0502
[Journal-full-title]
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
[ISO-abbreviation]
Transfus. Apher. Sci.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
[Number-of-references]
15
32.
Weigert O, Dreyling M, Unterhalt M, Hiddemann W, Buske C:
Investigational strategies in autologous stem cell transplantation for follicular lymphoma.
Curr Oncol Rep
; 2006 Sep;8(5):368-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Investigational strategies in autologous stem
cell
transplantation for follicular
lymphoma
.
Recent retrospective analyses indicate prolonged survival for patients with follicular
lymphoma
over the past 25 years, attributed most likely to improved supportive care and sequential application of effective therapies.
Encouraging results were obtained from several randomized trials evaluating myeloablative therapy followed by autologous stem
cell
transplantation (ASCT) as consolidation therapy applied to patients with advanced-
stage
follicular
lymphoma
either in first remission or as salvage therapy.
Combination of these novel strategies into a multimodal approach justifies hope that the treatment outcome of patients suffering from follicular
lymphoma
will be further improved.
[MeSH-major]
Clinical Trials as Topic. Hematopoietic Stem
Cell
Transplantation.
Lymphoma
, Follicular / therapy
Genetic Alliance.
consumer health - Follicular Lymphoma
.
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Clinical Trials
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2005 Aug 1;23(22):5019-26
[
15983392.001
]
[Cites]
J Clin Oncol. 2004 Dec 15;22(24):4926-33
[
15611507.001
]
[Cites]
Blood. 2005 Feb 15;105(4):1417-23
[
15494430.001
]
[Cites]
J Clin Oncol. 1997 Feb;15(2):445-50
[
9053464.001
]
[Cites]
Blood. 2005 May 15;105(10):3817-23
[
15687232.001
]
[Cites]
Blood. 2000 Nov 1;96(9):2934-42
[
11049969.001
]
[Cites]
Blood. 1984 Jun;63(6):1424-33
[
6609729.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3918-27
[
14517188.001
]
[Cites]
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
[
12568441.001
]
[Cites]
Blood. 2004 Sep 1;104(5):1258-65
[
15126323.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
J Clin Oncol. 2004 Apr 15;22(8):1460-8
[
15084619.001
]
[Cites]
Blood. 2000 Aug 1;96(3):864-9
[
10910898.001
]
[Cites]
Blood. 2006 Sep 1;108(5):1504-8
[
16690968.001
]
[Cites]
Bone Marrow Transplant. 2003 Aug;32(3):317-24
[
12858205.001
]
[Cites]
Radiother Oncol. 2000 Jul;56(1):1-8
[
10869748.001
]
[Cites]
Blood. 1995 Jun 1;85(11):3334-41
[
7538824.001
]
[Cites]
Blood. 2003 Oct 1;102(7):2351-7
[
12750161.001
]
[Cites]
Blood. 2003 Nov 15;102(10):3521-9
[
12893748.001
]
[Cites]
Int J Radiat Biol Relat Stud Phys Chem Med. 1982 Apr;41(4):411-20
[
7042622.001
]
[Cites]
Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6
[
2456618.001
]
[Cites]
Blood. 2005 Dec 1;106(12):3725-32
[
16123223.001
]
[Cites]
Blood. 2005 Oct 15;106(8):2896-902
[
16002426.001
]
[Cites]
Blood. 1987 Feb;69(2):584-91
[
3492224.001
]
[Cites]
Lancet. 2003 Aug 16;362(9383):516-22
[
12932382.001
]
[Cites]
J Clin Oncol. 2000 Mar;18(5):947-55
[
10694543.001
]
[Cites]
J Clin Oncol. 1997 Mar;15(3):1110-7
[
9060552.001
]
[Cites]
Blood. 2004 Nov 1;104(9):2667-74
[
15238420.001
]
[Cites]
Lancet Oncol. 2004 Dec;5(12):711-7
[
15581541.001
]
[Cites]
J Clin Oncol. 2000 Feb;18(3):527-36
[
10653868.001
]
[Cites]
Blood. 1999 Nov 15;94(10):3325-33
[
10552941.001
]
[Cites]
J Immunol. 1985 Aug;135(2):973-9
[
3925015.001
]
[Cites]
Blood. 2004 Nov 15;104(10):3064-71
[
15284112.001
]
[Cites]
J Clin Oncol. 2005 Jan 20;23 (3):461-7
[
15534357.001
]
[Cites]
Bone Marrow Transplant. 2003 Apr;31(8):667-78
[
12692607.001
]
[Cites]
Bone Marrow Transplant. 2003 Jul;32(1):57-63
[
12815479.001
]
[Cites]
Semin Oncol. 2003 Apr;30(2 Suppl 4):10-21
[
12728403.001
]
[Cites]
Semin Oncol. 1993 Oct;20(5 Suppl 5):75-88
[
8211209.001
]
(PMID = 16901398.001).
[ISSN]
1523-3790
[Journal-full-title]
Current oncology reports
[ISO-abbreviation]
Curr Oncol Rep
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal
[Number-of-references]
48
33.
Bacon CM, Diss TC, Ye H, Liu H, Goatly A, Hamoudi R, Wotherspoon A, Gascoyne RD, Dogan A, Du MQ, Isaacson PG:
Follicular lymphoma of the thyroid gland.
Am J Surg Pathol
; 2009 Jan;33(1):22-34
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Follicular
lymphoma
of the thyroid gland.
The majority of lymphomas arising in the thyroid gland are mucosa-associated lymphoid tissue lymphomas and diffuse large B-
cell
lymphomas, which arise from a background of chronic lymphocytic thyroiditis.
Follicular
lymphoma
may also present in the thyroid gland, but its clinicopathologic features at this site are not well characterized, leading to difficulties in diagnosis and clinical management.
All cases showed morphology characteristic of follicular
lymphoma
, however, in many the interfollicular neoplastic infiltrate was particularly prominent and all lymphomas contained readily identifiable and often striking lymphoepithelial lesions, features heretofore considered indicative of mucosa-associated lymphoid tissue
lymphoma
at this site.
In 1 group, similar to typical adult follicular
lymphoma
, cases carried a t(14;18)/IGH-BCL2 and/or expressed Bcl-2, and were mostly CD10-positive and of World Health Organization (WHO) grade 1 to 2.
The 2 groups differed in clinical
stage
at presentation, 11 patients in the former group but none in the latter group having disease beyond the thyroid gland.
Appreciation of the spectrum of morphologic, immunophenotypic, and genetic characteristics of follicular
lymphoma
presenting in the thyroid gland should aid both diagnosis and clinical management.
Genetic Alliance.
consumer health - Follicular Lymphoma
.
Genetic Alliance.
consumer health - Thyroid Lymphoma
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Trends Immunol. 2008 Jan;29(1):25-33
[
18061541.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1254
[
10561186.001
]
[Cites]
Am J Surg Pathol. 2000 May;24(5):623-39
[
10800981.001
]
[Cites]
Am J Surg Pathol. 2000 Jun;24(6):846-52
[
10843287.001
]
[Cites]
Blood. 2000 Jun 15;95(12):3922-8
[
10845929.001
]
[Cites]
Histopathology. 2000 Jul;37(1):10-8
[
10931213.001
]
[Cites]
Cancer. 2001 Feb 15;91(4):629-35
[
11241227.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Jan;87(1):105-11
[
11788631.001
]
[Cites]
Am J Surg Pathol. 2002 Feb;26(2):216-24
[
11812943.001
]
[Cites]
J Clin Oncol. 2002 Feb 1;20(3):647-55
[
11821444.001
]
[Cites]
Leukemia. 2002 Nov;16(11):2309-17
[
12399977.001
]
[Cites]
Virchows Arch. 2002 Dec;441(6):614-7
[
12461620.001
]
[Cites]
Int J Surg Pathol. 2001 Oct;9(4):287-93
[
12574844.001
]
[Cites]
Blood. 2003 Mar 15;101(6):2335-9
[
12406890.001
]
[Cites]
Blood. 2003 Apr 1;101(7):2489-95
[
12456507.001
]
[Cites]
Ann Oncol. 2003 Apr;14(4):623-9
[
12649111.001
]
[Cites]
Blood. 2003 Aug 1;102(3):1012-8
[
12676782.001
]
[Cites]
J Clin Oncol. 2003 Nov 15;21(22):4157-64
[
14615444.001
]
[Cites]
Leukemia. 2003 Dec;17(12):2257-317
[
14671650.001
]
[Cites]
Histopathology. 2004 Mar;44(3):268-76
[
14987231.001
]
[Cites]
Curr Treat Options Oncol. 2004 Aug;5(4):307-13
[
15233907.001
]
[Cites]
Nat Rev Cancer. 2004 Aug;4(8):644-53
[
15286744.001
]
[Cites]
Leukemia. 2004 Oct;18(10):1722-6
[
15356642.001
]
[Cites]
Cancer Res. 1971 Nov;31(11):1860-1
[
5121694.001
]
[Cites]
Cancer. 1972 Jan;29(1):252-60
[
5007387.001
]
[Cites]
Histopathology. 1978 May;2(3):201-13
[
580930.001
]
[Cites]
Cancer. 1979 Aug;44(2):529-42
[
383257.001
]
[Cites]
Virchows Arch A Pathol Anat Histol. 1979 Aug 23;383(3):293-317
[
158873.001
]
[Cites]
Am J Clin Pathol. 1980 Jul;74(1):1-11
[
7395811.001
]
[Cites]
Cancer. 1984 Jun 1;53(11):2515-24
[
6424928.001
]
[Cites]
N Engl J Med. 1985 Mar 7;312(10):601-4
[
3838363.001
]
[Cites]
Histopathology. 1985 Jan;9(1):81-97
[
3884481.001
]
[Cites]
Cancer. 1986 Jul 1;58(1):100-4
[
3708539.001
]
[Cites]
Hum Pathol. 1988 Nov;19(11):1315-26
[
3141260.001
]
[Cites]
Blood. 1991 Aug 1;78(3):581-5
[
1859876.001
]
[Cites]
Eur J Cancer. 1991;27(10):1201-8
[
1835586.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1992;22(5):929-33
[
1555984.001
]
[Cites]
Am J Pathol. 1992 Jul;141(1):43-52
[
1632470.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6770-4
[
1495966.001
]
[Cites]
J Exp Med. 1992 Oct 1;176(4):1137-48
[
1402658.001
]
[Cites]
Histopathology. 1994 Apr;24(4):323-7
[
8045521.001
]
[Cites]
J Clin Oncol. 1995 Jan;13(1):140-7
[
7799014.001
]
[Cites]
Am J Clin Pathol. 1995 Apr;103(4):472-8
[
7726146.001
]
[Cites]
Histopathology. 1996 Jan;28(1):25-32
[
8838117.001
]
[Cites]
Blood. 1998 Jun 15;91(12):4708-14
[
9616169.001
]
[Cites]
Mod Pathol. 1998 Sep;11(9):864-9
[
9758366.001
]
[Cites]
Cell. 1999 Jan 8;96(1):35-45
[
9989495.001
]
[Cites]
Cancer. 1999 Apr 1;85(7):1626-35
[
10193956.001
]
[Cites]
Blood. 1999 Jun 1;93(11):3601-9
[
10339464.001
]
[Cites]
Semin Oncol. 1999 Jun;26(3):316-23
[
10375088.001
]
[Cites]
Am J Clin Pathol. 1999 Aug;112(2):263-70
[
10439808.001
]
[Cites]
Am J Surg Pathol. 2005 Jan;29(1):69-82
[
15613857.001
]
[Cites]
J Pathol. 2005 Feb;205(3):329-35
[
15682435.001
]
[Cites]
J Pathol. 2005 Feb;205(3):293-301
[
15682443.001
]
[Cites]
Best Pract Res Clin Haematol. 2005 Mar;18(1):1-10
[
15694181.001
]
[Cites]
Int J Surg Pathol. 2005 Jan;13(1):73-8
[
15735858.001
]
[Cites]
Leukemia. 2005 Apr;19(4):652-8
[
15703784.001
]
[Cites]
Leukemia. 2005 Jun;19(6):1058-63
[
15815725.001
]
[Cites]
J Clin Oncol. 2005 Sep 10;23(26):6358-63
[
16155020.001
]
[Cites]
Am J Surg Pathol. 2006 Apr;30(4):529-36
[
16625101.001
]
[Cites]
Histopathology. 2006 Sep;49(3):229-41
[
16918969.001
]
[Cites]
Histopathology. 2006 Oct;49(4):426-9
[
16978207.001
]
[Cites]
Am J Surg Pathol. 2006 Dec;30(12):1546-53
[
17122510.001
]
[Cites]
Am J Surg Pathol. 2007 Feb;31(2):170-84
[
17255761.001
]
[Cites]
Blood. 2007 Apr 1;109(7):3076-9
[
17138820.001
]
[Cites]
Am J Surg Pathol. 2007 Jul;31(7):1050-8
[
17592272.001
]
(PMID = 18830125.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P50 CA097274-069001; United States / NCI NIH HHS / CA / P50 CA097274-079001; United States / NCI NIH HHS / CA / CA097274-069001; United States / NCI NIH HHS / CA / CA097274-079001; United Kingdom / Wellcome Trust / /
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS80966; NLM/ PMC2673478
34.
Saif MW, Khubchandani S, Walczak M:
Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis.
World J Gastroenterol
; 2007 Sep 28;13(36):4909-11
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Secondary pancreatic involvement by a diffuse large B-
cell lymphoma
presenting as acute pancreatitis.
Diffuse large B-
cell lymphoma
is the most common type of
non
-
Hodgkin
's
lymphoma
.
However, a diffuse large B-
cell lymphoma
presenting as acute pancreatitis is rare.
Biopsy of the axillary mass revealed a large B-
cell lymphoma
.
The patient was classified as
stage
IV, based on the Ann Arbor Classification, and as having a high-risk
lymphoma
, based on the International Prognostic Index.
A literature search revealed only seven cases of primary involvement of the pancreas in B-
cell lymphoma
presenting as acute pancreatitis.
However, only one case of secondary pancreatic involvement by B-
cell lymphoma
presenting as acute pancreatitis has been published.
[MeSH-major]
Lymphoma
, Large B-
Cell
, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / etiology
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Genetic Alliance.
consumer health - Pancreatitis
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatitis
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17828824.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Other-IDs]
NLM/ PMC4611771
35.
Tesfa D, Gelius T, Sander B, Kimby E, Fadeel B, Palmblad J, Hägglund H:
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis.
Med Oncol
; 2008;25(4):374-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte
stage
of granulopoiesis.
Late-onset neutropenia, i.e. an absolute neutrophil count of <1.5 x 10(9)/l, may follow 4 weeks or more after therapy with rituximab for
lymphoma
.
In a retrospective study of 113 consecutive
lymphoma
patients treated with rituximab, with or without chemotherapy, we found eight patients (7%) with late-onset neutropenia (LON).
Four of the eight patients underwent stem
cell
transplantation.
In four subsequently identified patients with severe LON, a maturation arrest at the (pro)myelocyte
stage
was observed in the bone marrow, similar to that found in severe congenital neutropenia or Kostmann disease.
[MeSH-minor]
Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived.
Cell
Differentiation / drug effects. DNA Mutational Analysis. Female. Humans.
Lymphoma
/ drug therapy. Male. Middle Aged. Proteins / genetics. Rituximab. Time
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Semin Hematol. 2002 Apr;39(2):113-20
[
11957194.001
]
[Cites]
Eur J Haematol Suppl. 2007 Jan;(67):5-14
[
17206982.001
]
[Cites]
Eur J Haematol Suppl. 1996;60:93-7
[
8987249.001
]
[Cites]
Haematologica. 2007 Feb;92(2):e20-3
[
17405749.001
]
[Cites]
Int J Hematol. 2006 Oct;84(3):242-7
[
17050199.001
]
[Cites]
Biol Blood Marrow Transplant. 2000;6(6):628-32
[
11128813.001
]
[Cites]
Acta Paediatr. 2007 Jun;96(6):813-9
[
17537008.001
]
[Cites]
Ann Pharmacother. 2005 Dec;39(12):2091-5
[
16249269.001
]
[Cites]
Autoimmun Rev. 2006 Jan;5(1):18-24
[
16338207.001
]
[Cites]
Curr Drug Metab. 2006 Apr;7(3):219-29
[
16611018.001
]
[Cites]
Blood. 2005 Aug 1;106(3):795-802
[
15718416.001
]
[Cites]
Br J Haematol. 2003 Jun;121(6):913-8
[
12786803.001
]
[Cites]
J Immunol. 2005 Jul 15;175(2):1232-8
[
16002727.001
]
[Cites]
Haematologica. 2004 Mar;89(3):361-3
[
15020279.001
]
[Cites]
Acta Paediatr. 2006 Dec;95(12):1526-32
[
17129957.001
]
[Cites]
Leuk Lymphoma. 2006 Jun;47(6):1013-7
[
16840190.001
]
[Cites]
Leuk Res. 2002 Jun;26(6):597-600
[
12007508.001
]
[Cites]
Bull Cancer. 2007 Feb;94(2):198-202
[
17337389.001
]
[Cites]
Cancer Treat Rev. 2005 Oct;31(6):456-73
[
16054760.001
]
[Cites]
Nature. 1996 Aug 15;382(6592):635-8
[
8757135.001
]
[Cites]
Semin Hematol. 2006 Jul;43(3):189-95
[
16822461.001
]
[Cites]
Blood. 2004 May 1;103(9):3355-61
[
14764541.001
]
[Cites]
Bone Marrow Transplant. 2004 May;33(9):921-3
[
15034544.001
]
[Cites]
Nat Genet. 2007 Jan;39(1):86-92
[
17187068.001
]
[Cites]
Br J Haematol. 2005 Apr;129(2):275-8
[
15813856.001
]
[Cites]
Ann Oncol. 2007 Feb;18(2):364-9
[
17079695.001
]
[Cites]
N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4
[
12826650.001
]
(PMID = 18278570.001).
[ISSN]
1357-0560
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / HAX1 protein, human; 0 / Proteins; 4F4X42SYQ6 / Rituximab
36.
Strumane K, Rygiel TP, Collard JG:
The Rac activator Tiam1 and Ras-induced oncogenesis.
Methods Enzymol
; 2006;407:269-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In vitro studies indicate that Tiam1 localizes to adherens junctions and plays a role in the formation and maintenance of cadherin-based
cell
adhesions, thereby regulating migration of epithelial cells.
This two-
stage
carcinogenesis protocol allows us to study initiation, promotion, and progression of tumors in a Tiam1-positive and Tiam1-negative background.
Moreover, we describe methods to study the role of Tiam1 in susceptibility to apoptosis,
cell
growth, and Ras transformation by in vivo and in vitro experiments.
[MeSH-minor]
9,10-Dimethyl-1,2-benzanthracene. Animals. Apoptosis / physiology.
Cell
Separation. Down-Regulation. Keratinocytes / cytology. Mice. Mice, Knockout. NIH 3T3 Cells. Skin Neoplasms / etiology. Skin Neoplasms / pathology
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
7,12-DIMETHYLBENZ(A)ANTHRACENE
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16757331.001).
[ISSN]
0076-6879
[Journal-full-title]
Methods in enzymology
[ISO-abbreviation]
Meth. Enzymol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Guanine Nucleotide Exchange Factors; 0 / Tiam1 protein, mouse; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; EC 3.6.5.2 / ras Proteins
37.
Schüler F, Hirt C, Dölken L, Krüger W, Dölken G:
[Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
Dtsch Med Wochenschr
; 2005 Sep 23;130(38):2130-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Minimal residual disease in follicular and mantle
cell lymphoma
. Detection using quantitative molecular monitoring of circulating
lymphoma
cells].
BACKGROUND AND OBJECTIVE: In patients with follicular
lymphoma
and mantle
cell lymphoma
circulating
lymphoma
cells can be detected by quantitative real-time PCR with a high sensitivity and reproducibility.
With this study we wanted to ascertain whether a continuous molecular remission achieved in patients with mantle
cell lymphoma
and follicular
lymphoma
has an impact on survival of these patients.
PATIENT AND METHODS: We conducted these investigations in 32 patients (24 with follicular
lymphoma
and 8 with mantle
cell lymphoma
) who were treated in a randomized trial with chemotherapy plus/minus rituximab (MCP, R-MCP).
A further ten patients had follicular
lymphoma
(
stage I
and II) in long-term complete remission after radiation therapy.
RESULTS: Up to 18 years after initial diagnoses of a
stage I
or II follicular
lymphoma
circulating t(14;18) positive cells could be detected in the peripheral blood.
In advanced
stage
follicular
lymphoma
patients molecular remissions could only be achieved when they were treated with combined chemo-immunotherapy (MCP+R).
In contrast, the frustrating clinical results obtained from the treatment of patients with mantle
cell lymphoma
corresponded to an achievement of only short molecular remissions in very few patients.
CONCLUSIONS: The consequent application of quantitative real-time PCR will further improve current treatment strategies in
lymphoma
patients.
[MeSH-major]
Lymphoma
, Follicular / pathology.
Lymphoma
, Mantle-
Cell
/ pathology. Neoplasm, Residual / diagnosis. Neoplastic Cells, Circulating. Polymerase Chain Reaction / methods
Genetic Alliance.
consumer health - Follicular Lymphoma
.
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16172952.001).
[ISSN]
0012-0472
[Journal-full-title]
Deutsche medizinische Wochenschrift (1946)
[ISO-abbreviation]
Dtsch. Med. Wochenschr.
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
38.
Masunaga A, Iwamoto S, Nakamura H, Usuda R, Masuda M, Suzuki S, Miyazaki A, Suzuki T, Mitsuya T, Yoshitake T:
Thymic epithelial cells expressed unusual follicular dendritic cell markers: thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Pathol Int
; 2008 Jun;58(6):402-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Thymic epithelial cells expressed unusual follicular dendritic
cell
markers: thymic extranodal marginal zone B-
cell lymphoma
of mucosa-associated lymphoid tissue.
Described herein is a case of thymic extranodal marginal zone B-
cell lymphoma
of mucosa-associated lymphoid tissue.
Using immunohistochemical double staining it was found that most of the thymic lymphoid follicles in this case possessed cytokeratin-positive and follicular dendritic
cell
(FDC) marker-positive cells.
The present case indicates a possibility that some thymic epithelial cells become FDC, although it was uncertain whether they were derived from the epithelia of Hassall's corpuscles or whether they were at the same differentiation
stage
as Hassall's corpuscles.
[MeSH-major]
Dendritic Cells, Follicular / metabolism.
Lymphoma
, B-
Cell
, Marginal Zone / metabolism. Thymus Gland / metabolism. Thymus Neoplasms / metabolism
Genetic Alliance.
consumer health - Follicular Lymphoma
.
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18477221.001).
[ISSN]
1440-1827
[Journal-full-title]
Pathology international
[ISO-abbreviation]
Pathol. Int.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Australia
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Receptors, Complement 3d
39.
Abuzayed B, Dashti R, Turk O, Kaynar MY:
Aneurysmal frontal bone cyst in a child with history of acute lymphoblastic leukemia: a case of rare location and history.
J Pediatr Hematol Oncol
; 2010 Jan;32(1):e1-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A preoperative diagnosis of myeloproliferative disorder was made and it was surgically resected and cranioplasty with porous polyethylene sheets (Medpor, Porex Surgical Inc, GA) was performed in the same
stage
.
[MeSH-major]
Bone Cysts, Aneurysmal / diagnosis. Bone Cysts, Aneurysmal / surgery. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ complications
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19636268.001).
[ISSN]
1536-3678
[Journal-full-title]
Journal of pediatric hematology/oncology
[ISO-abbreviation]
J. Pediatr. Hematol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
40.
Tisdale G, Mahadevan A, Matthews RH:
T-cell lymphoma of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.
Oncologist
; 2005 Apr;10(4):292-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
T-
cell lymphoma
of the rectum in a patient with AIDS and hepatitis C: a case report and discussion.
Primary T-
cell
non
-
Hodgkin
's
lymphoma
(NHL) occurring in the context of acquired immune deficiency syndrome (AIDS) is uncommon.
Although typical in some respects, the case is, in other ways, somewhat unusual for an AIDS-related NHL (ARL); ARL tends to be
B cell
and advanced
stage
and our case was T
cell
and
stage
IE.
Although this has largely been mitigated by the advent of highly active antiretroviral therapy, our patient eventually suffered complications of chemotherapy, apparently related more to his liver disease than to either his
lymphoma
or AIDS, that ultimately brought about his demise.
[MeSH-major]
AIDS-Related Opportunistic Infections / complications. Hepatitis C / complications.
Lymphoma
, AIDS-Related / diagnosis.
Lymphoma
, T-
Cell
/ diagnosis. Rectal Neoplasms / diagnosis
Genetic Alliance.
consumer health - AIDS-HIV
.
Genetic Alliance.
consumer health - Hepatitis
.
MedlinePlus Health Information.
consumer health - Hepatitis C
.
MedlinePlus Health Information.
consumer health - HIV/AIDS and Infections
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15821249.001).
[ISSN]
1083-7159
[Journal-full-title]
The oncologist
[ISO-abbreviation]
Oncologist
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
41.
Ansell SM, Inwards DJ, Rowland KM Jr, Flynn PJ, Morton RF, Moore DF Jr, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE:
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
Cancer
; 2008 Aug 1;113(3):508-14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Low-dose, single-agent temsirolimus for relapsed mantle
cell lymphoma
: a phase 2 trial in the North Central Cancer Treatment Group.
BACKGROUND: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle
cell lymphoma
(MCL).
The median age was 69 years (range, 51-85 years), 86% of patients had
stage
IV disease, and 71% had > or = 2 extranodal sites.
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
SIROLIMUS
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 American Cancer Society
[Cites]
Curr Treat Options Oncol. 2006 Jul;7(4):285-94
[
16916489.001
]
[Cites]
J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12
[
16088404.001
]
[Cites]
Ann Oncol. 2007 Jan;18(1):116-21
[
16971665.001
]
[Cites]
Leukemia. 2007 Feb;21(2):333-9
[
17136116.001
]
[Cites]
N Engl J Med. 2007 May 31;356(22):2271-81
[
17538086.001
]
[Cites]
Leuk Lymphoma. 2007 Jul;48(7):1299-306
[
17613757.001
]
[Cites]
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5291-4
[
17875757.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
J Clin Oncol. 2004 Mar 1;22(5):909-18
[
14990647.001
]
[Cites]
Leuk Lymphoma. 2004 Sep;45(9):1821-7
[
15223642.001
]
[Cites]
Blood. 2004 Oct 15;104(8):2269-71
[
15166030.001
]
[Cites]
Control Clin Trials. 1989 Mar;10(1):1-10
[
2702835.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3909-18
[
9166827.001
]
[Cites]
J Clin Oncol. 2005 May 20;23(15):3383-9
[
15908650.001
]
[Cites]
J Clin Oncol. 2005 Aug 10;23(23):5347-56
[
15983389.001
]
[Cites]
J Clin Oncol. 2006 Oct 20;24(30):4867-74
[
17001068.001
]
(PMID = 18543327.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / U10 CA035267; United States / NCI NIH HHS / CA / CA112904; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / CA-35090; United States / NCI NIH HHS / CA / U10 CA060276; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / U10 CA037404; United States / NCI NIH HHS / CA / U10 CA035448; United States / NCI NIH HHS / CA / U10 CA063848; United States / NCI NIH HHS / CA / U10 CA035195; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-37403; United States / PHS HHS / / CS-35431; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / U10 CA035101; United States / NCI NIH HHS / CA / U10 CA035113; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / U10 CA035415; United States / NCI NIH HHS / CA / CA-63826; United States / NCI NIH HHS / CA / R21 CA112904; United States / NCI NIH HHS / CA / CA-35415; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / U10 CA025224; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-35267; United States / NCI NIH HHS / CA / N01 CA015083
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 624KN6GM2T / temsirolimus; W36ZG6FT64 / Sirolimus
[Other-IDs]
NLM/ NIHMS454018; NLM/ PMC3627208
42.
Saunders TS, Anis S, Doych Y, Moran A, Hou JS, Chen X, Yanoff M:
Systemic non-Hodgkin's lymphoma involving the orbit and leptomeninges.
Digit J Ophthalmol
; 2010;16(3):9-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Systemic
non
-
Hodgkin
's
lymphoma
involving the orbit and leptomeninges.
We report a case of diffuse large B-
cell lymphoma
in a 46-year-old female presenting in an unusual manner with
stage
IVB disease including concurrent orbital and leptomeningeal involvement.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Ophthalmol. 2001 Jan;85(1):63-9
[
11133714.001
]
[Cites]
Invest Ophthalmol Vis Sci. 2002 Jan;43(1):9-14
[
11773006.001
]
[Cites]
Clin Experiment Ophthalmol. 2001 Dec;29(6):387-93
[
11778809.001
]
[Cites]
Eye (Lond). 2003 Oct;17(7):809-20
[
14528242.001
]
[Cites]
Graefes Arch Clin Exp Ophthalmol. 2004 Feb;242(2):130-45
[
14685876.001
]
[Cites]
Ophthalmology. 2004 May;111(5):997-1008
[
15121380.001
]
[Cites]
Cancer. 1985 May 1;55(9):1907-12
[
3872159.001
]
[Cites]
Am J Pathol. 1999 May;154(5):1449-52
[
10329598.001
]
[Cites]
Ophthal Plast Reconstr Surg. 2005 May;21(3):177-88
[
15942490.001
]
[Cites]
Hematol Oncol Clin North Am. 2005 Aug;19(4):597-609, v
[
16083825.001
]
[Cites]
Curr Opin Ophthalmol. 2006 Dec;17(6):523-31
[
17065920.001
]
[Cites]
Am J Surg Pathol. 2007 Feb;31(2):170-84
[
17255761.001
]
[Cites]
Arch Ophthalmol. 2007 Dec;125(12):1663-7
[
18071119.001
]
[Cites]
Eye (Lond). 2010 Jun;24(6):954-61
[
19942938.001
]
(PMID = 23362375.001).
[Journal-full-title]
Digital journal of ophthalmology : DJO
[ISO-abbreviation]
Digit J Ophthalmol
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC3516149
43.
McNutt DM, Holdsworth MT, Wong C, Hanrahan JD, Winter SS:
Rasburicase for the management of tumor lysis syndrome in neonates.
Ann Pharmacother
; 2006 Jul-Aug;40(7-8):1445-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
One patient was a 21-day-old infant who received 2 days of induction chemotherapy for the treatment of congenital
Stage
IV-S neuroblastoma.
The second patient was a 4-day-old neonate with congenital precursor-
B cell
acute lymphoblastic leukemia who presented with spontaneous TLS complicated by renal dysfunction.
[MeSH-minor]
Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / congenital. Adrenal Gland Neoplasms / drug therapy. Antineoplastic Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Female. Humans. Infant, Newborn. Male. Neuroblastoma / blood. Neuroblastoma / complications. Neuroblastoma / congenital. Neuroblastoma / drug therapy. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ blood. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ complications. Precursor
Cell
Lymphoblastic Leukemia-
Lymphoma
/ drug therapy. Uric Acid / blood
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16868218.001).
[ISSN]
1060-0280
[Journal-full-title]
The Annals of pharmacotherapy
[ISO-abbreviation]
Ann Pharmacother
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
44.
Golling P, Cozzio A, Dummer R, French L, Kempf W:
Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.
Leuk Lymphoma
; 2008 Jun;49(6):1094-103
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary cutaneous B-
cell
lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.
Clinical, prognostic and therapeutic features of 54 primary cutaneous marginal zone B-
cell lymphoma
(pcMZL), follicle centre
lymphoma
(pcFCL) and diffuse large B-
cell lymphoma
, leg type (pcDLBL) were analysed applying the WHO-EORTC classification for cutaneous lymphomas and the new TNM staging scheme of the International Society of Cutaneous Lymphomas.
Disseminated tumors (T3
stage
) were found in 26% of patients with pcMZL and in one patient with pcDLBL.
Three of 7 patients (43%) with pcDLBL died due to
lymphoma
.
The new TNM staging system is easily applicable for disease documentation, but our relatively small number of patients in each T
stage
does not allow the assessment of its prognostic value.
[MeSH-major]
Lymphoma
, B-
Cell
/ classification. Mycosis Fungoides / classification. Sezary Syndrome / classification. Skin Neoplasms / classification. World Health Organization
[MeSH-minor]
Adolescent. Adult. Aged. Female. Humans.
Lymphoma
, B-
Cell
, Marginal Zone / pathology.
Lymphoma
, B-
Cell
, Marginal Zone / therapy.
Lymphoma
, Follicular / pathology.
Lymphoma
, Follicular / therapy.
Lymphoma
, Large B-
Cell
, Diffuse / pathology.
Lymphoma
, Large B-
Cell
, Diffuse / therapy. Male. Middle Aged. Neoplasm Staging. Prognosis
Genetic Alliance.
consumer health - Cutaneous B-Cell Lymphomas
.
Genetic Alliance.
consumer health - Mycosis fungoides
.
Genetic Alliance.
consumer health - Sezary syndrome
.
Genetic Alliance.
consumer health - B-Cell Lymphomas
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18569636.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
45.
Flory AB, Rassnick KM, Stokol T, Scrivani PV, Erb HN:
Stage migration in dogs with lymphoma.
J Vet Intern Med
; 2007 Sep-Oct;21(5):1041-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Stage
migration in dogs with
lymphoma
.
BACKGROUND: Various diagnostic tests have been used to assign a clinical
stage
to dogs with
lymphoma
.
As more sensitive staging methods are introduced, dogs are reclassified as having a higher disease
stage
, thereby affecting comparisons of dogs across differently staged clinical trials, and possibly, prognosis.
HYPOTHESIS: The addition of more sensitive staging tests causes
stage
migration in dogs with
lymphoma
.
ANIMALS: Fifty-nine client-owned dogs with previously untreated cytologically or histologically confirmed
lymphoma
METHODS: For every dog, the World Health Organization
stage
classification (I-V) was based on 5 groupings of various diagnostic tests: A (physical examination [PE] and quantitative blood count [QBC]), B (PE, QBC, thoracic and abdominal radiographs), C (PE, complete blood count with blood-smear evaluation [CBC], thoracic and abdominal radiographs), D (PE, CBC, thoracic radiographs, abdominal ultrasound), and E (PE, CBC, thoracic radiographs, abdominal ultrasound, and bone-marrow cytology).
However, the
stage
was not a predictor of remission rate, remission duration, or survival, regardless of staging method used.
CONCLUSIONS AND CLINICAL IMPORTANCE: These data emphasized the need for standardized methods to determine the clinical
stage
in dogs with
lymphoma
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17939562.001).
[ISSN]
0891-6640
[Journal-full-title]
Journal of veterinary internal medicine
[ISO-abbreviation]
J. Vet. Intern. Med.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
80168379AG / Doxorubicin
46.
Shen Y, Yao Y, Li JM, Chen QS, You JH, Zhao HJ, Chen S, Shen ZX:
[Prognostic factors analysis for R-CHOP regimen therapy in diffuse large B cell lymphoma].
Zhonghua Xue Ye Xue Za Zhi
; 2008 Apr;29(4):252-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Prognostic factors analysis for R-CHOP regimen therapy in diffuse large
B cell lymphoma
].
OBJECTIVE: To reassess the prognostic factors of diffuse large
B cell lymphoma
(DLBCL) treated with R-CHOP therapy.
In univariate analysis, performance status (PS), clinical
stage
, LDH level, extranodal disease, international prognostic index (IPI) and bulky disease were statistically significantly correlated with the induction of CR; however, only PS, clinical
stage
and bulky disease remained significant in multi-variate analysis (P = 0.0098, 0.000 and 0.004, respectively).
In univariate analysis, LDH, clinical
stage
and PS exerted significant effect on TTF and OS rate, but not on DFS rate; age and extranodal disease was not related with TTF, OS and DFS rate.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, Large B-
Cell
, Diffuse / drug therapy
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18843980.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
47.
Attarbaschi A, Dworzak M, Steiner M, Urban C, Fink FM, Reiter A, Gadner H, Mann G:
Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
Pediatr Blood Cancer
; 2005 Jan;44(1):70-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcome of children with primary resistant or relapsed
non
-
Hodgkin
lymphoma
and mature B-
cell
leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group.
BACKGROUND: Children and adolescents with
Non
-
Hodgkin
lymphoma
(NHL) and mature B-
cell
leukemia (B-ALL) have an excellent prognosis with contemporary chemotherapy stratified according to the histologic subtype and clinical
stage
of disease.
RESULTS: Nine of 140 (6.5%) patients with B-
cell
NHL/B-ALL (relapse, n = 6; progress, n = 3) failed initial treatment.
Four of them underwent a hematopoietic stem
cell
transplantation (HSCT) as second-line therapy, two patients received intensive chemotherapy alone and in three patients treatment was palliative.
Four of 65 (6%) patients with lymphoblastic
lymphoma
(LBL) (relapse, n = 2; progress, n = 2) had a treatment failure.
Nine of 29 (31%) patients with anaplastic large
cell lymphoma
(ALCL) (relapse, n = 7; progress, n = 2) failed first-line therapy.
CONCLUSIONS: Conclusively, patients with early relapsed and progressive B-
cell
neoplasia or LBL have a very poor prognosis with current treatment approaches, while those with ALCL have a respectable chance to achieve a sustained complete second remission with high-dose chemotherapy and HSCT.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, B-
Cell
/ drug therapy.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2004 Wiley-Liss, Inc.
(PMID = 15368550.001).
[ISSN]
1545-5009
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
48.
Laport GG:
The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma.
Biol Blood Marrow Transplant
; 2006 Jan;12(1 Suppl 1):59-65
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The role of hematopoietic
cell
transplantation for follicular
non
-
Hodgkin
's
lymphoma
.
The overall survival with follicular
lymphoma
has not significantly changed over the last few decades, and there is no universal agreement as to the optimal first-line or subsequent therapy.
High-dose chemotherapy with autologous hematopoietic
cell
transplantation (HCT) confers high response rates and improved progression-free survival in advanced-
stage
disease, and more recent data indicate a positive effect on overall survival.
This review summarizes current and new developments regarding the role of HCT for patients with follicular
lymphoma
.
[MeSH-major]
Hematopoietic Stem
Cell
Transplantation.
Lymphoma
, Follicular / therapy. Transplantation Conditioning
Genetic Alliance.
consumer health - Follicular Lymphoma
.
Genetic Alliance.
consumer health - Transplantation
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16399587.001).
[ISSN]
1083-8791
[Journal-full-title]
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
[ISO-abbreviation]
Biol. Blood Marrow Transplant.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunoconjugates; 4F4X42SYQ6 / Rituximab
[Number-of-references]
36
49.
Ishikawa M, Kitayama J, Nagawa H:
Expression pattern of leptin and leptin receptor (OB-R) in human gastric cancer.
World J Gastroenterol
; 2006 Sep 14;12(34):5517-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The expression levels of both leptin and OB-R tended to increase as the depth of tumor invasion or TMN
stage
increased (P < 0.01).
[MeSH-major]
Adenocarcinoma / metabolism. Carcinoma, Signet Ring
Cell
/ metabolism. Leptin / metabolism. Receptors,
Cell
Surface / metabolism. Stomach Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Horm Metab Res. 2001 Jan;33(1):1-6
[
11280707.001
]
[Cites]
Surgery. 1970 Jul;68(1):209-16
[
10483471.001
]
[Cites]
Gastroenterology. 2001 Jul;121(1):79-90
[
11438496.001
]
[Cites]
Cytokine. 2001 May 21;14(4):225-9
[
11448122.001
]
[Cites]
Gut. 2001 Sep;49(3):324-9
[
11511551.001
]
[Cites]
Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S94-100
[
12570341.001
]
[Cites]
Clin Neurol Neurosurg. 2003 Apr;105(2):111-6
[
12691803.001
]
[Cites]
N Engl J Med. 2003 Apr 24;348(17):1625-38
[
12711737.001
]
[Cites]
Nat Rev Cancer. 2003 Aug;3(8):592-600
[
12894247.001
]
[Cites]
Ann Oncol. 2004 Apr;15(4):581-4
[
15033662.001
]
[Cites]
Cancer Res. 1981 Sep;41(9 Pt 2):3685-90
[
6266659.001
]
[Cites]
Fertil Steril. 2000 Mar;73(3):493-8
[
10689001.001
]
[Cites]
Leuk Lymphoma. 2000 Feb;36(5-6):457-61
[
10784389.001
]
[Cites]
Mol Cell Endocrinol. 2000 Jul 25;165(1-2):97-105
[
10940488.001
]
[Cites]
Gut. 2000 Oct;47(4):481-6
[
10986207.001
]
[Cites]
FASEB J. 2000 Nov;14(14):2329-38
[
11053255.001
]
[Cites]
Biol Reprod. 2000 Nov;63(5):1219-28
[
11058523.001
]
[Cites]
Int J Cancer. 2001 Feb 1;91(3):421-30
[
11169969.001
]
[Cites]
Cancer Res. 1981 Sep;41(9 Pt 2):3695-9
[
7260926.001
]
[Cites]
Cancer Res. 1988 Jun 15;48(12):3518-23
[
3370645.001
]
[Cites]
Nature. 1994 Dec 1;372(6505):425-32
[
7984236.001
]
[Cites]
Diabetes. 1996 May;45(5):695-8
[
8621026.001
]
[Cites]
Nature. 1996 Apr 25;380(6576):677
[
8614460.001
]
[Cites]
Nat Med. 1996 May;2(5):585-9
[
8616721.001
]
[Cites]
Diabetes. 1996 Nov;45(11):1455-62
[
8866547.001
]
[Cites]
Diabetes. 1997 Feb;46(2):313-6
[
9000710.001
]
[Cites]
J Nutr. 1997 May;127(5 Suppl):921S-923S
[
9164264.001
]
[Cites]
Proc Soc Exp Biol Med. 1997 Oct;216(1):28-43
[
9316608.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11073-8
[
9380761.001
]
[Cites]
J Natl Cancer Inst. 1998 Jan 21;90(2):150-5
[
9450576.001
]
[Cites]
Cell. 1998 Feb 20;92(4):437-40
[
9491885.001
]
[Cites]
Int J Epidemiol. 1998 Apr;27(2):173-80
[
9602395.001
]
[Cites]
Nature. 1998 Aug 20;394(6695):790-3
[
9723619.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):749-56
[
9752982.001
]
[Cites]
J Clin Endocrinol Metab. 1998 Dec;83(12):4459-66
[
9851794.001
]
[Cites]
Lipids. 1998 Nov;33(11):1055-9
[
9870899.001
]
[Cites]
Eur J Pharmacol. 1999 Jan 22;365(2-3):273-9
[
9988112.001
]
[Cites]
Ann Intern Med. 1999 Jun 1;130(11):883-90
[
10375336.001
]
[Cites]
Nutrition. 1999 Jun;15(6):523-6
[
10378216.001
]
[Cites]
Eur J Pharmacol. 1999 Jun 18;374(2):263-76
[
10422768.001
]
[Cites]
Nature. 2001 May 17;411(6835):390-5
[
11357148.001
]
(PMID = 17006991.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human
[Other-IDs]
NLM/ PMC4088236
50.
Ria R, Cirulli T, Giannini T, Bambace S, Serio G, Portaluri M, Ribatti D, Vacca A, Dammacco F:
Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas.
Clin Exp Med
; 2008 Sep;8(3):141-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Serum levels of angiogenic cytokines decrease after radiotherapy in
non
-
Hodgkin
lymphomas.
Herein, we set out to determine whether circulating fibroblast growth factor-2 (FGF-2), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and platelet-derived growth factor-beta (PDGF-beta) decrease after radiotherapy in patients with
non
-
Hodgkin
lymphomas (NHLs) and if so, whether their decrease correlates with age, tumour histotype and
stage
, and radiation dose.
These levels were correlated both reciprocally and with age, histotype,
stage
and radiation dose.
Haemoglobin levels did not decrease after radiotherapy, while FGF-2, VEGF, HGF and PDGF-beta levels did not correlate with age, NHL
stage
and histotype.
[MeSH-major]
Cytokines / blood.
Lymphoma
,
Non
-
Hodgkin
/ radiotherapy. Neovascularization, Pathologic
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Oncol. 2001 Feb 15;19(4):1207-25
[
11181687.001
]
[Cites]
Nat Med. 1999 Dec;5(12):1359-64
[
10581076.001
]
[Cites]
Nat Med. 2001 May;7(5):575-83
[
11329059.001
]
[Cites]
Radiother Oncol. 2003 Jan;66(1):1-9
[
12559515.001
]
[Cites]
Head Neck. 2000 Oct;22(7):666-73
[
11002321.001
]
[Cites]
Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67
[
17828470.001
]
[Cites]
Oncogene. 2007 Nov 29;26(54):7508-16
[
17563752.001
]
[Cites]
Semin Oncol. 2001 Dec;28(6):536-42
[
11740806.001
]
[Cites]
Eur Cytokine Netw. 2003 Jan-Mar;14(1):40-51
[
12799213.001
]
[Cites]
Cancer Lett. 2002 May 28;179(2):197-203
[
11888674.001
]
[Cites]
Br J Haematol. 2001 Dec;115(3):514-21
[
11736931.001
]
[Cites]
Am J Physiol Cell Physiol. 2002 May;282(5):C947-70
[
11940508.001
]
[Cites]
Nat Med. 2000 Apr;6(4):389-95
[
10742145.001
]
[Cites]
Breast Cancer Res. 2003;5(2):83-8
[
12631386.001
]
[Cites]
Int J Cancer. 2001 Dec 1;94(5):690-8
[
11745464.001
]
[Cites]
Blood. 2002 Nov 1;100(9):3344-51
[
12384436.001
]
[Cites]
Int J Oncol. 2008 Jan;32(1):41-8
[
18097541.001
]
[Cites]
J Clin Oncol. 2007 Sep 10;25(26):4033-42
[
17827451.001
]
[Cites]
Cancer Res. 2007 Oct 1;67(19):8980-4
[
17908997.001
]
[Cites]
Int J Cancer. 2002 Sep 1;101(1):86-94
[
12209593.001
]
[Cites]
Cancer Lett. 2004 Dec 8;216(1):103-7
[
15500953.001
]
[Cites]
Hormones (Athens). 2006 Apr-Jun;5(2):137-46
[
16807226.001
]
(PMID = 18791686.001).
[ISSN]
1591-8890
[Journal-full-title]
Clinical and experimental medicine
[ISO-abbreviation]
Clin. Exp. Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
0 / Cytokines
51.
Ulmeanu R, Mihăltan F, Crişan E, Alexe M, Grigore P, Andreescu I, Galbenu P, Leonte D:
[Practical issues of transbronchial lung biopsy (TLB) in pneumology].
Pneumologia
; 2007 Apr-Jun;56(2):59-67
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The diagnosis of lung pathology was: diffuse lung fibrosis, tuberculosis, sarcoidosis
stage
II-III, malignant
lymphoma
, carcinomatosis, undifferentiated carcinoma, bronchioloalveolar carcinoma, squamous carcinoma, adenocarcinoma.
[MeSH-minor]
Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Aged. Carcinoma, Squamous
Cell
/ pathology. Diagnosis, Differential. Female. Granulomatosis with Polyangiitis / pathology. Health Surveys. Humans. Lung Neoplasms / pathology.
Lymphoma
,
Non
-
Hodgkin
/ pathology. Male. Middle Aged. Practice Guidelines as Topic. Pulmonary Fibrosis / pathology. Sarcoidosis, Pulmonary / pathology. Sensitivity and Specificity. Tuberculosis, Pulmonary / pathology
MedlinePlus Health Information.
consumer health - Lung Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18019749.001).
[ISSN]
2067-2993
[Journal-full-title]
Pneumologia (Bucharest, Romania)
[ISO-abbreviation]
Pneumologia
[Language]
rum
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Romania
52.
Lam J, Pope E:
Pediatric pityriasis lichenoides and cutaneous T-cell lymphoma.
Curr Opin Pediatr
; 2007 Aug;19(4):441-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pediatric pityriasis lichenoides and cutaneous T-
cell lymphoma
.
PURPOSE OF REVIEW: The purpose of this review is to educate the reader about two cutaneous lymphoproliferative diseases in childhood: pityriasis lichenoides and cutaneous T-
cell lymphoma
.
Cutaneous T-
cell lymphoma
is a rare but underrecognized cutaneous malignancy in children.
Early
stage
disease and hypopigmented presentation are characteristic of pediatric cutaneous T-
cell lymphoma
.
RECENT FINDINGS: This article will summarize recent articles on pityriasis lichenoides and pediatric cutaneous T-
cell lymphoma
, including recent findings from an international registry of pediatric cutaneous T-
cell lymphoma
.
SUMMARY: After reading this review, the reader should be able to recognize the clinical presentation of pityriasis lichenoides, to understand the overlap between its acute and chronic forms, and to recognize its relationship with cutaneous T-
cell lymphoma
.
In addition, the reader will appreciate the challenges in diagnosing and treating pediatric cutaneous T-
cell lymphoma
.
[MeSH-major]
Lymphoma
, T-
Cell
, Cutaneous / diagnosis. Pityriasis Lichenoides / diagnosis. Skin Neoplasms / diagnosis
Genetic Alliance.
consumer health - Cutaneous T-Cell Lymphoma
.
Genetic Alliance.
consumer health - Pityriasis lichenoides
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17630609.001).
[ISSN]
1040-8703
[Journal-full-title]
Current opinion in pediatrics
[ISO-abbreviation]
Curr. Opin. Pediatr.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
54
53.
Valli VE, Vernau W, de Lorimier LP, Graham PS, Moore PF:
Canine indolent nodular lymphoma.
Vet Pathol
; 2006 May;43(3):241-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Canine indolent nodular
lymphoma
.
B-
Cell
lymphomas (CD79a+) predominated.
Marginal zone
lymphoma
(MZL), the largest group, involved lymph node (33 cases) and spleen (13 cases), with both tissues involved in five of these cases.
Follicular
lymphoma
(FL) involved lymph nodes (five cases), and mantle
cell lymphoma
(MCL) occurred as solitary splenic masses (three cases).
Nodal CD3+ T-zone lymphomas (TZL) (10 cases), were included since they resembled late-
stage
MZL at the architectural level.
Clonality status was determined in 54 cases by analysis of immunoglobulin heavy chain (IGH) and T-
cell
antigen receptor gamma (TCRG) gene rearrangement.
Limited survival data obtained for 18 dogs indicated that the B-
cell
lymphomas (MZL, MCL, and FL) and the T-
cell lymphoma
(TZL) were associated with indolent behavior and long survival.
[MeSH-major]
Dog Diseases / diagnosis.
Lymphoma
, Follicular / veterinary
[MeSH-minor]
Animals. Antineoplastic Agents / therapeutic use. Dogs. Female.
Lymphoma
, Mantle-
Cell
/ diagnosis.
Lymphoma
, Mantle-
Cell
/ pathology.
Lymphoma
, Mantle-
Cell
/ veterinary. Male. Splenic Neoplasms / diagnosis. Splenic Neoplasms / drug therapy. Splenic Neoplasms / pathology. Splenic Neoplasms / veterinary
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16672571.001).
[ISSN]
0300-9858
[Journal-full-title]
Veterinary pathology
[ISO-abbreviation]
Vet. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents
54.
Wang H, Li XJ, Zhang SW, Xi Y:
[Clinical study of extranodal NK-T cell lymphoma-nasal type].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
; 2005 Nov;40(11):850-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Clinical study of extranodal NK-T
cell lymphoma
-nasal type].
OBJECTIVE: To discuss how the diagnosis, misdiagnosis and different treatment modalities affect the prognosis of the patients with extranodal NK-T
cell lymphoma
-nasal type.
METHODS: A retrospective study was made on the clinical characteristics, treatment modality, short-term effect, and survival rate of 68 patients with extranodal NK-T
cell lymphoma
-nasal type.
CONCLUSIONS: The early clinical manifestation of extranodal NK-T
cell lymphoma
-nasal type is not typical,which is easy to be misdiagnosed and mistreated.
Diseased
stage I
(E) out-cavity and above should be treated with combined therapy.
[MeSH-major]
Lymphoma
, Extranodal NK-T-
Cell
. Nose Neoplasms
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16408753.001).
[ISSN]
1673-0860
[Journal-full-title]
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
[ISO-abbreviation]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
55.
Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS:
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
Ann Oncol
; 2005 Dec;16(12):1928-35
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Burkitt
lymphoma
in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt
lymphoma
and L3 acute lymphoblastic leukemia.
Group A (resected
stage I
and abdominal
stage
II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone.
CONCLUSION: Patients with advanced-
stage
Burkitt
lymphoma
, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.
Hazardous Substances Data Bank.
CYTARABINE
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
HYDROCORTISONE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
LEUCOVORIN
.
Hazardous Substances Data Bank.
METHOTREXATE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16284057.001).
[ISSN]
0923-7534
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
England
[Chemical-registry-number]
04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
56.
Behler CM, Kaplan LD:
Advances in the management of HIV-related non-Hodgkin lymphoma.
Curr Opin Oncol
; 2006 Sep;18(5):437-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Advances in the management of HIV-related
non
-
Hodgkin
lymphoma
.
PURPOSE OF REVIEW: Human immunodeficiency virus infection is associated with an increased risk of
non
-
Hodgkin
lymphoma
.
Even with a decrease in AIDS-defining illnesses after the advent of highly active antiretroviral therapy, HIV-associated
non
-
Hodgkin
lymphoma
remains an important problem.
RECENT FINDINGS: Low CD4+ T-lymphocyte count, disease
stage
, performance status, serum lactate dehydrogenase, and number of extranodal sites of disease are all important prognostic factors for HIV-
non
-
Hodgkin
lymphoma
.
Recent studies have examined the role of infusional chemotherapy, as well as immunotherapy, in the treatment of aggressive HIV-
non
-
Hodgkin
lymphoma
, and autologous stem
cell
transplantation for relapsed or refractory HIV-
non
-
Hodgkin
lymphoma
.
New developments in the association of viral infection and pathogenesis of certain subtypes of HIV-
non
-
Hodgkin
lymphoma
have also recently been reported.
SUMMARY: Outcomes of HIV-
non
-
Hodgkin
lymphoma
are improving with the routine use of highly active antiretroviral therapy and combination chemotherapy.
For aggressive HIV-
non
-
Hodgkin
lymphoma
, infusional chemotherapy regimens are well tolerated and lead to complete response in about 50-75% of cases and a 2-3 years overall survival of 40-60%.
HIV-associated Burkitt
lymphoma
should be treated with an intensive regimen rather than standard cyclophosphamide, doxorubicin, vincristine, prednisone-like chemotherapy.
Autologous stem
cell
transplantation should be considered for selected patients with relapsed or refractory HIV-
non
-
Hodgkin
lymphoma
.
[MeSH-major]
Anti-Retroviral Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, AIDS-Related / therapy.
Lymphoma
,
Non
-
Hodgkin
/ therapy. Stem
Cell
Transplantation
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
Genetic Alliance.
consumer health - Non-Hodgkin Lymphoma
.
Genetic Alliance.
consumer health - HIV
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16894290.001).
[ISSN]
1040-8746
[Journal-full-title]
Current opinion in oncology
[ISO-abbreviation]
Curr Opin Oncol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Anti-Retroviral Agents
[Number-of-references]
65
57.
Takino H, Okabe M, Li C, Ohshima K, Yoshino T, Nakamura S, Ueda R, Eimoto T, Inagaki H:
p16/INK4a gene methylation is a frequent finding in pulmonary MALT lymphomas at diagnosis.
Mod Pathol
; 2005 Sep;18(9):1187-92
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
However, their significance in mucosa-associated lymphoid tissue (MALT)
lymphoma
is unclear.
We investigated p16 gene methylation and mutation in a large series of untreated cases of pulmonary MALT
lymphoma
and diffuse large B-
cell lymphoma
(DLBL), and correlated p16 gene alterations with a MALT
lymphoma
-specific API2-MALT1 fusion and the clinicopathologic features of MALT
lymphoma
.
The API2-MALT1 fusion was detected by multiplex reverse transcription polymerase chain reaction in 25/60 (42%) cases of MALT
lymphoma
, but none of 11 DLBLs.
Methylation-sensitive single-strand conformation analysis showed that p16 gene methylation was frequently detected in 36/60 (60%) cases of MALT
lymphoma
.
A p16 gene mutation was found in one (p16 gene-methylation) of 44 MALT lymphomas and in none of six diffuse large B-
cell
lymphomas.
Statistical analysis showed that the p16 gene methylation status did not correlate with API2-MALT1 fusion or any of the clinicopathologic factors including serum LDH, clinical
stage
, and increased large cells.
[MeSH-major]
DNA Methylation. Genes, p16. Lung Neoplasms / genetics.
Lymphoma
, B-
Cell
, Marginal Zone / genetics
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans.
Lymphoma
, B-
Cell
/ genetics.
Lymphoma
, Large B-
Cell
, Diffuse / genetics. Male. Middle Aged. Mutation. Oncogene Proteins, Fusion / genetics. Polymorphism, Single-Stranded Conformational. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15832193.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / API2-MALT1 fusion protein, human; 0 / Oncogene Proteins, Fusion
58.
Huang AC, Hu L, Kauffman SA, Zhang W, Shmulevich I:
Using cell fate attractors to uncover transcriptional regulation of HL60 neutrophil differentiation.
BMC Syst Biol
; 2009;3:20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Using
cell
fate attractors to uncover transcriptional regulation of HL60 neutrophil differentiation.
BACKGROUND: The process of cellular differentiation is governed by complex dynamical biomolecular networks consisting of a multitude of genes and their products acting in concert to determine a particular
cell
fate.
Thus, a systems level view is necessary for understanding how a
cell
coordinates this process and for developing effective therapeutic strategies to treat diseases, such as cancer, in which differentiation plays a significant role.
Theoretical considerations and recent experimental evidence support the view that
cell
fates are high dimensional attractor states of the underlying molecular networks.
The temporal behavior of the network states progressing toward different
cell
fate attractors has the potential to elucidate the underlying molecular mechanisms governing differentiation.
RESULTS: Using the HL60 multipotent promyelocytic leukemia
cell
line, we performed experiments that ultimately led to two different
cell
fate attractors by two treatments of varying dosage and duration of the differentiation agent all-trans-retinoic acid (ATRA).
The dosage and duration combinations of the two treatments were chosen by means of flow cytometric measurements of CD11b, a well-known early differentiation marker, such that they generated two intermediate populations that were poised at the apparently same
stage
of differentiation.
We monitored the gene expression changes in the two populations after their respective treatments over a period of five days and identified a set of genes that diverged in their expression, a subset of which promotes neutrophil differentiation while the other represses
cell
cycle progression.
By employing promoter based transcription factor binding site analysis, we found enrichment in the set of divergent genes, of transcription factors functionally linked to tumor progression,
cell
cycle, and development.
[MeSH-major]
Cell
Differentiation / physiology. Gene Expression Regulation / physiology. Neutrophils / cytology
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ALL-TRANS-RETINOIC ACID
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2006 Jun 2;281(22):15138-44
[
16574653.001
]
[Cites]
Leukemia. 2006 Jul;20(7):1326-9
[
16688227.001
]
[Cites]
J Neuroendocrinol. 2006 Sep;18(9):633-42
[
16879162.001
]
[Cites]
Dev Biol. 2006 Oct 15;298(2):555-70
[
16949568.001
]
[Cites]
J Biol Chem. 2007 Jan 5;282(1):208-15
[
17062569.001
]
[Cites]
Nucleic Acids Res. 2007 Jan;35(Database issue):D610-7
[
17148474.001
]
[Cites]
Leukemia. 2007 Feb;21(2):288-96
[
17183364.001
]
[Cites]
Cell Cycle. 2007 Mar 15;6(6):714-24
[
17361102.001
]
[Cites]
J Theor Biol. 2007 May 21;246(2):234-44
[
17289080.001
]
[Cites]
Am J Physiol Cell Physiol. 2007 Jul;293(1):C172-83
[
17360815.001
]
[Cites]
Stem Cells. 2007 Sep;25(9):2302-11
[
17569791.001
]
[Cites]
Curr Top Dev Biol. 2008;81:311-40
[
18023733.001
]
[Cites]
FASEB J. 2007 Dec;21(14):4059-69
[
17675532.001
]
[Cites]
Cell. 2007 Dec 28;131(7):1354-65
[
18160043.001
]
[Cites]
J Immunol. 2008 Feb 1;180(3):1686-93
[
18209065.001
]
[Cites]
J Neurosci. 2008 Feb 6;28(6):1410-20
[
18256261.001
]
[Cites]
BMC Bioinformatics. 2007;8:462
[
18039375.001
]
[Cites]
PLoS Comput Biol. 2008 Mar;4(3):e1000021
[
18369420.001
]
[Cites]
Cancer Cell. 2008 Apr;13(4):289-91
[
18394549.001
]
[Cites]
Cancer Cell. 2008 Apr;13(4):299-310
[
18394553.001
]
[Cites]
Nat Rev Immunol. 2008 May;8(5):372-9
[
18362948.001
]
[Cites]
Mol Cell. 2008 May 9;30(3):290-302
[
18471975.001
]
[Cites]
Nature. 2008 May 22;453(7194):544-7
[
18497826.001
]
[Cites]
Environ Health Perspect. 1993 Dec;101 Suppl 5:15-26
[
7516873.001
]
[Cites]
Leukemia. 1994 Jul;8(7):1131-8
[
7518549.001
]
[Cites]
Proc Soc Exp Biol Med. 1995 Jan;208(1):109-15
[
7892284.001
]
[Cites]
Biosci Rep. 1994 Dec;14(6):259-81
[
7620078.001
]
[Cites]
Cell. 1996 Jan 26;84(2):321-30
[
8565077.001
]
[Cites]
Nucleic Acids Res. 1996 Jan 1;24(1):238-41
[
8594589.001
]
[Cites]
Exp Cell Res. 1996 Mar 15;223(2):290-300
[
8601406.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12359-63
[
8901586.001
]
[Cites]
Nat Genet. 2000 May;25(1):25-9
[
10802651.001
]
[Cites]
J Neurosci Res. 2000 Aug 15;61(4):364-70
[
10931522.001
]
[Cites]
EMBO J. 2000 Nov 1;19(21):5711-9
[
11060022.001
]
[Cites]
Exp Cell Res. 2000 Nov 25;261(1):91-103
[
11082279.001
]
[Cites]
Mol Cell Biol. 2001 Jan;21(1):224-34
[
11113197.001
]
[Cites]
Nat Genet. 2001 Mar;27(3):263-70
[
11242107.001
]
[Cites]
Nat Med. 2001 Apr;7(4):444-51
[
11283671.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
[
11309499.001
]
[Cites]
Exp Cell Res. 2001 May 15;266(1):126-34
[
11339831.001
]
[Cites]
Curr Opin Cell Biol. 2001 Dec;13(6):706-14
[
11698186.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13120-5
[
11687616.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):757-62
[
11805330.001
]
[Cites]
Blood. 2002 Feb 15;99(4):1364-72
[
11830488.001
]
[Cites]
EMBO J. 2002 Apr 2;21(7):1723-32
[
11927556.001
]
[Cites]
Genome Res. 2002 Jun;12(6):996-1006
[
12045153.001
]
[Cites]
Genes Dev. 2002 Jul 15;16(14):1760-5
[
12130536.001
]
[Cites]
Bioinformatics. 2002 Oct;18(10):1319-31
[
12376376.001
]
[Cites]
Haematologica. 2002 Dec;87(12):1307-23
[
12495904.001
]
[Cites]
Bioinformatics. 2003 Jan 22;19(2):185-93
[
12538238.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):992-7
[
12552125.001
]
[Cites]
Biochem Pharmacol. 2003 Mar 1;65(5):813-21
[
12628493.001
]
[Cites]
Front Biosci. 2003 May 1;8:s206-22
[
12700034.001
]
[Cites]
Genome Biol. 2003;4(4):R28
[
12702209.001
]
[Cites]
Immunobiology. 2003;207(3):217-21
[
12777063.001
]
[Cites]
Mol Cell Biol. 2003 Dec;23(24):8934-45
[
14645506.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14875-80
[
14657364.001
]
[Cites]
Immunobiology. 2003;208(4):391-9
[
14748512.001
]
[Cites]
Curr Cancer Drug Targets. 2004 Feb;4(1):65-75
[
14965268.001
]
[Cites]
Bioinformatics. 2004 Apr 12;20(6):924-30
[
14751971.001
]
[Cites]
Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28
[
15207251.001
]
[Cites]
Leukemia. 2004 Jul;18(7):1231-7
[
15103390.001
]
[Cites]
Curr Biol. 2004 Oct 5;14(19):1712-22
[
15458642.001
]
[Cites]
J Theor Biol. 1969 Mar;22(3):437-67
[
5803332.001
]
[Cites]
Proc Natl Acad Sci U S A. 1970 Jun;66(2):352-9
[
5271168.001
]
[Cites]
Proc Natl Acad Sci U S A. 1978 May;75(5):2458-62
[
276884.001
]
[Cites]
Proc Natl Acad Sci U S A. 1979 Jun;76(6):2779-83
[
288066.001
]
[Cites]
Blood. 1979 Sep;54(3):713-33
[
288488.001
]
[Cites]
Proc Natl Acad Sci U S A. 1980 May;77(5):2936-40
[
6930676.001
]
[Cites]
Leuk Res. 1983;7(1):51-5
[
6682163.001
]
[Cites]
J Cell Physiol. 1984 Mar;118(3):277-86
[
6583206.001
]
[Cites]
Exp Cell Res. 1984 Jun;152(2):493-9
[
6586426.001
]
[Cites]
Leuk Res. 1985;9(1):51-71
[
3857406.001
]
[Cites]
Blood. 1986 Jan;67(1):31-6
[
3484427.001
]
[Cites]
J Cell Sci Suppl. 1989;12:21-7
[
2699735.001
]
[Cites]
EMBO J. 1990 Oct;9(10):3343-51
[
2209547.001
]
[Cites]
Genomics. 1992 Jul;13(3):565-74
[
1386335.001
]
[Cites]
Cell. 1993 May 7;73(3):487-97
[
8343202.001
]
[Cites]
Leuk Lymphoma. 1993 Nov;11(5-6):331-8
[
8124204.001
]
[Cites]
Science. 1994 May 27;264(5163):1326-9
[
8191287.001
]
[Cites]
Bull Math Biol. 1997 Jan;59(1):139-96
[
8980305.001
]
[Cites]
Oncogene. 1997 Jan 16;14(2):195-202
[
9010221.001
]
[Cites]
Mol Biol Cell. 1999 Mar;10(3):785-98
[
10069818.001
]
[Cites]
Blood. 1999 May 1;93(9):2760-70
[
10216069.001
]
[Cites]
Blood. 1999 May 15;93(10):3167-215
[
10233871.001
]
[Cites]
J Biol Chem. 2005 Feb 18;280(7):5468-74
[
15590664.001
]
[Cites]
J Theor Biol. 2005 May 21;234(2):173-86
[
15757677.001
]
[Cites]
Curr Opin Hematol. 2005 May;12(3):210-6
[
15867577.001
]
[Cites]
Phys Rev Lett. 2005 Apr 1;94(12):128701
[
15903968.001
]
[Cites]
Cancer Cell. 2005 Sep;8(3):175-6
[
16169461.001
]
[Cites]
Leukemia. 2005 Dec;19(12):2241-6
[
16239915.001
]
[Cites]
Nat Genet. 2006 Feb;38(2):228-33
[
16380711.001
]
[Cites]
BMC Cell Biol. 2006;7:11
[
16507101.001
]
[Cites]
Biosystems. 2006 May;84(2):101-14
[
16386358.001
]
[Cites]
Nature. 2006 May 11;441(7090):173-8
[
16688168.001
]
(PMID = 19222862.001).
[ISSN]
1752-0509
[Journal-full-title]
BMC systems biology
[ISO-abbreviation]
BMC Syst Biol
[Language]
eng
[Grant]
United States / NIGMS NIH HHS / GM / P50 GM076547; United States / NIGMS NIH HHS / GM / P50 GM076547; United States / NIGMS NIH HHS / GM / R01 GM072855; United States / NIGMS NIH HHS / GM / R21 GM070600
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD11b; 5688UTC01R / Tretinoin
[Other-IDs]
NLM/ PMC2652435
59.
Chin KM, Foss FM:
Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox.
Clin Lymphoma Myeloma
; 2006 Nov;7(3):199-204
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Biologic correlates of response and survival in patients with cutaneous T-
cell lymphoma
treated with denileukin diftitox.
BACKGROUND: Denileukin diftitox, a fusion protein consisting of peptide sequences for the enzymatically active and membrane translocation domains of diphtheria toxin and human interleukin, resulted in a response rate of 30% in the phase III registration trial in patients with recurrent or persistent cutaneous T-
cell lymphoma
(CTCL).
PATIENTS AND METHODS: In our single-center series of 37 patients with early- and advanced-
stage
disease with CTCL treated with denileukin diftitox at a dose of 9 microg/kg or 18 microg/kg per day, we observed an overall response rate of 51%.
RESULTS: In 8 patients with early-
stage
(< IIA) CTCL, there were 5 responses (62.5%), and the median survival has not been reached, with 70% of patients still alive at 46 months.
In 29 patients with advanced-
stage
(>/= IIB) disease, there were 14 responses (49.3%), and the median survival was 31 months.
Changes in the number of CD4+ CD25+ T-
cell
populations were observed in 7 of 19 responders, with no overall changes in the absolute lymphocyte counts during the course of therapy.
CONCLUSION: Denilekin diftitox was a well-tolerated treatment in early- and advanced-
stage
CTCL and was not associated with detrimental immunologic efects on lymphocyte populations.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Diphtheria Toxin / therapeutic use. Interleukin-2 / therapeutic use.
Lymphoma
, T-
Cell
, Cutaneous / drug therapy.
Lymphoma
, T-
Cell
, Cutaneous / mortality. Skin Neoplasms / drug therapy. Skin Neoplasms / mortality
Genetic Alliance.
consumer health - Cutaneous T-Cell Lymphoma
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17229335.001).
[ISSN]
1557-9190
[Journal-full-title]
Clinical lymphoma & myeloma
[ISO-abbreviation]
Clin Lymphoma Myeloma
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
60.
Shen L, Suresh L, Li H, Zhang C, Kumar V, Pankewycz O, Ambrus JL Jr:
IL-14 alpha, the nexus for primary Sjögren's disease in mice and humans.
Clin Immunol
; 2009 Mar;130(3):304-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Transgenic mice in which IL-14a expression was increased constitutively were previously demonstrated to develop hypergammaglobulinemia, autoantibodies, infiltration of the parotid glands with lymphocytes, mild immune-complex mediated renal disease and large
B cell lymphoma
.
In this paper we expand these observations to demonstrate that these mice develop all the clinical and immunological features of primary Sjögren's disease in the same relative time frame as patients with primary Sjögren's disease:
stage
1-early hypergammaglobulinemia and autoantibody production,
stage
2-decreased salivary gland function with early lymphocytic infiltration of the submandibular glands only, but antibody deposition in the submandibular and parotid glands,
stage
3-lymphocytic infiltration of the submandibular, parotid and lacrimal glands with B and T lymphocytes and plasma cells along with interstitial lung disease and mild renal disease, and
stage
4-large
B cell lymphoma
.
MedlinePlus Health Information.
consumer health - Sjogren's Syndrome
.
COS Scholar Universe.
author profiles
.
Jackson Laboratory JAX®Mice Database.
culture/stock collections - B6.Cg-Tg(Emu-TXLNA)1Amjr/J
(subscription/membership/fee required).
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19038581.001).
[ISSN]
1521-7035
[Journal-full-title]
Clinical immunology (Orlando, Fla.)
[ISO-abbreviation]
Clin. Immunol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Interleukins; 0 / RNA, Messenger
61.
Kim JH, Lee JH, Lee J, Oh SO, Chang DK, Rhee PL, Kim JJ, Rhee JC, Lee J, Kim WS, Ko YH:
Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings.
Endoscopy
; 2007 Feb;39(2):156-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary NK-/T-
cell lymphoma
of the gastrointestinal tract: clinical characteristics and endoscopic findings.
BACKGROUND AND STUDY AIMS: Primary NK-/T-
cell lymphoma
of the gastrointestinal tract is a very rare disease with a poor prognosis.
The aim of this study was to determine the clinical and endoscopic characteristics of patients with primary gastrointestinal NK-/T-
cell lymphoma
.
PATIENTS AND METHODS: The clinical features of 14 patients with primary gastrointestinal NK-/T-
cell lymphoma
and the endoscopic findings in 11 of these patients were reviewed.
RESULTS: The initial presenting symptoms of primary gastrointestinal NK-/T-
cell lymphoma
were gastrointestinal bleeding (n = 6, 42%), abdominal pain (n = 4, 29%), and epigastric soreness (n = 4, 29%).
The disease was at an advanced
stage
at the time of diagnosis:
stage
II in 5 patients (36%);
stage
III in 4 (28%); and
stage
IV in 5 (36%).
CONCLUSIONS: Primary gastrointestinal NK-/T-
cell lymphoma
was endoscopically characterized by superficial/erosive, ulcerative, or ulceroinfiltrative lesions without fungating mass.
[MeSH-major]
Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / pathology. Killer Cells, Natural / pathology.
Lymphoma
, T-
Cell
/ pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17657701.001).
[ISSN]
1438-8812
[Journal-full-title]
Endoscopy
[ISO-abbreviation]
Endoscopy
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
62.
Oscier D, Wade R, Davis Z, Morilla A, Best G, Richards S, Else M, Matutes E, Catovsky D, Chronic Lymphocytic Leukaemia Working Group, UK National Cancer Research Institute:
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.
Haematologica
; 2010 Oct;95(10):1705-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CONCLUSIONS: This study demonstrates the role of biomarkers in prognosis and shows that, in patients requiring treatment, disease
stage
may no longer be an independent predictor of outcome.
[MeSH-major]
Leukemia, Lymphocytic, Chronic, B-
Cell
/ mortality. Leukemia, Lymphocytic, Chronic, B-
Cell
/ pathology
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Haematol. 2009 Jun;145(6):801-5
[
19388937.001
]
[Cites]
J Clin Oncol. 2009 Apr 1;27(10):1637-43
[
19224852.001
]
[Cites]
Br J Haematol. 2009 Jun;146(1):44-53
[
19438486.001
]
[Cites]
N Engl J Med. 2000 Dec 28;343(26):1910-6
[
11136261.001
]
[Cites]
Blood. 2001 Nov 1;98(9):2633-9
[
11675331.001
]
[Cites]
Blood. 2002 Mar 15;99(6):2262-4
[
11877310.001
]
[Cites]
Blood. 2002 Aug 15;100(4):1177-84
[
12149195.001
]
[Cites]
Blood. 2002 Aug 15;100(4):1410-6
[
12149225.001
]
[Cites]
N Engl J Med. 2003 May 1;348(18):1764-75
[
12724482.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3928-32
[
14581416.001
]
[Cites]
Lancet. 2004 Jan 10;363(9403):105-11
[
14726163.001
]
[Cites]
Blood. 2004 Feb 15;103(4):1202-10
[
14576043.001
]
[Cites]
N Engl J Med. 2004 Aug 26;351(9):893-901
[
15329427.001
]
[Cites]
Blood. 1999 Sep 15;94(6):1840-7
[
10477712.001
]
[Cites]
Blood. 1999 Sep 15;94(6):1848-54
[
10477713.001
]
[Cites]
Haematologica. 2005 Apr;90(4):465-9
[
15820941.001
]
[Cites]
Cancer. 2005 Nov 15;104(10):2124-32
[
16211545.001
]
[Cites]
J Clin Oncol. 2006 Jan 20;24(3):437-43
[
16344317.001
]
[Cites]
Blood. 2006 Apr 1;107(7):2889-94
[
16317103.001
]
[Cites]
Blood. 2007 Jan 1;109(1):259-70
[
16985177.001
]
[Cites]
J Clin Oncol. 2007 Mar 1;25(7):799-804
[
17283363.001
]
[Cites]
Lancet. 2007 Jul 21;370(9583):230-9
[
17658394.001
]
[Cites]
Blood. 2007 Nov 1;110(9):3352-9
[
17684154.001
]
[Cites]
Blood. 2007 Dec 1;110(12):4012-21
[
17699742.001
]
[Cites]
Blood. 2008 Feb 1;111(3):1524-33
[
17959859.001
]
[Cites]
Blood. 2008 May 15;111(10):5173-81
[
18326821.001
]
[Cites]
Blood. 2008 Sep 1;112(5):1923-30
[
18577710.001
]
[Cites]
Blood. 2008 Oct 15;112(8):3322-9
[
18689542.001
]
[Cites]
Leuk Lymphoma. 2008 Nov;49(11):2108-15
[
19021053.001
]
[Cites]
Cancer. 2009 Jan 15;115(2):373-80
[
19117034.001
]
[Cites]
Clin Cancer Res. 2009 Feb 1;15(3):995-1004
[
19188171.001
]
(PMID = 20511662.001).
[ISSN]
1592-8721
[Journal-full-title]
Haematologica
[ISO-abbreviation]
Haematologica
[Language]
eng
[Databank-accession-numbers]
ISRCTN/ ISRCTN58585610; ClinicalTrials.gov/ NCT00004218
[Grant]
United Kingdom / Medical Research Council / / MC/ U137686856
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Other-IDs]
NLM/ PMC2948096
[Investigator]
Bloor A; Nathwani A; Duncombe A; Pettitt A; Schuh A; Kennedy B; Pepper C; Fegan C; Pocock C; Dearden C; Catovsky D; Oscier D; Cohen D; Matutes E; Follows G; Gribben J; Leach M; Else M; Fenwick N; Hillmen P; Wade R; Marshall S; Devereux S; Richards S; Hambin T; Gregory W
63.
Tanţău M, Tanţău A, Zaharia T, Cucuianu A:
Gastrointestinal lymphomatous polyposis--clinical, endoscopical and evolution features. A case report.
Rom J Gastroenterol
; 2005 Sep;14(3):273-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Primary gastrointestinal
non
-
Hodgkin
lymphoma
accounts for 13-18% of all malignant tumours of small bowel and only 1 % of large bowel tumours (1).
Majority of cases with gastrointestinal primary
lymphoma
are classified histologically as "mantle
cell
" lymphomas.
Histopathological and immunohistochemical studies on biopsy specimens from colon and duodenum confirmed gastrointestinal
non
-
Hodgkin
lymphoma
, probably "mantle
cell
"
lymphoma
.
Because she was in an advanced
stage
she received only cytostatic treatment.
[MeSH-major]
Intestinal Polyps / pathology.
Lymphoma
, Mantle-
Cell
/ pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16200239.001).
[ISSN]
1221-4167
[Journal-full-title]
Romanian journal of gastroenterology
[ISO-abbreviation]
Rom J Gastroenterol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Romania
64.
Wada N, Ikeda J, Kohara M, Ogawa H, Hino M, Fukuhara S, Kanamaru A, Sugiyama H, Kanakura Y, Morii E, Aozasa K:
Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group.
Virchows Arch
; 2009 Sep;455(3):285-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diffuse large B-
cell lymphoma
with a high number of epithelioid histiocytes (lymphoepithelioid B-
cell lymphoma
): a study of Osaka
Lymphoma
Study Group.
The aim of this study was to clarify whether diffuse large B-
cell lymphoma
(DLBCL) with a high number of epithelioid histiocytes (DLBCL-EH) could have distinctive clinicopathological characteristics.
Stage
of disease was I in five cases, II in three, III in nine, and IV in five.
[MeSH-major]
Histiocytes / pathology.
Lymphoma
, Large B-
Cell
, Diffuse / pathology
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 1993 Sep 30;329(14 ):987-94
[
8141877.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
Blood. 2004 Jan 1;103(1):275-82
[
14504078.001
]
[Cites]
Leuk Lymphoma. 2007 Sep;48(9):1764-73
[
17786712.001
]
[Cites]
Leuk Res. 2004 Mar;28(3):229-36
[
14687617.001
]
[Cites]
Blood. 2009 Mar 19;113(12):2765-3775
[
19096012.001
]
[Cites]
N Engl J Med. 2008 Nov 27;359(22):2313-23
[
19038878.001
]
[Cites]
Histopathology. 2002 Jan;40(1):31-45
[
11903596.001
]
[Cites]
Pediatr Blood Cancer. 2008 Oct;51(4):557-9
[
18523988.001
]
[Cites]
Am J Surg Pathol. 1992 Apr;16(4):351-63
[
1373580.001
]
[Cites]
Leukemia. 2003 Dec;17(12):2257-317
[
14671650.001
]
[Cites]
Nature. 2000 Feb 3;403(6769):503-11
[
10676951.001
]
[Cites]
J Clin Exp Hematop. 2007 Apr;47(1):23-6
[
17510535.001
]
[Cites]
Eur J Haematol. 2007 Dec;79(6):501-7
[
17986209.001
]
[Cites]
J Clin Oncol. 2003 Apr 1;21(7):1271-7
[
12663714.001
]
[Cites]
Cancer. 1978 Feb;41(2):562-7
[
630538.001
]
[Cites]
Blood. 1997 Jun 1;89(11):3909-18
[
9166827.001
]
[Cites]
Am J Clin Pathol. 1995 Jan;103(1):65-75
[
7817948.001
]
[Cites]
Oncologist. 2006 Apr;11(4):384-92
[
16614234.001
]
[Cites]
N Engl J Med. 2002 Jun 20;346(25):1937-47
[
12075054.001
]
[Cites]
Blood. 1992 Apr 1;79(7):1789-95
[
1373088.001
]
(PMID = 19727807.001).
[ISSN]
1432-2307
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
65.
Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES:
Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
Mod Pathol
; 2010 Jul;23(7):991-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Plasmablastic
lymphoma
with MYC translocation: evidence for a common pathway in the generation of plasmablastic features.
Plasmablastic
lymphoma
, which is considered a subtype of diffuse large B-
cell lymphoma
, shares many similar morphological and immunophenotypic features with plasmablastic transformation of plasma
cell
myeloma.
We report four unique cases of plasmablastic
lymphoma
occurring in the setting of HIV infection that had overlapping clinical and genetic features with plasma
cell
myeloma.
In addition to extra-nodal disease, plasmablastic morphology, and phenotype typical of plasmablastic
lymphoma
, three of the four cases also showed clinical findings overlapping with plasma
cell
myeloma, that is, monoclonal serum immunoglobulin and lytic bone lesions.
Furthermore, these cases showed complex cytogenetic changes that are more commonly observed in plasma
cell
myeloma.
MYC translocation has been associated with tumor progression in multiple myeloma but has only rarely been previously reported in plasmablastic
lymphoma
.
These cases show a clinical and biological relationship between plasmablastic
lymphoma
and the plasmablastic variant of plasma
cell
myeloma.
Dysregulation of MYC may be a common genetic mechanism that imparts plasmablastic morphology and aggressive clinical course to B-
cell
neoplasms at a later
stage
of differentiation.
[MeSH-major]
Lymphoma
, Large B-
Cell
, Diffuse / genetics.
Lymphoma
, Large B-
Cell
, Diffuse / pathology. Multiple Myeloma / genetics. Multiple Myeloma / pathology. Proto-Oncogene Proteins c-myc / genetics
MedlinePlus Health Information.
consumer health - Multiple Myeloma
.
COS Scholar Universe.
author profiles
.
HIV InSite.
treatment guidelines - Cardiac Cardiac Manifestations of HIV
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20348882.001).
[ISSN]
1530-0285
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Proto-Oncogene Proteins c-myc
66.
Kneile JR, Tan G, Suster S, Wakely PE Jr:
Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large cell lymphoma.
Histopathology
; 2006 Jun;48(7):855-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma. A comparison study with anaplastic large
cell lymphoma
.
AIMS: Undifferentiated nasopharyngeal
non
-keratinizing carcinoma (UNPC), formerly known as lymphoepithelioma, frequently metastasizes at an early
stage
to regional lymph nodes and, thus, may be difficult to distinguish from
Hodgkin
's
lymphoma
(HL) or anaplastic large
cell lymphoma
(ALCL).
The aim of this study was to evaluate CD30 expression in UNPC and lymphoepithelioma-like carcinoma (LELC) from other anatomic locations and compare it with ALCL and squamous
cell
carcinoma (SCC).
[MeSH-major]
Antigens, CD30 / biosynthesis. Carcinoma / pathology. Carcinoma, Squamous
Cell
/ pathology.
Lymphoma
, Large-
Cell
, Anaplastic / pathology. Nasopharyngeal Neoplasms / pathology
Genetic Alliance.
consumer health - Anaplastic Large Cell Lymphoma
.
Genetic Alliance.
consumer health - Lymphoma, large-cell
.
Genetic Alliance.
consumer health - Nasopharyngeal carcinoma
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16722935.001).
[ISSN]
0309-0167
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD30
67.
Matignon M, Cacoub P, Colombat M, Saadoun D, Brocheriou I, Mougenot B, Roudot-Thoraval F, Vanhille P, Moranne O, Hachulla E, Hatron PY, Fermand JP, Fakhouri F, Ronco P, Plaisier E, Grimbert P:
Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection.
Medicine (Baltimore)
; 2009 Nov;88(6):341-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
MC was related to primary Sjögren Syndrome (pSS) in 9 patients, and to
non
-
Hodgkin
lymphoma
in 1 patient, while MC was classified as essential in the remaining 10 cases.
However, renal relapse occurred in most patients, with 10% reaching end-
stage
renal disease.
Three patients with essential MC developed B-
cell lymphoma
36-48 months after the diagnosis of MC.
Unexpectedly, B-
cell lymphoma
induced by Epstein-Barr virus infection occurred in only 1 of the 9 pSS patients.
Forty percent of patients died as a result of extrarenal causes.Renal disease associated with MC unrelated to HCV is characterized by the high prevalence of pSS (45%), the finding of CD20+ B-lymphocyte nodular infiltrates in the kidney interstitium, and a high incidence of overt B-
cell lymphoma
during follow-up.
Genetic Alliance.
consumer health - Cryoglobulinemia
.
Genetic Alliance.
consumer health - Hepatitis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19910748.001).
[ISSN]
1536-5964
[Journal-full-title]
Medicine
[ISO-abbreviation]
Medicine (Baltimore)
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study
[Publication-country]
United States
68.
Feng LJ, Zhang GP, Xie M, Cao PF, Fu CY, Hu ZL, Dai M:
[Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal lymphoma].
Zhongguo Dang Dai Er Ke Za Zhi
; 2009 Jul;11(7):555-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Relationship between p53 gene and chromosome 13q14 variations and prognosis in primary intestinal
lymphoma
].
OBJECTIVE: Some research has shown that primary intestinal
lymphoma
with the same immunophenotype has different prognosis.
This study aimed to explore the role of the p53 gene and chromosome 13q14 variations in the assessment of prognosis in primary intestinal
lymphoma
.
METHODS: p53 gene and chromosome 13q14 expression in paraffin sections of 30 cases of primary intestinal
lymphoma
and 10 cases of lymph node reactive hyperplasia were ascertained using an improved FISH technique.
RESULTS: p53 gene deletion was found in 22.7% of patients with primary intestinal
lymphoma
at
stage I
-II and in 75.0% of patients at
stage
III-IV (x2=6.903, p<0.01).
The 30 patients with primary intestinal
lymphoma
were pathologically classified into-mucosa-associated lymphoid tissue (MALT) (n=14) and
non
-MALT types (n=16).
The MALT
lymphoma
group had significantly lower incidence of p53 gene deletion (14.3% vs 56.3%; x2=5.662, p<0.05).
13q14 deletion was found in 40.0% of patients with primary intestinal
lymphoma
, but none of patients with lymph node reactive hyperplasia showed 13q14 deletion.
13q14 deletion was not significantly related to the pathological type and the clinical
stage
of primary intestinal
lymphoma
as well as the survival time.
CONCLUSIONS: There was a high incidence of p53 gene deletion in patients with
non
-MALT
lymphoma
or at
stage
III-IV. p53 gene deletion is related to a high tumor malignant degree and a poor prognosis, while-chromosome 13q14 variation is not associated with the prognosis in patients with primary intestinal
lymphoma
.
[MeSH-major]
Chromosome Aberrations. Chromosomes, Human, Pair 13. Genes, p53. Intestinal Neoplasms / genetics.
Lymphoma
/ genetics
[MeSH-minor]
Adolescent. Adult. Aged. Child. Humans. In Situ Hybridization, Fluorescence.
Lymphoma
, B-
Cell
, Marginal Zone / genetics.
Lymphoma
, B-
Cell
, Marginal Zone / mortality. Middle Aged. Prognosis
MedlinePlus Health Information.
consumer health - Lymphoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19650989.001).
[ISSN]
1008-8830
[Journal-full-title]
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
[ISO-abbreviation]
Zhongguo Dang Dai Er Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
69.
Mazloom A, Fowler N, Medeiros LJ, Iyengar P, Horace P, Dabaja BS:
Outcome of patients with diffuse large B-cell lymphoma of the testis by era of treatment: the M. D. Anderson Cancer Center experience.
Leuk Lymphoma
; 2010 Jul;51(7):1217-24
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcome of patients with diffuse large B-
cell lymphoma
of the testis by era of treatment: the M. D. Anderson Cancer Center experience.
The purpose of this study was to assess the clinicopathologic characteristics and outcomes in patients with diffuse large B-
cell lymphoma
(DLBCL) of the testis, and to assess the impact of changes in the therapeutic approach that have occurred over the years.
Factors analyzed included: age, clinical
stage
, B-symptoms, serum levels of lactate dehydrogenase (LDH), beta(2)-microglobulin, treatment received, and outcome.
Immunophenotypic data were available for 43 cases, all of which showed B-
cell
lineage.
Advanced
stage
, elevated serum LDH, B-symptoms, and high IPI are poor prognostic markers.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, Large B-
Cell
, Diffuse / therapy. Testicular Neoplasms / therapy
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Leuk Lymphoma. 2010 Jul;51(7):1159-60
[
20497004.001
]
(PMID = 20443676.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30 CA016672
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / beta 2-Microglobulin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone
70.
Kojima M, Shimizu K, Nishikawa M, Tamaki Y, Ito H, Tsukamoto N, Masawa N:
Primary salivary gland lymphoma among Japanese: A clinicopathological study of 30 cases.
Leuk Lymphoma
; 2007 Sep;48(9):1793-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary salivary gland
lymphoma
among Japanese: A clinicopathological study of 30 cases.
To clarify the clinicopathological findings of primary salivary gland
lymphoma
as defined by the World Health Organization (WHO) classification, 30 Japanese patients with this disease were studied.
Twenty-four (80%) cases demonstrated
Stage
IE, whereas only six (20%) had
Stage
IIE-1.
Histologically, 15 cases were mucosa-associated lymphoid tissue (MALT)
lymphoma
, seven were follicular
lymphoma
(FL), and six were diffuse large B-
cell lymphoma
(DLBCL) + MALT
lymphoma
and only two were DLBCL without a MALT
lymphoma
component.
MALT
lymphoma
is the most frequent type of primary salivary gland
lymphoma
.
However, FL comprised 20% of primary salivary gland
lymphoma
.
The majority of the primary salivary gland DLBCL appear to arise from MALT type
lymphoma
.
When appropriate therapy for histologic subtype is used, outcome of the primary salivary gland B-
cell lymphoma
appears excellent whether histologically indolent or aggressive.
[MeSH-major]
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
, B-
Cell
, Marginal Zone / pathology. Salivary Gland Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Salivary Gland Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17786716.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
71.
Mansour MR:
Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma.
Expert Rev Hematol
; 2009 Apr;2(2):133-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Oncogenic Kras and Notch-1 cooperate in T-
cell
acute lymphoblastic leukemia/
lymphoma
.
Mutations of the Ras family are one of the most common somatic events found in all human cancers, although they are relatively rare in T-
cell
acute lymphoblastic leukemia (T-ALL).
In the article being evaluated, the authors demonstrate that primary mice expressing oncogenic Kras have a block in T-
cell
differentiation at the double-negative 1
stage
.
Cell
lines established from some of the mice demonstrated sensitivity to γ-secretase inhibition, suggesting that even when NOTCH-1 mutations occur as secondary collaborating events, tumors retain a dependency on this pathway that might be exploitable clinically.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Blood. 2008 Oct 15;112(8):3373-82
[
18663146.001
]
(PMID = 21083447.001).
[ISSN]
1747-4094
[Journal-full-title]
Expert review of hematology
[ISO-abbreviation]
Expert Rev Hematol
[Language]
eng
[Publication-type]
Comment; Journal Article
[Publication-country]
England
72.
Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R:
Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.
Am J Hematol
; 2009 Jul;84(7):414-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-
cell lymphoma
.
(1) study the incidence and clinical relevance of WHO grade 3/4 LON in a uniform group of patients with diffuse large B-
cell lymphoma
(DLBCL) in complete remission following curative rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) chemotherapy;.
Results of Fischer's exact test revealed that age,
stage
, LDH level, ECOG, marrow involvement, and hematologic parameters did not predict for LON development.
[MeSH-major]
Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects.
Lymphoma
, Large B-
Cell
, Diffuse / drug therapy. Neutropenia / chemically induced
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19415727.001).
[ISSN]
1096-8652
[Journal-full-title]
American journal of hematology
[ISO-abbreviation]
Am. J. Hematol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
73.
Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik JE:
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
J Clin Oncol
; 2008 Jun 1;26(16):2717-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-
cell lymphoma
with analysis of germinal center and post-germinal center biomarkers.
PURPOSE: To assess the clinical outcome and the influence of biomarkers associated with apoptosis inhibition (Bcl-2), tumor proliferation (MIB-1), and cellular differentiation on the outcome with dose-adjusted (DA) EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) plus rituximab (R) infusional therapy in diffuse large B-
cell lymphoma
(DLBCL) with analysis of germinal center B-
cell
(GCB) and post-GCB subtypes by immunohistochemistry.
PATIENTS AND METHODS: Phase II study of 72 patients with untreated
de
novo DLBCL who were at least 18 years of age and
stage
II or higher.
[MeSH-major]
Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / classification. Germinal Center / drug effects.
Lymphoma
, Large B-
Cell
, Diffuse / drug therapy
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 1990 Oct;62(4):551-2
[
2223571.001
]
[Cites]
Cancer Chemother Rep. 1966 Mar;50(3):163-70
[
5910392.001
]
[Cites]
N Engl J Med. 1993 Sep 30;329(14):987-94
[
8141877.001
]
[Cites]
Blood. 1994 Mar 15;83(6):1460-6
[
8123837.001
]
[Cites]
Blood. 1997 Jan 15;89(2):601-9
[
9002964.001
]
[Cites]
Cancer Chemother Rep. 1964 Feb;35:1-111
[
14117037.001
]
[Cites]
Nature. 2004 Dec 2;432(7017):635-9
[
15577913.001
]
[Cites]
J Clin Oncol. 2005 Jun 20;23(18):4117-26
[
15867204.001
]
[Cites]
J Clin Oncol. 2005 Aug 1;23(22):5027-33
[
15955905.001
]
[Cites]
Histopathology. 2005 Sep;47(3):281-91
[
16115229.001
]
[Cites]
Nat Immunol. 2005 Oct;6(10):1054-60
[
16142238.001
]
[Cites]
Leuk Lymphoma. 2005 Nov;46(11):1569-73
[
16236611.001
]
[Cites]
Haematologica. 2006 Apr;91(4):496-502
[
16537117.001
]
[Cites]
Lancet Oncol. 2006 May;7(5):379-91
[
16648042.001
]
[Cites]
Haematologica. 2006 May;91(5):715-6
[
16670080.001
]
[Cites]
Blood. 2006 Jun 1;107(11):4207-13
[
16449523.001
]
[Cites]
J Clin Oncol. 2006 Jul 1;24(19):3121-7
[
16754935.001
]
[Cites]
Semin Hematol. 2006 Oct;43(4):230-9
[
17027657.001
]
[Cites]
Blood. 2007 Jan 15;109(2):843-4; discussion 844-5
[
17210865.001
]
[Cites]
Br J Haematol. 2007 Jan;136(2):276-85
[
17233819.001
]
[Cites]
J Clin Oncol. 2007 Feb 10;25(5):579-86
[
17242396.001
]
[Cites]
Blood. 2007 Mar 1;109(5):1857-61
[
17105812.001
]
[Cites]
J Clin Oncol. 2007 Mar 1;25(7):805-12
[
17327602.001
]
[Cites]
Blood. 2007 Apr 1;109(7):2759-66
[
17132720.001
]
[Cites]
Blood. 2007 Jun 1;109(11):4930-5
[
17299093.001
]
[Cites]
Oncogene. 2007 May 28;26(25):3629-36
[
17530016.001
]
[Cites]
Blood. 2007 Jul 1;110(1):339-44
[
17379744.001
]
[Cites]
Nat Immunol. 2007 Jul;8(7):705-14
[
17558410.001
]
[Cites]
J Clin Oncol. 1999 Apr;17(4):1244
[
10561185.001
]
[Cites]
Nature. 2000 Feb 3;403(6769):503-11
[
10676951.001
]
[Cites]
J Exp Med. 2001 Dec 17;194(12):1861-74
[
11748286.001
]
[Cites]
Biochem Biophys Res Commun. 2001 Dec 21;289(5):1199-204
[
11741320.001
]
[Cites]
N Engl J Med. 2002 Jan 24;346(4):235-42
[
11807147.001
]
[Cites]
Blood. 2002 Apr 15;99(8):2685-93
[
11929754.001
]
[Cites]
N Engl J Med. 2002 Jun 20;346(25):1937-47
[
12075054.001
]
[Cites]
Blood. 2003 Jun 1;101(11):4279-84
[
12576316.001
]
[Cites]
J Exp Med. 2003 Sep 15;198(6):851-62
[
12975453.001
]
[Cites]
Blood. 2004 Jan 1;103(1):275-82
[
14504078.001
]
[Cites]
Mol Cancer Ther. 2004 May;3(5):621-32
[
15141020.001
]
[Cites]
Am J Pathol. 2004 Jul;165(1):159-66
[
15215171.001
]
[Cites]
N Engl J Med. 1993 Apr 8;328(14):1002-6
[
7680764.001
]
(PMID = 18378569.001).
[ISSN]
1527-7755
[Journal-full-title]
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
[ISO-abbreviation]
J. Clin. Oncol.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / / Z01 SC006741-13
[Publication-type]
Clinical Trial, Phase II; Journal Article; Multicenter Study
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
[Other-IDs]
NLM/ NIHMS44847; NLM/ PMC2409217
74.
Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M:
Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
Cancer
; 2008 Aug 15;113(4):791-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Incidence trends of mantle
cell lymphoma
in the United States between 1992 and 2004.
BACKGROUND: Mantle
cell lymphoma
(MCL) is a distinct subtype of B-
cell
non
-
Hodgkin
's
lymphoma
.
RESULTS: Of the 87,166 patients diagnosed with
non
-
Hodgkin
's
lymphoma
during the 13-year period between 1992 and 2004, 2459 (2.8%) had confirmed MCL.
Late-
stage
(III-IV) MCL was diagnosed in 74.6% of patients.
Most patients were diagnosed with late-
stage
MCL, and there also were considerable geographic variations observed in incidence rate.
[MeSH-major]
Lymphoma
, Mantle-
Cell
/ epidemiology
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2008 American Cancer Society
(PMID = 18615506.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Grant]
United States / AHRQ HHS / HS / R01-HS016743
[Publication-type]
Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
75.
Magné N, Foa C, Castadot P, Otto J, Birtwisle-Peyrottes I, Thyss A:
[Guillain-Barré syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature].
Rev Med Brux
; 2005 Mar-Apr;26(2):108-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Guillain-Barré syndrome and
non
-
Hodgkin
's
lymphoma
. Report of one case and review of literature].
[Transliterated title]
Syndrome
de
Guillain-Barré et
lymphome non
-hodgkinien. A propos d'une observation et revue
de
la littérature.
Patients with
lymphoma
frequently develop neurologic abnormalities mainly due to nervous system infiltration but also direct drug toxicity.
Moreover Guillain-Barré syndrome (GBS) remains a possible neuropathy, rarely described in
non
-
Hodgkin
's
lymphoma
.
We describe a case of GBS in a patient with
non
-
Hodgkin
's high grade
lymphoma
.
A 74-year old man with a newly diagnosed
stage I
high-grade
lymphoma
(precursor B-
cell
Burkitt like type according to the R.E.A.L.
The low number of cases described in the international literature doesn't permit to understand the association of this neurologic disease with
non
-
Hodgkin
's
lymphoma
.
[MeSH-major]
Burkitt
Lymphoma
/ complications. Guillain-Barre Syndrome / complications
Genetic Alliance.
consumer health - Guillain-Barre Syndrome
.
MedlinePlus Health Information.
consumer health - Guillain-Barre Syndrome
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15945423.001).
[ISSN]
0035-3639
[Journal-full-title]
Revue médicale de Bruxelles
[ISO-abbreviation]
Rev Med Brux
[Language]
fre
[Publication-type]
Case Reports; English Abstract; Journal Article; Review
[Publication-country]
Belgium
[Number-of-references]
16
76.
Harrington CR, Guillén DR, Pandya AG:
Evaluation of new tumors in the setting of stage I/IIA mycosis fungoides.
Clin Lymphoma Myeloma
; 2007 Jul;7(7):480-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Evaluation of new tumors in the setting of
stage I
/IIA mycosis fungoides.
Although mycosis fungoides is usually a slowly progressive indolent
lymphoma
, new cutaneous tumors might signal an aggressive phase of the disease.
These tumors represented the following: mycosis fungoides without transformation, large-
cell
transformation of mycosis fungoides, lymphomatoid papulosis-associated CD30(+) lymphoproliferative disorder arising in a patient with mycosis fungoides, and a primary cutaneous CD30(+) lymphoproliferative disorder arising in a patient with mycosis fungoides.
Genetic Alliance.
consumer health - Mycosis fungoides
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17875239.001).
[ISSN]
1557-9190
[Journal-full-title]
Clinical lymphoma & myeloma
[ISO-abbreviation]
Clin Lymphoma Myeloma
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD30
77.
Huang HQ, Peng YL, Cai QQ, Lin XB, Li YH, Xia ZJ, Lin TY, Sun XF, Zhang L, Xu GC, He YJ, Jiang WQ, Guan ZZ:
[Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens].
Zhonghua Xue Ye Xue Za Zhi
; 2005 Oct;26(10):577-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Long-term outcomes of 392
non
-
Hodgkin
's
lymphoma
patients treated with pirarubicin based regimens].
OBJECTIVE: To analyse the effectiveness and toxicity of combined chemotherapy regimen containing pirarubicin (THP) in the treatment of
non
-
Hodgkin
's
lymphoma
(NHL).
B-
cell
and T/NK
cell
NHL accounted for 68.4% and 23.2% respectively with 56.9% of diffuse large
B cell lymphoma
and 12.5% of peripheral T
cell lymphoma
.
92.6% of the patients were ECOG < 1, 63.2% in
stage I
+ II, 84.7% with IPI score 0 - 2 and 25% with B symptoms, 93.9% (368/392) of the patients received CTOP (containing THP) regimen chemotherapy and among them 28.5% (112/392) plus involved field radiotherapy.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy
Hazardous Substances Data Bank.
DOXORUBICIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16532963.001).
[ISSN]
0253-2727
[Journal-full-title]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[ISO-abbreviation]
Zhonghua Xue Ye Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
80168379AG / Doxorubicin; D58G680W0G / pirarubicin
78.
Karsai S, Hou JS, Telang G, Kantor GR, Nowell PC, Vonderheid EC:
Sézary syndrome coexisting with B-cell chronic lymphocytic leukemia: case report and review of the literature.
Dermatology
; 2008;216(1):68-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sézary syndrome coexisting with B-
cell
chronic lymphocytic leukemia: case report and review of the literature.
INTRODUCTION: The simultaneous presentation of chronic B-
cell
lymphocytic leukemia (B-CLL) and cutaneous T-
cell lymphoma
(CTCL) is extremely rare.
DISCUSSION: We speculate that the coexistence of B-CLL and CTCL is the result of an initiating genetic or epigenetic defect at the level of the common lymphoid stem
cell
that predisposes both B-
cell
and T-
cell
lineages to additional oncogenic changes at a more advanced
stage
of differentiation.
[MeSH-major]
Leukemia, Lymphocytic, Chronic, B-
Cell
/ complications. Sezary Syndrome / complications. Skin Neoplasms / complications
[MeSH-minor]
Aged. Aged, 80 and over. Antigens, CD / analysis. B-Lymphocytes / metabolism. Fatal Outcome. Female. Humans. Male. Middle Aged. Receptors, Antigen, T-
Cell
, alpha-beta / analysis. Skin / pathology. T-Lymphocytes / metabolism
Genetic Alliance.
consumer health - Chronic Lymphocytic Leukemia
.
Genetic Alliance.
consumer health - Leukemia, B-cell, chronic
.
Genetic Alliance.
consumer health - Sezary syndrome
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 S. Karger AG, Basel.
(PMID = 18032903.001).
[ISSN]
1421-9832
[Journal-full-title]
Dermatology (Basel, Switzerland)
[ISO-abbreviation]
Dermatology (Basel)
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Antigens, CD; 0 / Receptors, Antigen, T-Cell, alpha-beta
[Number-of-references]
59
79.
Pott C, Schrader C, Brüggemann M, Ritgen M, Harder L, Raff T, Tiemann M, Dreger P, Kneba M:
Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
Eur J Haematol
; 2005 Apr;74(4):353-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Blastoid variant of mantle
cell lymphoma
: late progression from classical mantle
cell lymphoma
and quantitation of minimal residual disease.
OBJECTIVES: Classical mantle
cell lymphoma
(MCL) and its blastoid variant (MCL-BV) are characterized by an extremely poor prognosis.
We present a case of a 41-year-old male with a 12 yr history of MCL
stage I
to show, that very late relapses in MCL are possible and may present as a transformation into an aggressive blastoid variant and to illustrate the value of quantitative minimal residual disease (MRD) monitoring for treatment guidance.
Therefore, treatment was early intensified by myeloablative radio-chemotherapy and allogeneic peripheral stem
cell
transplantation from an unrelated HLA-identical donor.
CONCLUSION: This report presents a rare case of long-term survivor of MCL with a progression of the original MCL
cell
clone to MCL-BV and demonstrates the clinical value of quantitative MRD assessment for optimized therapeutic management.
[MeSH-major]
Lymphoma
, Mantle-
Cell
/ pathology
[MeSH-minor]
Adult. Base Sequence. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 14 / genetics. DNA, Neoplasm / genetics. Fatal Outcome. Genes, Immunoglobulin. Humans. Male. Peripheral Blood Stem
Cell
Transplantation. Time Factors. Translocation, Genetic
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 Blackwell Munksgaard.
(PMID = 15777349.001).
[ISSN]
0902-4441
[Journal-full-title]
European journal of haematology
[ISO-abbreviation]
Eur. J. Haematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / DNA, Neoplasm
80.
Dreyling M, Hoster E, Bea S, Hartmann E, Horn H, Hutter G, Salaverria I, Pott C, Trneny M, Le Gouill S, Cortelazzo S, Szymczyk M, Jurczak W, Shpilberg O, Ribrag V, Hermine O, European MCL Network:
Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
Leuk Lymphoma
; 2010 Sep;51(9):1612-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Update on the molecular pathogenesis and clinical treatment of Mantle
Cell Lymphoma
(MCL): minutes of the 9th European MCL Network conference.
Mantle
cell lymphoma
(MCL) is a distinct subtype of malignant
lymphoma
which is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in constitutional overexpression of cyclin D1 and
cell
cycle dysregulation in virtually all cases.
Advanced
stage
disease is usually apparent already at first clinical manifestation; thus, conventional chemotherapy is only palliative, and the median duration of remissions is only 1-2 years.
Emerging strategies including proteasome inhibitors, immune modulatory drugs (IMiDs), mTOR inhibitors, and others are based on the dysregulated control of
cell
cycle machinery and impaired apoptotic pathways.
In 2000 the European MCL Network ( http://www.european-mcl.net ) was founded, consisting of 15 national
lymphoma
study groups supplemented by experts in histopathology and molecular genetics.
In detail, in prospective randomized studies, the addition of a B-lymphocyte specific antibody doubled the median progression-free survival from 14 to 28 months, and a dose-intensified consolidation with high-dose radiochemotherapy and subsequent autologous stem
cell
transplant resulted in superior response duration (3.7 vs. 1.6 years) and even improved overall survival in a recent analysis.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, Mantle-
Cell
/ etiology.
Lymphoma
, Mantle-
Cell
/ therapy. Stem
Cell
Transplantation
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20629519.001).
[ISSN]
1029-2403
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
81.
Su ZY, Zhang DS, Zhu MQ, Shi YX, Jiang WQ:
[Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
Ai Zheng
; 2007 Aug;26(8):919-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Primary
non
-
Hodgkin
's
lymphoma
of the paranasal sinuses: a report of 14 cases].
BACKGROUND & OBJECTIVE: Primary paranasal sinus
lymphoma
(PPSL) is a rare presentation of extranodal
non
-
Hodgkin
's
lymphoma
with a natural history distinct from other lymphomas.
All patients were at
stage I
-II (Ann Arbor system).
Of the 14 patients, 12 had B-
cell
PPSL, 1 had T-
cell
PPSL, and 1 had unclassified PPSL.
The most common type was diffuse large B-
cell
PPSL (6 cases, 42.9%).
CONCLUSIONS: PPSL is an uncommon presentation of
lymphoma
characterized by bulky local disease.
Diffuse large B-
cell lymphoma
is the most common histologic type and the maxillary sinus is the most common original site of PPSL.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, B-
Cell
/ drug therapy.
Lymphoma
, Large B-
Cell
, Diffuse / drug therapy. Paranasal Sinus Neoplasms / drug therapy
[MeSH-minor]
Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Follow-Up Studies. Humans.
Lymphoma
, T-
Cell
/ drug therapy.
Lymphoma
, T-
Cell
/ pathology.
Lymphoma
, T-
Cell
/ radiotherapy.
Lymphoma
, T-
Cell
/ surgery. Maxillary Sinus / surgery. Middle Aged. Neoplasm Staging. Paranasal Sinuses / pathology. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17697560.001).
[Journal-full-title]
Ai zheng = Aizheng = Chinese journal of cancer
[ISO-abbreviation]
Ai Zheng
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
82.
Marcus R, Hagenbeek A:
The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Eur J Haematol Suppl
; 2007 Jan;(67):5-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The therapeutic use of rituximab in
non
-
Hodgkin
's
lymphoma
.
The
non
-
Hodgkin
's lymphomas (NHLs) comprise a heterogeneous collection of lymphoproliferative malignancies, which are most common in people aged over 55 years.
Diffuse large B-
cell lymphoma
(DLBCL) is the most common type of NHL, accounting for approximately 30% of all new patients.
Follicular
lymphoma
(FL) is the second most common NHL sub-type, and accounts for a further 22% of cases.
Over the last five years, the introduction of monoclonal antibodies, and specifically the anti-CD20 monoclonal antibody, rituximab, has radically changed treatment of B-
cell
NHL.
Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody which binds to the transmembrane antigen, CD20,
a non
-glycosylated phosphoprotein, located on pre-B and mature B lymphocytes.
This antigen is expressed on over 95% of all
B cell
NHLs, and on normal B cells, but not on haematopoietic stem cells, normal or malignant plasma cells.
The Fc domain of rituximab recruits immune effector functions to mediate
B cell
lysis.
It is also possible that the binding of rituximab to the CD20 antigen on the
cell
surface may directly induce apoptosis.
For patients with both follicular and diffuse large B-
cell
NHL, several large scale prospective randomised trials have demonstrated prolongation of remission when rituximab is incorporated into first line treatment, and, in follicular
lymphoma
, as a component of salvage therapy.
As a result of these studies, current European indications for rituximab include: the treatment of previously untreated patients with
stage
III-IV follicular
lymphoma
in combination with cyclophosphamide, vincristine and prednisone (CVP) chemotherapy; as maintenance therapy in patients with relapsed follicular
lymphoma
responding to induction therapy with chemotherapy or immuno-chemotherapy; the treatment of patients with diffuse large
B cell
NHL in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy.
[MeSH-major]
Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use.
Lymphoma
,
Non
-
Hodgkin
/ drug therapy
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
Hazardous Substances Data Bank.
RITUXIMAB
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17206982.001).
[ISSN]
0902-4506
[Journal-full-title]
European journal of haematology. Supplementum
[ISO-abbreviation]
Eur J Haematol Suppl
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
[Number-of-references]
39
83.
Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M, Schmid U:
IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome.
J Pathol
; 2005 Jul;206(3):320-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
IgV H mutations in blastoid mantle
cell lymphoma
characterize a subgroup with a tendency to more favourable clinical outcome.
Mantle
cell lymphoma
(MCL) is associated with a very unfavourable clinical course.
This is particularly true for mantle
cell lymphoma
of the blastoid subtype (MCL-b).
Thirteen of 21 cases of MCL-b revealed a homology rate of > or = 99% compared to IgV H germ-line sequences in the databases and were scored as
non
-mutated.
In MCL-b the mutation frequency was usually low and the mutation pattern was only rarely antigen-selected, in contrast to a control group of 11 cases with morphologically almost identical, but phenotypically and genotypically clearly distinguishable, diffuse large
B cell lymphoma
, derived, most likely, from germinal centre B cells.
However, mutated MCL-b tended to present more frequently at an earlier
stage
and without bone marrow involvement and to show lower rates of relapse and death, resulting in a more favourable clinical outcome.
[MeSH-major]
Genes, Immunoglobulin / genetics.
Lymphoma
, Mantle-
Cell
/ genetics
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
(PMID = 15887292.001).
[ISSN]
0022-3417
[Journal-full-title]
The Journal of pathology
[ISO-abbreviation]
J. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
84.
Dargent JL, Lespagnard L, Feoli F, Debusscher L, Greuse M, Bron D:
De novo CD5-positive diffuse large B-cell lymphoma of the skin arising in chronic limb lymphedema.
Leuk Lymphoma
; 2005 May;46(5):775-80
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
De
novo CD5-positive diffuse large B-
cell lymphoma
of the skin arising in chronic limb lymphedema.
We report the case of a 79-year-old woman with a longstanding lymphedema of the right arm who developed a skin
lymphoma
involving the right wrist area.
No expression of anaplastic large
cell lymphoma
kinase (ALK), CD10, CD23, CD30, CD43, bcl-6, cyclin D1, p53 or p16INK4a could be seen.
The tumor was classified as
stage
IE and was first cured by complete surgical excision.
This study further illustrates that
lymphoma
of the skin may complicate chronic limb lymphedema.
Like most of the previously reported cases, this neoplasm belonged to the category of diffuse large B-
cell lymphoma
.
[MeSH-major]
Antigens, CD5 / biosynthesis. Lymphedema / complications.
Lymphoma
, B-
Cell
/ complications.
Lymphoma
, Large B-
Cell
, Diffuse / complications. Skin Neoplasms / complications
Genetic Alliance.
consumer health - Large B cell diffuse lymphoma
.
Genetic Alliance.
consumer health - Lymphedema
.
MedlinePlus Health Information.
consumer health - Lymphedema
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16019518.001).
[ISSN]
1042-8194
[Journal-full-title]
Leukemia & lymphoma
[ISO-abbreviation]
Leuk. Lymphoma
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, CD5
[Number-of-references]
25
85.
Wang T, Liu YH, Zheng HY, Sun QN, Jin HZ, Li F, Fang K, Yan Y:
[Hypopigmented mycosis fungoides in children: a clinicopathological study of 6 cases].
Zhonghua Yi Xue Za Zhi
; 2010 Dec 14;90(46):3287-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The immunohistochemical staining revealed a pattern of T
lymphoma
and a predominance of CD8+ T
cell
.
All patients were of T2N0M0/IB except for one at the
stage
of T1N0M0/IA.
The
non
-treated patient progressed gradually.
The prognosis of early-
stage
treatment is satisfactory.
NB-UVB alone or plus alpha interferon achieves a clinical CR in most early-
stage
patients.
[MeSH-major]
Hypopigmentation / pathology.
Lymphoma
, T-
Cell
, Cutaneous / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology
Genetic Alliance.
consumer health - Mycosis fungoides
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21223789.001).
[ISSN]
0376-2491
[Journal-full-title]
Zhonghua yi xue za zhi
[ISO-abbreviation]
Zhonghua Yi Xue Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
86.
Miyoshi N, Tanaka H, Ito T, Katayama Y, Niimi H, Hyodo H, Kimura A:
Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase.
Int J Hematol
; 2005 Nov;82(4):333-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The treatment also maintained the patient in good condition for approximately 3 months, even though the number of blast cells, serum calcium level, serum PTHrP level, and PTHrP mRNA level increased at the terminal
stage
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Chronic Myeloid Leukemia
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 1993 Oct;7(10):1672-5
[
8412332.001
]
[Cites]
J Biol Chem. 1995 Dec 29;270(52):30857-61
[
8537338.001
]
[Cites]
Blood. 2003 Jan 15;101(2):690-8
[
12509383.001
]
[Cites]
Leukemia. 1995 Nov;9(11):1926-34
[
7475285.001
]
[Cites]
N Engl J Med. 1986 Apr 24;314(17):1065-9
[
3457264.001
]
[Cites]
J Biol Chem. 2004 Aug 13;279(33):34227-39
[
15175350.001
]
[Cites]
Int J Hematol. 1997 Oct;66(3):353-7
[
9401281.001
]
[Cites]
Blood. 1984 Apr;63(4):789-99
[
6584184.001
]
[Cites]
J Korean Med Sci. 2000 Oct;15(5):598-600
[
11069001.001
]
[Cites]
Nat Med. 2004 Nov;10 (11):1187-9
[
15502840.001
]
[Cites]
Rinsho Ketsueki. 2002 Feb;43(2):102-6
[
11925871.001
]
[Cites]
J Biol Chem. 1997 Feb 21;272(8):4953-8
[
9030555.001
]
[Cites]
Blood. 2004 Jun 1;103(11):4010-22
[
14982876.001
]
[Cites]
Mol Cell Biol. 1992 Sep;12(9):3784-95
[
1508184.001
]
[Cites]
Nat Genet. 2004 May;36(5):453-61
[
15098032.001
]
[Cites]
Neth J Med. 1999 Jan;54(1):21-6
[
10048292.001
]
[Cites]
Acta Haematol. 2004;112(3):160-3
[
15345899.001
]
[Cites]
J Natl Cancer Inst. 1998 Jun 3;90(11):850-8
[
9625174.001
]
[Cites]
J Biol Chem. 1994 Mar 4;269(9):6263-6
[
8119972.001
]
[Cites]
Br J Haematol. 1997 Jan;96(1):165-7
[
9012703.001
]
[Cites]
Pediatr Blood Cancer. 2005 Sep;45(3):333-9
[
15700250.001
]
[Cites]
Leuk Lymphoma. 1998 May;29(5-6):499-506
[
9643563.001
]
[Cites]
Am J Hematol. 1994 Nov;47(3):251-2
[
7942801.001
]
(PMID = 16298826.001).
[ISSN]
0925-5710
[Journal-full-title]
International journal of hematology
[ISO-abbreviation]
Int. J. Hematol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Benzamides; 0 / Parathyroid Hormone-Related Protein; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 8A1O1M485B / Imatinib Mesylate
87.
Huang ML, Chen CC, Chang LC:
Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer.
Int J Colorectal Dis
; 2009 Nov;24(11):1281-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gene expressions of HMGI-C and HMGI(Y) are associated with
stage
and metastasis in colorectal cancer.
METHODS: The gene expressions of HMGI-C and HMGI(Y) in 31 paired samples of colorectal tumor and corresponding
non
-tumor were determined by real-time reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: The expression of HMGI(Y) in a colorectal cancer tumor was associated with Dukes staging (p = 0.044), while, in
non
-tumor, the expression of this gene was significant with metastasis (p = 0.003).
Patients with Dukes
stage
A and B present high HMGI(Y) expression in
non
-tumor of colorectal cancer (p = 0.006).
However, patients with Dukes
stage
C and D present high HMGI-C expression in colorectal tumor (p = 0.023).
In the
non
-metastasis group, HMGI(Y) was highly expressed in
non
-tumor of colorectal cancer.
However, in the metastasis group, there was no significant difference between tumor and
non
-tumor tissues in both HMGI-C and HMGI(Y) gene expressions.
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Int J Colorectal Dis. 2010 May;25(5):661
[
19921219.001
]
[Cites]
Langenbecks Arch Surg. 2004 Jun;389(3):193-7
[
15107999.001
]
[Cites]
Mol Cancer Res. 2008 May;6(5):743-50
[
18505920.001
]
[Cites]
Adv Anat Pathol. 1999 Sep;6(5):237-46
[
10472377.001
]
[Cites]
Am J Pathol. 1997 Jul;151(1):37-43
[
9212729.001
]
[Cites]
Oncogene. 1998 Jul 23;17(3):377-85
[
9690519.001
]
[Cites]
Clin Cancer Res. 2004 Mar 15;10(6):2007-14
[
15041719.001
]
[Cites]
Oncogene. 2002 May 9;21(20):3190-8
[
12082634.001
]
[Cites]
J Biol Chem. 1997 Oct 3;272(40):25062-70
[
9312114.001
]
[Cites]
Int J Cancer. 1999 Aug 20;84(4):376-80
[
10404089.001
]
[Cites]
Cancer Res. 1999 Mar 15;59(6):1169-74
[
10096541.001
]
[Cites]
Hum Genet. 1997 Jan;99(1):103-5
[
9003504.001
]
[Cites]
Am J Pathol. 1996 Sep;149(3):775-9
[
8780382.001
]
[Cites]
Cancer Res. 2009 Mar 1;69(5):1844-50
[
19223528.001
]
[Cites]
Cancer Res. 2005 Aug 1;65(15):6622-30
[
16061642.001
]
[Cites]
Eur J Biochem. 1991 May 23;198(1):211-6
[
2040281.001
]
[Cites]
Endocr Relat Cancer. 2007 Sep;14(3):875-86
[
17914116.001
]
[Cites]
Prog Nucleic Acid Res Mol Biol. 1996;54:35-100
[
8768072.001
]
[Cites]
Br J Cancer. 2003 May 6;88(9):1406-10
[
12778070.001
]
[Cites]
Leuk Lymphoma. 2007 Oct;48(10):2008-13
[
17917968.001
]
[Cites]
J Biol Chem. 1995 Mar 3;270(9):4355-60
[
7876198.001
]
[Cites]
Nucleic Acids Res. 1993 Sep 11;21(18):4259-67
[
8414980.001
]
[Cites]
Oncogene. 2001 Sep 27;20(43):6132-41
[
11593421.001
]
[Cites]
Anal Biochem. 1986 Aug 15;157(1):53-62
[
3464222.001
]
[Cites]
Cancer Res. 1996 Apr 15;56(8):1896-901
[
8620511.001
]
[Cites]
Eur J Cancer. 2000 Oct;36(15):1944-8
[
11000575.001
]
[Cites]
Environ Health Perspect. 2000 Oct;108 Suppl 5:803-9
[
11035986.001
]
[Cites]
Cancer Res. 2004 Mar 15;64(6):2024-9
[
15026339.001
]
[Cites]
EMBO J. 1997 Sep 1;16(17):5310-21
[
9311991.001
]
[Cites]
Br J Cancer. 1996 Aug;74(4):573-8
[
8761372.001
]
[Cites]
Pathol Res Pract. 2003;199(10):641-6
[
14666966.001
]
[Cites]
Mol Cell Biol. 1992 Sep;12(9):3919-29
[
1508193.001
]
[Cites]
Cancer Res. 1998 Sep 15;58(18):4193-8
[
9751634.001
]
(PMID = 19609535.001).
[ISSN]
1432-1262
[Journal-full-title]
International journal of colorectal disease
[ISO-abbreviation]
Int J Colorectal Dis
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / HMGA2 Protein; 124544-67-8 / HMGA1a Protein
88.
Koumarianou AA, Xiros N, Papageorgiou E, Pectasides D, Economopoulos T:
Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Anticancer Res
; 2007 Mar-Apr;27(2):1191-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Survival improvement of young patients, aged 16-23, with
Hodgkin
lymphoma
(HL) during the last three decades.
The prognostic factors, treatments and outcomes of 55 young adults (16-23 years old) with
Hodgkin
lymphoma
(HL) treated in the Second Department of Internal Medicine Propaedeutic, Medical Oncology Unit, Athens University, over the past 25 years, are reviewed.
Additionally, the patients were retrospectively divided according to risk factors (abnormal erythrocyte sedimentation rate (ESR), bulky mediastinal disease, > 3 involved nodes and extranodal involvement) into low [
stage I
/II; five patients (9%)], intermediate [
stage
III with adverse prognostic factors; 18 patients (33%)] and high risk categories [stages IIB bulky and III/IV; 32 patients (58%)].
Current controversial issues surrounding this disease, including the role of radiotherapy, positron emission tomography (PET), bone marrow biopsy and stem
cell
transplantation are discussed.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Hodgkin
Disease / drug therapy
Genetic Alliance.
consumer health - Hodgkin lymphoma
.
MedlinePlus Health Information.
consumer health - Hodgkin Disease
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
DACARBAZINE
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
MECHLORETHAMINE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
MECHLORETHAMINE HYDROCHLORIDE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
PROCARBAZINE
.
Hazardous Substances Data Bank.
VINBLASTINE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17465262.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; MOPP protocol
89.
Baris S, Celkan T, Batar B, Guven M, Ozdil M, Ozkan A, Apak H, Yildiz I:
Association between genetic polymorphism in DNA repair genes and risk of B-cell lymphoma.
Pediatr Hematol Oncol
; 2009 Sep;26(6):467-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Association between genetic polymorphism in DNA repair genes and risk of B-
cell lymphoma
.
OBJECTIVES: The authors evaluated the possible effect of DNA repair genes, XPD (Xeroderma pigmentosum group D) codon (312 and 751) and XRCC1 (X-ray repair cross-complementing group 1) codon (194 and 399) SNPs (single-nucleotide polymorphisms) on the risk of childhood B-
cell lymphoma
.
RESULTS: The authors observed no association between variation in the XPD codon Asp312Asn, Lys751Gln, and XRCC1 codon Arg399Gln polymorphisms and B-
cell lymphoma
for any parameter.
The frequency of XRCC1 194Arg/Trp genotype in B-
cell lymphoma
was significantly lower than that in controls (p = .005).
No significant relationship was found between genotypes and
stage
, lactate dehydrogenase, or bone marrow involvement.
CONCLUSIONS: XRCC1 194Trp allele may be associated with a protective effect against development of childhood B-
cell lymphoma
.
[MeSH-major]
DNA Repair / genetics. DNA-Binding Proteins / genetics.
Lymphoma
, B-
Cell
/ genetics. Polymorphism, Single Nucleotide / genetics. Xeroderma Pigmentosum Group D Protein / genetics
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19657998.001).
[ISSN]
1521-0669
[Journal-full-title]
Pediatric hematology and oncology
[ISO-abbreviation]
Pediatr Hematol Oncol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Codon; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein
90.
Kim WY, Jeon YK, Kim TM, Kim JE, Kim YA, Lee SH, Kim DW, Heo DS, Kim CW:
Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma.
Ann Oncol
; 2009 Oct;20(10):1688-96
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-
cell lymphoma
.
BACKGROUND: Extranodal natural killer/T-
cell lymphoma
(NKTCL) is a clinically heterogeneous disease with a poor prognosis, requiring risk-stratified management in affected patients.
Recently, tumor microenvironment including regulatory T cells (Tregs) has been implicated as a prognostic marker in certain types of
lymphoma
.
The decreased number of Tregs (<50/0.40 mm(2)) was more common in patients with poor performance status or in those presented in
non
-upper aerodigestive tract.
However, the level of Tregs was not associated with other prognostic factors, including
stage
, lactate dehydrogenase level, International Prognostic Index, and NKTCL Prognostic Index.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19542249.001).
[ISSN]
1569-8041
[Journal-full-title]
Annals of oncology : official journal of the European Society for Medical Oncology
[ISO-abbreviation]
Ann. Oncol.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
91.
Nickenig C, Dreyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, Wandt H, Lengfelder E, Unterhalt M, Hiddemann W, German Low-Grade Lymphoma Study Group:
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Cancer
; 2006 Sep 1;107(5):1014-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle
cell
lymphomas: results of a prospective randomized trial of the German Low-Grade
Lymphoma
Study Group.
BACKGROUND: In patients with advanced-
stage
follicular
lymphoma
(FL) and mantle
cell lymphoma
(MCL), conventional chemotherapy remains a noncurative approach, and no major improvement in overall survival has been achieved in recent decades.
METHODS: The German Low-Grade
Lymphoma
Study Group performed a randomized trial comparing combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) chemotherapy with combined mitoxantrone, chlorambucil, and prednisone (MCP) chemotherapy as first-line therapy for patients with advanced-
stage
FL or MCL.
RESULTS: Three hundred sixty-three patients with advanced-
stage
FL (n = 277 patients) or MCL (n = 86 patients) entered the trial and were evaluable fully.
The proportion of patients who successfully underwent peripheral blood stem
cell
collection was significantly lower after MCP (44% vs. 93% after CHOP; P = .0003).
Particularly in younger, high-risk patients who are candidates for autologous stem
cell
transplantation, CHOP should be preferred over MCP.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Lymphoma
, Follicular / drug therapy.
Lymphoma
, Mantle-
Cell
/ drug therapy
Genetic Alliance.
consumer health - Follicular Lymphoma
.
Genetic Alliance.
consumer health - Mantle cell lymphoma
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
CHLORAMBUCIL
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
PREDNISOLONE
.
Hazardous Substances Data Bank.
PREDNISONE
.
Hazardous Substances Data Bank.
VINCRISTINE
.
Hazardous Substances Data Bank.
NOVANTRONE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16878325.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial
[Publication-country]
United States
[Chemical-registry-number]
18D0SL7309 / Chlorambucil; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone; CHOP protocol; MCP protocol
92.
Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT:
Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia.
Proc Natl Acad Sci U S A
; 2005 Apr 26;102(17):6068-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T
cell
acute lymphoblastic leukemia.
We have created a stable transgenic rag2-EGFP-mMyc zebrafish line that develops GFP-labeled T
cell
acute lymphoblastic leukemia (T-ALL), allowing visualization of the onset and spread of this disease.
These T
cell
leukemias are clonally aneuploid, can be transplanted into irradiated recipient fish, and express the zebrafish orthologues of the human T-ALL oncogenes tal1/scl and lmo2, thus providing an animal model for the most prevalent molecular subgroup of human T-ALL.
Transgenic progeny from one of these lines can be induced to develop T-ALL by injecting Cre RNA into one-
cell
-
stage
embryos, demonstrating the utility of the Cre/lox system in the zebrafish and providing an essential step in preparing this model for chemical and genetic screens designed to identify modifiers of Myc-induced T-ALL.
Genetic Alliance.
consumer health - Acute Lymphoblastic Leukemia
.
COS Scholar Universe.
author profiles
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
SciCrunch.
ZFIN: Data: Gene Expression
.
The Lens.
Cited by Patents in
.
ZFIN.
ZFIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Genes Dev. 1999 Oct 15;13(20):2658-69
[
10541552.001
]
[Cites]
Development. 1996 Dec;123:1-36
[
9007226.001
]
[Cites]
Immunogenetics. 2000 Sep;51(11):915-23
[
11003385.001
]
[Cites]
Genes Chromosomes Cancer. 2000 Dec;29(4):371-7
[
11066085.001
]
[Cites]
Semin Hematol. 2000 Oct;37(4):381-95
[
11071360.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):12965-9
[
11087852.001
]
[Cites]
Genesis. 2001 Apr;29(4):156-62
[
11309848.001
]
[Cites]
Nucleic Acids Res. 2001 Jun 1;29(11):E53-3
[
11376165.001
]
[Cites]
Leukemia. 2001 Oct;15(10):1495-504
[
11587205.001
]
[Cites]
Curr Biol. 2001 Oct 2;11(19):1481-91
[
11591315.001
]
[Cites]
Oncogene. 2001 Nov 1;20(50):7447-52
[
11704876.001
]
[Cites]
Hum Mutat. 2002 Jun;19(6):607-14
[
12007217.001
]
[Cites]
Nat Genet. 2002 Jun;31(2):135-40
[
12006978.001
]
[Cites]
Cancer Cell. 2002 Feb;1(1):75-87
[
12086890.001
]
[Cites]
Cancer Cell. 2002 Mar;1(2):133-43
[
12086872.001
]
[Cites]
Blood. 2002 Aug 1;100(3):991-7
[
12130513.001
]
[Cites]
Mech Dev. 2002 Sep;117(1-2):243-8
[
12204264.001
]
[Cites]
Science. 2003 Feb 7;299(5608):887-90
[
12574629.001
]
[Cites]
Hum Mutat. 2003 Mar;21(3):176-81
[
12619103.001
]
[Cites]
Nucleic Acids Res. 2003 Apr 15;31(8):e44
[
12682379.001
]
[Cites]
Leukemia. 2003 May;17(5):887-93
[
12750702.001
]
[Cites]
Semin Hematol. 2003 Oct;40(4):274-80
[
14582078.001
]
[Cites]
Blood. 2004 Mar 1;103(5):1909-11
[
14604958.001
]
[Cites]
Lancet. 2004 Feb 14;363(9408):535-6
[
14975618.001
]
[Cites]
Nat Biotechnol. 2004 May;22(5):595-9
[
15097998.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 May 11;101(19):7369-74
[
15123839.001
]
[Cites]
Science. 2004 Oct 8;306(5694):269-71
[
15472075.001
]
[Cites]
N Engl J Med. 1987 Jan 8;316(2):79-84
[
3537802.001
]
[Cites]
Cell. 1989 Dec 22;59(6):1035-48
[
2598259.001
]
[Cites]
Science. 1990 Jun 22;248(4962):1517-23
[
2360047.001
]
[Cites]
Leukemia. 1991 Oct;5(10):839-40
[
1961018.001
]
[Cites]
Science. 1994 Jul 1;265(5168):103-6
[
8016642.001
]
[Cites]
Blood. 1994 Nov 1;84(9):3105-12
[
7949183.001
]
[Cites]
Blood. 1995 May 1;85(9):2321-30
[
7727766.001
]
[Cites]
Science. 1995 Sep 8;269(5229):1427-9
[
7660125.001
]
[Cites]
Science. 1997 Nov 7;278(5340):1059-64
[
9353180.001
]
[Cites]
Genes Dev. 1998 Aug 1;12(15):2424-33
[
9694806.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):407-12
[
15630097.001
]
[Cites]
Blood. 2005 Apr 15;105(8):3278-85
[
15618471.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3497-502
[
10737801.001
]
(PMID = 15827121.001).
[ISSN]
0027-8424
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
ENG
[Databank-accession-numbers]
PIR/ AF398514
[Grant]
United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / CA-06516; United States / NCI NIH HHS / CA / CA-68484
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / Genetic Markers; 0 / Nuclear Proteins; 0 / RAG2 protein, human; 0 / Rag2 protein, mouse; 0 / V(D)J recombination activating protein 2; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 149137-54-2 / Lox protein, mouse; EC 1.4.3.13 / Protein-Lysine 6-Oxidase; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
[Other-IDs]
NLM/ PMC1087915
93.
Xue LY, Lü N, Li AD, Zou SM, Lin DM, He ZG, Xie YQ, Liu XY:
[A clinicopathological analysis of gastric lymphoma].
Zhonghua Bing Li Xue Za Zhi
; 2005 Jun;34(6):332-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[A clinicopathological analysis of gastric
lymphoma
].
OBJECTIVE: To discuss the clinicopathological features and prognostic factors of gastric
lymphoma
.
METHODS: 83 gastric
lymphoma
cases were analyzed retrospectively in accordance to the criteria of the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues.
According to the new World Health Organization classification for neoplastic diseases of the hematopoietic and lymphoid tissues, 57 cases were extranodal marginal zone
lymphoma
of mucosa-associated lymphoid tissue (MALT)-type (MALT
lymphoma
), 23 were diffuse large
B cell lymphoma
accompanying MALT
lymphoma
, 2 were diffuse large
B cell lymphoma
and 1 was follicular
lymphoma
.
Of all the cases, 31 were
stage I
E, 38
stage
II E, 8
stage
III E and 6
stage
IV by the Ann Arbor staging system (1972).
The 5-year and 10-year survival rates of MALT
lymphoma
were 77.4% and 72.3%, the 5-year and 10-year survival rates of diffuse large
B cell lymphoma
accompanying MALT
lymphoma
were 81.8% and 68.2%, the 5-year survival rate of diffuse large
B cell lymphoma
was 50.0%.
CONCLUSIONS: There are no specific symptoms in gastric
lymphoma
patients.
Extranodal marginal zone
lymphoma
of MALT-type is the main histopathological type of gastric
lymphoma
, often accompanied by multiple mucosa involvement and also often accompanied by a history of chronic gastric disease.
Survival rate has a significant correlation with lymph node involvement and clinical
stage
.
[MeSH-major]
Gastrectomy.
Lymphoma
/ pathology.
Lymphoma
, B-
Cell
, Marginal Zone / pathology. Stomach Neoplasms / pathology
[MeSH-minor]
Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis.
Lymphoma
, B-
Cell
/ pathology.
Lymphoma
, B-
Cell
/ surgery.
Lymphoma
, B-
Cell
/ therapy.
Lymphoma
, Large B-
Cell
, Diffuse / pathology.
Lymphoma
, Large B-
Cell
, Diffuse / surgery.
Lymphoma
, Large B-
Cell
, Diffuse / therapy. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate
Genetic Alliance.
consumer health - Gastric Lymphoma
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address: